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Abstract
Human mesenchymal stem cells (hMSCs) are considered to have promising
applications in cell therapy and tissue regeneration. The chemical molecules in the
local environments are known to be important in controlling the functions of MSCs.
The intrinsic mechanisms activated by such extracellular molecules are not fully
understood. ATP is a well-established extracellular signalling molecule and
activates two structurally and functionally different subfamilies of purinergic
receptors on the cell surface, ATP-gated ion channel P2X receptors and
G-protein-coupled P2Y receptors. Activation of the P2Y receptors leads to depletion
of intracellular Ca2+ store and subsequent activation of the store-operated Ca2+ (SOC)
channels. ATP is released by MSCs constitutively or in response to stimulation. This
study using MSCs isolated from human dental pulp (hDP-MSCs), investigated the
effects of extracellular ATP on proliferation, migration, osteogenic and adipogenic
differentiation and the underlying signalling mechanisms.
Exposure of hDP-MSC to extracellular ATP up to 300 μM resulted in no effect on 
cell proliferation as shown in the MTT assays and cell counting. ATP at 30 μM 
promoted cell migration using the wound healing assays. ATP also inhibited the
ALP expression and activity or osteogenesis of hDP-MSCs in basal medium (BM)
and osteogenic differentiation medium (ODM), and by contrast increased the
number of Oil red O-stained, fact droplet-containing cells or adipogenesis of
hDP-MSCs cultured in adipogenic differentiation medium (ADM).
RT-PCR revealed consistent expression of mRNA transcripts for P2X4, P2X6,
P2X7, P2Y1, P2Y11 and also the SOC channel components, Orai1, Orai2, Orai3,
Stim1 and Stim2. Single cell imaging and FLEXstation experiments in a
combination of pharmacological intervention using selective inhibitors or genetic
intervention using specific siRNA provide consistent evidence to show functional
expression of the P2X7, P2Y1 and P2Y11 receptors and Stim1/Orai SOC channels.
For example, ATP-induced Ca2+ responses were inhibited by AZ11645373 (a P2X7
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antagonist), 2-APB (a SOC channel inhibitor), Synta66 (a SOC channel inhibitor) or
siP2X7, siP2Y1, siP2Y11, siOrai1, siOrai2, siOrai3 and siStim1.
Treatment with AZ11645373 or siP2X7 significantly inhibited ATP-induced
stimulation of cell migration, but had no effect on ATP-induced inhibition of
osteogenesis and stimulation of adipogenesis. Treatment with siP2Y1 or siP2Y11
strongly blocked ATP-induced stimulation of cell migration and adipogenesis, and
inhibition of osteogenesis. Finally, treatment with siStim1/siOrai1 attenuated
ATP-evoked stimulation of cell migration and inhibition of osteogenesis.
ATP-induced increase in adipogenesis was reduced by treatment with 2-APB and
siOrai3 but not with siStim1/siOrai1.
In summary, the present study shows that extracellular ATP regulates cell migration
via the P2X7, P2Y1 and P2Y11 receptors and Stim1/Orai1 SOC channels,
osteogenic differentiation mainly via the P2Y1 and P2Y11 receptors and
Stim1/Orai1 SOC channels, and adipogenic differentiation via the P2Y1 and P2Y11
receptor and Orai3 in hDP-MSCs. These findings provide a better understanding of
the mechanisms underlying the actions of extracellular ATP on hDP-MSCs and
useful information that facilitates developing better applications of hMSCs for
regenerative medicines.
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Chapter 1
Introduction
1.1 Stem cells
Stem cells are defined as undifferentiated cells and have the ability to self-renew and to
produce mature progeny cells of a particular tissue through differentiation (Reya,
Morrison et al. 2001).
According to their ability or potency of differentiation (also known as potency), stem
cells are now commonly classified into totipotent, pluripotent, multipotent and
unipotent categories, as shown in Table 1.1 (Wagers and Weissman 2004; Ranganathan
and Lakshminarayanan 2012). Totipotent stem cells (for example, zygotes’s cells) are
able to divide and produce all type of cells in an organism, including extraembryonic
tissues (for example, placenta) (Friedlander, Cullinan et al. 2009). Pluripotent stem cells
(for example, embryonic stem cells (ESCs) from blastocysts (Thomson, Itskovitz-Eldor
et al. 1998) can differentiate into almost any of the three germ layers: endoderm (for
example, interior stomach lining, gastrointestinal tract and lung), mesoderm (for
example, muscle, bone and blood) or ectoderm (for example, epidermal tissues and
nervous system), excluding extraembryonic tissues (Friedlander, Cullinan et al. 2009;
Ranganathan and Lakshminarayanan 2012). Multipotent stem cells (for example,
mesenchymal stem cells (MSCs)) are able to give rise to cells from a multiple, but more
limited number of lineages (Friedlander, Cullinan et al. 2009; Ranganathan and
Lakshminarayanan 2012). Unipotent stem cells (for example, skin cells, hepatocytes
and precursors) have the capacity to form only one specific type of cells (Wagers and
Weissman 2004). As shown in Table 1.1, induced pluripotent stem cells (iPSCs) are
created from multipotent stem cells or adult somatic cells (for example, fibroblasts)
(Takahashi and Yamanaka 2006; Takahashi, Okita et al. 2007), in the culture by
introducing a few defined factors, like Oct3/4, Klf4, Sox2 and c-myc; thus, these cells
have similar properties to that of pluripotent stem cells. Furthermore, somatic cell
nuclear transfer is a cloning technique by nucleus transfer from an adult somatic cell
into a de-nucleated ovum (totipotent) that then divides to form the entire organism. This
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method could be used to produce human stem cell lines for therapeutics (Wilmut 2002).
Particularly, if taken a tumour as an aberrant organ, tumorigenic cells can be considered
as cancer stem cells (CSCs) that undergo aberrant processes similar to the self-renewal
and differentiation of normal stem cells (Reya, Morrison et al. 2001).
The pluripotent ESCs and iPSCs are good sources of stem cells for biomedical research
and clinical applications (Alvarez, Garcia-Lavandeira et al. 2012; Bai, Desprat et al.
2013). However, the ethical issue concerning isolation of human ESCs (hESCs) from
embryos hinders their therapeutic use. Alternatively, although there is no ethical issue
about iPSCs as they are directly reprogrammed from adult cells, the potential biological
safety issue associated with production of iPSCs could undermine their use for
modelling diseases and therapeutic applications (Bai, Desprat et al. 2013). In order to
optimize the reprogramming process and ultimately provide medically safe iPSCs,
further investigations are required to carefully examine the impact on the genome
integrity by all factors, including expression of different reprogramming transcription
factors and carryover of non-human genetic materials from the vectors used,
reprogramming protocols and early culture/passaging conditions (Bai, Desprat et al.
2013).
Adult stem cells (ASCs) or postnatal stem cells have been extensively researched as a
potential cell source for both research and clinical application (Alvarez,
Garcia-Lavandeira et al. 2012). ASCs have been identified in a wide range of tissues,
such as mesenchymal stem cells (MSCs) (Zapata, Alfaro et al. 2012), hematopoietic
stem cells (HSCs) (Kiel, Yilmaz et al. 2005), muscle stem cells (MuSCs) (Cheung,
Quach et al. 2012), neural stem cells (NSCs) (Bonaguidi, Wheeler et al. 2011), lung
stem cells (LuSCs) (Kajstura, Rota et al. 2011), skin stem cells (bulge) (Fuchs and
Horsley 2011), small intestine stem cells (Formeister, Sionas et al. 2009), liver and
pancreas stem cells (Burke and Tosh 2012), cardiac stem cells (D'Amario, Fiorini et al.
2011), and pituitary stem cells (Castinetti, Davis et al. 2011).
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Table 1.1 Classification of stem cells.
Type of stem cells Source of stem cells Differentiation
potential/plasticity
Embryonic stem cells Fertilized Zygote Totipotent
Blastocyst-inner cell mass (5-7 day embryo) Pluripotent
Embryonic germ cells Gonadal ridge (6-week embryo) Pluripotent
Fetal tissue stem cells Primitive cell types of organs and tissues (neural crest stem cells, primitive
hematopoietic stem cells, progenitor cells of pancreatic islets, etc.)
Pluripotent/ Multipotent
Adult/postnatal stem
cells
Infant: umbilical cord blood/ Wharton jelly Pluripotent/ Multipotent
Hematopoietic stem cells Multipotent
Epidermal stem cells
Mesenchymal stem cells
Bone marrow stoma
Dental pulp
Adipose tissue stem cells
Neural stem cells
Limbal stem cells
Hepatic stem cells
Induced pluripotent
stem cells*
Multipotent stem/progenitor cells subjected to retroviral transcription of
embryonic genes
Pluripotent
Somatic cell nuclear
transfer*
Adult somatic cells introduced into ovum-therapeutic cloning Totipotent/Pluripotent
*Product of tissue engineering. Taken from (Ranganathan and Lakshminarayanan 2012)
- 4 -
1.2 Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, are the
most commonly studied adult stem cells. MSCs were initially isolated from bone
marrow by Friedenstein in 1970 (Friedenstein, Chailakhjan et al. 1970). MSCs were
defined as multipotent stem cells with the capability to differentiate into bone,
adipose tissue, and cartilage by Pittenger in 1999 (Pittenger, Mackay et al. 1999).
Apart from bone morrow, MSCs can be found in several other tissues and organs,
such as adipose tissue (Zuk, Zhu et al. 2001; Zuk, Zhu et al. 2002), dental pulp
(Gronthos, Mankani et al. 2000; Gronthos, Brahim et al. 2002), synovial membrane
(De Bari, Dell'Accio et al. 2001) and umbilical cord blood (Lee, Kuo et al. 2004).
Due to the absence of specific MSCs markers and the heterogeneity of the MSC
populations, the Mesenchymal and Tissue Stem Cell Committee of the International
Society for Cellular Therapy (ISCT) proposed three minimal criteria defining human
MSCs in 2006 (Dominici, Le Blanc et al. 2006; Wagner and Ho 2007). First, MSCs
must have the ability to adhere to the plastic surface when maintained in standard
culture conditions (alpha modified minimal essential medium plus 20% fetal bovine
serum). Second, MSCs must show strong expression of positive markers CD105
(endoglin), CD90 (Thy-1/Thy-1.1), CD73 (an ecto-5’-nuleotidase), and MSCs must
be deficient in expressing negative markers CD45 (a protein tyrosine phosphatase, a
common marker for leukocyte and hematopoietic origin), CD34 (a marker for
hematopoietic stem cells and endothelial cell lineage), CD14
(monocyte-macrophage differentiation antigen) or CD11b, CD79α or CD19 and 
HLA-DR. Finally, MSCs can differentiate in vitro into osteogenic, adipogenic, and
chondrogenic lineages.
MSCs can be expanded in vitro for several passages and can self-renew while
maintaining their multi-potency to differentiate into various tissues, as shown in Fig.
1.1 (Jiang, Jahagirdar et al. 2002; Phinney 2007; Bonfield, Nolan Koloze et al.
2010). Furthermore, MSCs have potent immunoregulatory functions (Lee, Lim et al.
2014; Wuchter, Bieback et al. 2014). Due to their regenerative potential and
immunoregulatory effect, MSCs can be considered as promising therapeutic
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candidates for the treatment of degenerative, inflammatory, and autoimmune
diseases (Fernandez Vallone, Romaniuk et al. 2013; Farini, Sitzia et al. 2014;
Figliuzzi, Bonandrini et al. 2014; Lee, Lim et al. 2014). Currently, a number (at least
88) of completed clinical trials using in vitro expanded MSCs were published in the
public clinical trials database (www.clinicaltrials.gov) showing potential
applications in cell-based therapies. However, there are still many questions to be
taken into account, such as safety (for example, tumor development and metastases),
quality control (for example, bacteriological tests, viability and phenotype tests,
oncogenic tests, and endotoxin assay), clinical grade production (for example, a
large number of cells), and clinical transition (for example, engraftment,
angiogenesis, tissue remodelling, and modulation of the immune response) (Farini,
Sitzia et al. 2014).
The following section will discuss MSCs from bone marrow, adipose tissue and
dental pulp.
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Figure 1.1 Differentiation capacities of multipotent MSCs.
Mesenchymal stem cells (MSCs) can be cultured in vitro to proliferate and differentiate into a number of phenotypes, which include cells capable of
forming bone, cartilage, muscle, marrow, tendon/ligament, adipocytes, and connective tissue in certain culture conditions (Bonfield, Nolan Koloze
et al. 2010).
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1.2.1 Bone marrow mesenchymal stem cells
The most commonly studied mesenchymal stem cells are isolated from bone marrow
(BM-MSCs) of various species, including human (Tao, Sun et al. 2011), rabbit
(Deng, Sun et al. 2006), rat (Deng, Sun et al. 2006; Li, Deng et al. 2006) and mouse
(Tao, Lau et al. 2007; Tao, Lau et al. 2008). An in vitro study using flow cytometry
analysis showed that human BM-MSCs expressed stromal-derived factor 1
(STRO-1, a commonly used marker for MSCs), Oct4, Nanog, CD13
(aminopeptidase N), CD44 (an adhesion molecule for hyaluronate and lymphocyte
homing-associated cells), CD90, CD146 (a melanoma cell adhesion molecule; a
marker for endothelial cell lineage and perivascular cell), and CD166 (an activated
leukocyte cell adhesion molecule; integrin α3; a MSCs marker), but not CD14, 
CD34, CD45 and CD117 (a c-kit receptor; a surface marker for hematopoietic stem
cells) (Karaoz, Dogan et al. 2010). By using immunohistochemistry and reverse
transcription-polymerase chain reaction (RT-PCR), it was demonstrated that human
BM-MSCs under different in vitro differentiation conditions expressed osteogenic
(alkaline phosphatase or ALP, osteonectin, osteocalcin, osteopontin, runt-related
transcription factor 2, bone morphogenetic protein-2 or BMP-2, BMP-4, type I
collagen), adipogenic (leptin, adipophilin, and peroxisomal proliferator activated
receptor gamma 2 or PPARγ2), chondrogenic (type II collagen, type X collagen and 
cartilage oligomeric matrix protein), myogenic (desmin, myogenin, myosin IIa, and
α-smooth muscle actin or α-SMA) and neurogenic (γ-enolase, 
microtubule-associated proteins 2 or MAP2, c-fos, nestin, neurofilament-heavy,
neurofilament-light, β3 tubulin, and glial fibrillary acid protein or GFAP) markers 
(Koyama, Okubo et al. 2009; Karaoz, Dogan et al. 2010). Other studies have
reported that BM-MSCs have the ability to differentiate into a variety of lineages,
such as osteoblasts, adipocytes, chondrocytes, skeletal muscle cells, neurons, and
cardiomyocytes (Tao, Lau et al. 2008; Ferrari, Gulinelli et al. 2011).
Therefore, human BM-MSCs are attractive candidates for stem cell based tissue
regeneration. For example, a gelatin/chondoitin-6-sulfate/hyaluronan tri-copolymer
scaffold containing bone marrow fluid and dental bud cells was implanted into
porcine mandibular alveolar sockets (Kuo, Lin et al. 2011). Histological analysis
showed formation of the crown, root, pulp, enamel, dentin, odontoblast, cementum,
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blood vessel, ameloblasts, periodontal ligament and dentin tubules, suggesting
generation of dentin-pulp-like complex tooth structures and formation of periodontal
tissues. However, many outstanding issues, including regulation of cell proliferation
and differentiation, determination of tooth shape, and control of the size and
eruption of the tooth, still need to be resolved.
Although BM-MSCs are still considered as the golden reference for the application
of MSCs, there are several limitations. For example, the patients experienced pain
during the cell isolation process (Scarfi 2014). Moreover, BM-MSCs appear low
frequency of prevalence (0.001 - 0.01% of the total population) in BM tissues
(Pittenger, Mackay et al. 1999) and must be expanded in vitro to obtain sufficient
cells prior to use. Additionally, the differentiation potential of isolated BM-MSCs
decreases with the age of the donor increasing (Tokalov, Gruner et al. 2007).
Currently, there is increasing interest in MSCs from other tissues, such as adipose
tissue and dental pulp.
1.2.2 Adipose tissue mesenchymal stem cells
Adipose tissue mesenchymal stem cells (AT-MSCs), also known as adipose-derived
stem/stromal cells (ADSCs), as a source of MSCs have attracted much attention in
recent years. Compared with BM-MSCs, a large number of AT-MSCs can be easily
isolated from adipose tissues without any ethical concerns (Zuk, Zhu et al. 2001;
Tobita and Mizuno 2013; Romagnoli and Brandi 2014). Generally, AT-MSCs can
be isolated in vitro by density gradient centrifugation of collagenase-digested tissues
after adipose tissues were lipoaspirated or minced (Boquest, Shahdadfar et al. 2006).
These cells exhibited expression of the positive markers, including STRO-1, CD9,
CD10, CD13, CD29, CD44, CD49, CD73, CD90, CD105 and CD166, but not the
negative cell markers, such as CD14, CD16, CD34, CD45, CD56, CD61, CD104
and CD106 (an endothelial cell lineage marker) (Zuk, Zhu et al. 2002; Cao, Sun et
al. 2005; Gimble, Guilak et al. 2008; Karaoz, Dogan et al. 2010; Baer and Geiger
2012; Baer, Kuci et al. 2013).
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Studies have shown that AT-MSCs possess a high plasticity; they can differentiate
into osteoblasts, adipocytes, chondrocytes, myocytes, neural cells, epithelial cells
and hepatocytes (Safford, Hicok et al. 2002; Zuk, Zhu et al. 2002; Brzoska, Geiger
et al. 2005; Banas, Teratani et al. 2007). Therefore, several tissue engineering and
cell therapy approaches using AT-MSCs have been carried out to repair or
regenerate cartilage (Mehlhorn, Zwingmann et al. 2009), bone (Chen, Yang et al.
2010), peripheral nerves (Santiago, Clavijo-Alvarez et al. 2009), hepatic integration
(Aurich, Sgodda et al. 2009), liver failure (Banas, Teratani et al. 2009),
insulin-producing islet cells (Kajiyama, Hamazaki et al. 2010), myocardial
infarction (Schenke-Layland, Strem et al. 2009) and renal function (Li, Han et al.
2010). However, there are still many hurdles that need to be overcome for clinical
applications, such as standardization in the isolation methods and culture protocols,
and good manufacturing practices (Bourin, Gadelorge et al. 2008; Baer and Geiger
2012; Romagnoli and Brandi 2014).
1.2.3 Dental pulp mesenchymal stem cells
Dental pulp mesenchymal stem cells (DP-MSCs) have gained increasing attention.
DP-MSCs were firstly isolated from permanent teeth by Gronthos in 2000 (known
as dental pulp stem cells or DPSCs) (Gronthos, Mankani et al. 2000) and from
exfoliated deciduous teeth by Miura in 2003 (known as stem cells from human
exfoliated deciduous teeth (SHEDs) or immature DPSCs (Miura, Gronthos et al.
2003). Compared with BM-MSCs, DP-MSCs have advantages for clinical
applications due to the fact that they are easily available from teeth after extraction
with very low morbidity and no ethical issues (Galler, Schweikl et al. 2011).
Moreover, DP-MSCs show high proliferation rates and potential of differentiation
into osteoblasts, odontoblasts, ameloblasts, and nerve cells (Galler, Schweikl et al.
2011). In addition, DP-MSCs retain their multipotent ability to differentiate, even
after temporary storage in liquid nitrogen (Perry, Zhou et al. 2008).
Immunohistochemical studies have shown that DP-MSCs, isolated from the dental
pulp of human third molar teeth and cultured under in vitro basal or undifferentiated
conditions, are positive for STRO-1, CD44, CD105, CD 106, CD146, VCAM-1
(vascular cell adhesion molecule 1 , an endothelial cell lineage marker), α-SMA, 
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ALP, osteonectin (an osteogenic marker), osteopontin (an osteogenic marker),
osteocalcin (an osteogenic marker), collagen type I (an osteogenic marker), collagen
type II (a cartilage marker), collagen type III (a fibroblasts marker ) and fibroblast
growth factor 2 (FGF-2, a fibroblasts marker), but they are negative for CD14,
CD31 (a marker for endothelial cell lineage), CD34, CD45, CD71 (a transferring
receptor), MyoD (a myocyte marker), neurofilament (a neuronal marker), PPARγ2 
(a fat marker), dentin sialophosphoprotein (DSPP, an odontoblast specific protein)
(Gronthos, Mankani et al. 2000; Shi, Bartold et al. 2005; Karaoz, Dogan et al. 2010).
Flow cytometry analysis has confirmed that human DP-MSCs express CD13, CD73,
CD90 and CD166, but not CD15 and CD117 (Karaoz, Dogan et al. 2010).
Moreover, human DP-MSCs can be induced to express not only osteoblast markers
such as osteocalcin and flk-1 (vascular endothelial growth factor receptor 2,
VEGF-R2), but also endothelial markers including CD54, von-Willebrand (domain
1 and 2), CD31 and angiotensin-converting enzyme (d'Aquino, Graziano et al.
2007). Furthermore, immunohistochemical and RT-PCR analysis revealed that
human DP-MSCs in different in vitro differentiation culture are able to express
osteogenic markers (ALP, osteonectin, osteocalcin, osteopontin, runt-related
transcription factor 2, type I collagen, BMP-2 and BMP-4), adipogenic markers
(leptin, adipophilin, and PPARγ2), chondrogenic markers (type II collagen, type X 
collagen and cartilage oligomeric matrix protein), myogenic markers (desmin,
myogenin, myosinIIa, and α-SMA) and neurogenic markers (γ-enolase, 
microtubule-associated proteins 2 or MAP 2, c-fos, nestin, neurofilament-heavy,
neurofilament-light, β3 tubulin, and GFAP) (Koyama, Okubo et al. 2009; Karaoz, 
Dogan et al. 2010). Therefore, when cultured in vitro, DP-MSCs show the ability to
differentiate into odontoblasts, osteoblasts, adipocytes, chondrocytes,
endoltheliocytes, myocytes and neurons (Gronthos, Mankani et al. 2000; Gronthos,
Brahim et al. 2002; d'Aquino, Graziano et al. 2007; Zhang, Chang et al. 2008;
Koyama, Okubo et al. 2009; Yu, Damek-Poprawa et al. 2009).
DP-MSCs in vivo can produce many complex tissues. For example, an early study
showed that human DP-MSCs could differentiate into adipocytes (PPARγ2 and 
lipoprotein lipase) and neural-like cells (nestin, and GFAP), and forming ectopic
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dentin and dentin-pulp-like tissue in vivo (Gronthos, Brahim et al. 2002). More
recent in vivo studies have reported that human DP-MSCs are able to form calcified
bone tissue with Haversian canals and osteocytes (Laino, d'Aquino et al. 2005;
Kumabe, Nakatsuka et al. 2006; Yu, Damek-Poprawa et al. 2009) and
dentin-pulp-like tissue complexes (Gronthos, Mankani et al. 2000; El-Backly,
Massoud et al. 2008). Therefore, DP-MSCs are promising for dental tissue
engineering and tooth regeneration.
In a recent study, DP-MSCs have been demonstrated to be induced to undergo
odontoblastic differentiation in response to optimal mechanical compression of
three-dimensional (3D) scaffolds with dentinal tubule-like pores. This effect is
through activation of mitogen-activated protein kinases (MAPK) signaling pathway
and expression of BMP7 and Wnt10a (Miyashita, Ahmed et al. 2014). But the
mechano-sensing mechanisms involved are not yet identified.
Therefore, a better understanding of the mechanisms of autocrine (such as bone
morphogenetic protein 2 [BMP-2], adenosine 5’-triphosphate [ATP]) and paracrine
(for example, interleukin-1 [IL-1]) extracellular signals involved in the regulation of
MSCs behaviors, is expected to facilitate tissue engineering and clinical applications
(Scarfi 2014). For example, BMP-2 secreted from MSCs has been shown to improve
the production of bone extracellular matrix during the induction of bone formation
(Lin, Wang et al. 2014). ATP released from MSCs also modulated hMSCs
proliferation (Coppi, Pugliese et al. 2007), suggesting an important role for
extracellular ATP in regulating stem cell functions through the P2 purinergic
receptors (Pedata, Melani et al. 2007). In addition, it has been reported that MSCs
were induced by IL-1 to secrete prostaglandin E 2 (PGE 2) and a group of cytokines
(such as IL-6 and IL-8) (Li, Reinhardt et al. 2012).
- 12 -
1.3 Extracellular ATP Signalling
1.3.1 ATP release, degradation and purinergic signalling
Since the discovery of ATP in 1929, it is well known that ATP acts as the energy
supplier for a variety of cellular and molecular processes inside the cell. ATP is
released from dying or damaged cells at the tissue injury or inflammation sites.
There is increasing evidence to show ATP release from healthy cells constitutively
or in response to stimulations, such as sensory nerves (Holton and Holton 1954;
Holton 1959), osteoclasts, osteoblasts (Burnstock 2009; Burnstock, Fredholm et al.
2010). There is a diversity of stimulations or conditions that cause ATP release from
cells, such as mechanical stress, hypoxia and inflammation (Burnstock, Fredholm et
al. 2010; Sun, Junger et al. 2013; Scarfi 2014). The mechanisms mediating ATP
efflux from the cell is not completely understood. However, several possible
mechanisms have been reported, such as ATP-conductive anion channels,
hemi-gap–junction channels and exocytosis (Kawano, Otsu et al. 2006).
Extracellular ATP can be converted through the actions of ecto-nucleotidases, to
adenosine 5′-diphosphate (ADP), adenosine 5’-monophosphate (AMP) and 
adenosine as shown in Figure 1.2 (Buckley, Golding et al. 2003). In 1972,
‘purinergic signalling’ concept was hypothesized by Burnstock (Burnstock 1972). In
1978, two different families of such ‘purinoceptors’ P1 for adenosine and P2
receptors for ADP/ATP, were proposed (Burnstock and Wong 1978).
Four different P1 receptors, which are more commonly referred to as the A1, A2A,
A2B and A3 receptors, are identified; they are all guanosine nucleotide-binding
proteins (G-proteins) coupled receptors. The P2 receptors are further divided into
two subfamilies, the ionotropic P2X receptors as cation channels and the
metabotropic P2Y receptors as G-protein-coupled receptors, as shown in Figure 1.2
(Burnstock and Kennedy 1985; Khakh and North 2006; Coddou, Yan et al. 2011;
von Kugelgen and Harden 2011; Baroja-Mazo, Barbera-Cremades et al. 2013).
Seven mammalian P2X receptor subunits and eight P2Y mammalian receptor
subunits have been characterized (Khakh and North 2006; Pedata, Melani et al.
2007; Burnstock 2014).
- 13 -
Intracellular Ca2+ is a ubiquitous signalling molecule that is involved in the
regulation of almost all known cellular functions and reactions (Berridge, Bootman
et al. 2003; Petersen, Michalak et al. 2005). Calcium signalling was mediated
directly through activation of Ca2+ permeable ion channels, for example, Ca2+ entry
though P2X receptors and store operated calcium (SOC) channels (discussed further
below), or indirectly via second messengers generated by signal transduction
pathways, for example, intracellular Ca2+ release mediated by inositol
1,4,5-triphosphate (IP3) following activation of the P2Y receptors. There is now
strong evidence to show that the P2 purinergic receptors have many functional roles
in a wide range of physiological processes (Lim and Mitchell 2012), including bone
remodelling (Burnstock, Fredholm et al. 2010; Orriss, Burnstock et al. 2010),
neuronal signalling (Burnstock 2011; Burnstock and Ulrich 2011), inflammation
(Ohta and Sitkovsky 2009), and epithelial transport (Novak 2011).
The following section will describe the P2 purinergic receptors, P2X and P2Y, and
P2Y-activated SOC channels.
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Figure 1.2 ATP degradation and the purinergic receptor family.
Extracellular ATP is the agonist for both P2X and P2Y receptors, and it can degrade
to ADP, AMP and adenosine though through actions of various ectonucleotidases.
The activation of P2X receptors by ATP results in extracellular Na+ and Ca2+ influx
and K+ efflux and thereby an increase in the intracellular Ca2+ concentrations and/or
membrane depolarization. The activation of P2Y receptors by ATP and ADP leads
to phospholipase C (PLC) activation, generation of IP3 and release of cytosolic Ca2+
from intracellular stores to increase the intracellular Ca2+ concentrations, or
inhibition of adenylate cyclase and reduction of the level of cyclic adenosine
monophosphate (cAMP). Adenosine receptors are also coupled to G-proteins and
regulate the production of cAMP through adenylate cyclise (Baroja-Mazo,
Barbera-Cremades et al. 2013).
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1.3.2 P2X receptors
There are seven P2X receptor protein or subunit subtypes (P2X1-P2X7) are
identified (Khakh and North 2006). They range from 388 (P2X4) to 595 (P2X7)
amino acid residues in length. Each subunit has two hydrophobic transmembrane
(TM) domains connected by a large extracellular loop of about 280 amino acids
residues, and both N- and C-termini are intracellular as shown in Figure 1.2. The
P2X receptors are trimmers formed in a homomeric and heteromeric fashion (Jiang
2012). The experimental evidence so far shows that the P2X6 subunit does not form
a homomeric receptor and the P2X7 subunit does not form a heteromeric receptor
with other P2X subunits. Several heteromeric P2X receptors have been reported,
including P2X1/2, P2X1/4, P2X1/5, P2X2/3, P2X2/5, P2X2/6, and P2X4/6 (Jiang
2012). P2X receptor are expressed in excitable cells like neurons and muscle cells
and also in a diversity of non-excitable cells (Table 1.2), where they play an
important role in a number of physiological and pathophysiological processes,
including cell proliferation and differentiation (North 2002; Burnstock, Fredholm et
al. 2010; Jiang 2012; Burnstock 2014).
All the P2X receptors are ligand-gated ion channels activated by extracellular ATP.
P2X receptors mediate rapid non-selective passage of cations such as Na+, K+ and
Ca2+ across the cell membrane, resulting in an increase in the intracellular Ca2+
concentrations and/or membrane depolarization (Burnstock, Fredholm et al. 2010).
Membrane depolarization can induce further an increase in the intracellular Ca2+
concentration via activation of the voltage-gated Ca2+ (CaV) channels. This
mechanism does not depend on the production and diffusion of second messengers
within the cytosol or cell membrane. So, the P2X receptors play an important role in
the rapid responses to extracellular ATP, during such as neuronal signalling and
regulation of muscle contractility.
The P2X receptor ion channels have fast activation and deactivation kinetics, that is,
they all open within a few milliseconds upon ATP binding and close within tens of
milliseconds after ATP is removed. They exhibit strikingly different inactivation
kinetics, manifested by the decline of the ionic currents during persistent application
of ATP. The P2X1 and P2X3 receptors desensitize very fast, with ATP-induced
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currents disappearing within tens or hundreds of milliseconds, whereas the P2X2,
P2X4 and P2X5 receptors show modest desensitization in a few seconds and the
P2X7 receptor exhibits no desensitization even over several minutes (Jarvis and
Khakh 2009; North and Jarvis 2013). Further details are discussed in the following
sections.
All P2X receptors are activated by ATP but show no or little sensitivity to ADP
AMP, adenosine or other purines (for example, GTP) or pyrimidines (for example,
UTP and CTP) (North and Jarvis 2013). However, there are several synthetic ATP
analogues that act as the P2X receptor agonists, including 2-methylthioadenosine
5’-triphosphate (2-MeSATP), αβ-methylene ATP (αβmeATP) and 
2′,3′-O-(benzoyl-4-benzoyl)-ATP (BzATP). ATP and 2-MeSATP activate almost all
P2X receptors (Jarvis and Khakh 2009; Khakh and North 2012). Suramin and
PPADS are two generic antagonists that inhibit all P2X receptors except the P2X4
receptor (Jarvis and Khakh 2009; Khakh and North 2012).
In recent years, significant advances have been made in the development of more
potent and selective antagonists with drug-like properties at certain P2X receptor
subtypes, particularly the P2X3 and P2X7 receptors (Jiang 2012). The main
distribution, agonists and antagonists of the P2X receptors are summarized in Table
1.2, and will be discussed further in the next section.
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Table 1.2 Main distribution, agonists and antagonists of P2X receptors.
Receptor Main distribution Agonists Antagonists
P2X1 Dorsal horn spinal neurons,
cerebellum, smooth muscle,
platelets
βγ-meATP ≥α,βmeATP ≈ 
ATP ≈ 2-MeSATP, BzATP, 
Ap4A
NF023, NF279, NF449, MRS2220, PPNDS, IP5I, RO1, RO
0437626, TNP-ATP, BBG, Suramin, PPADS
P2X1/2 — ATP, 2-MeSATP, α,βmeATP, 
BzATP
—
P2X1/4 — ATP, α,βmeATP  TNP-ATP, Suramin, PPADS
P2X1/5 Submucosal arterioles ATP, 2-MeSATP, α,βmeATP TNP-ATP, Suramin, PPADS
P2X2 Central nervous system (CNS)
tissue, smooth muscle, retina,
chromaffin cells, autonomic
and sensory ganglia
ATP ≥ ATPγS ≥ 2-MeSATP 
>> α,βmeATP  
PPADS, TNP-ATP, BBG, PSB-1011, Suramin,
PSB-1011,NF770, NF778
P2X2/3 Sensory neurons, sympathetic
ganglion cells, brain neurons
ATP, α,βmeATP, 2-MeSATP, 
BzATP
TNP-ATP, Suramin, PPADS, A317491, RO-3,
P2X2/5 Neurons ATP, BzATP, ATPγS TNP-ATP
P2X2/6 Respiratory neurons ATP, 2-MeSATP, αβmeATP  Suramin, PPADS
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Receptor Main distribution Agonists Antagonists
P2X3 Sensory neurons, some
sympathetic neurones
BzATP, 2-MeSATP ≥ ATP 
≥α,βmeATP ~ Ap4A
Suramin, PPADS, IP5I, TNP-ATP, A317491, RO-3, RO-4,
RO-5, RO-51, RO-85, MK-3901, AF219
P2X4 CNS, epithelia of ducted glands
and airways, smooth muscle of
bladder, gastrointestinal tract,
uterus, arteries, and fat cells
ATP, 2-MeSATP >
α,βmeATP  
TNP-ATP, BBG (weak antagonist), 5-BDBD, PSB-12062
P2X4/6 Hippocampal CA1 neurons ATP, 2-MeSATP,
α,βmeATP  
Suramin, PPADS
P2X5 Central neurons, bladder,
thymus, spinal cord, cardiac
muscle, skeletal muscle, skin,
eye, and epithelia
ATP, 2-MeSATP Suramin, PPADS
P2X6 Central nervous system tissue,
pinal cord
(Does not function as
homomultimer)
—
P2X7 CNS, peripheral nervous
system, pancreas, skin, the
immune system, and bone
BzATP > ATP-γ-S > ATP ≥ 
2-MeSATP > α,βmeATP 
KN62, BBG, A-438079, A-839977, A-740003, A-759029,
A-804598, AZ11645373, AZ10606120, CE-224535,
AZD9056
[Most of the data presented in this table are considered fully in the following papers (Burnstock 2009; Jarvis and Khakh 2009; Khakh and North
2012; Nawazish-i-Husain Syed and Kennedy 2012; Burnstock 2013; Burnstock 2014)].
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1.3.2.1 P2X1 subunit-containing receptors
The P2X1 receptor has been reported to be expressed at the mRNA or protein level
in dorsal horn spinal neurons, cerebellum, smooth muscle, platelets (Burnstock and
Knight 2004; Ashour, Atterbury-Thomas et al. 2006). It mediates muscle contraction,
and activation of platelets leading to prothrombotic phenotype (Oury, Kuijpers et al.
2003; Surprenant and North 2009). The heteromeric P2X1/5 receptor has been
observed in submucosal arterioles, and has a possible role in mediating excitatory
junction potentials (Surprenant, Schneider et al. 2000).
Agonists
P2X1 receptor activation can be elicited by αβmeATP at a half maximal effective 
concentration (EC50) of 0.3 μM, similar to that at the P2X3 receptor (0.8 μM) (Jarvis 
and Khakh 2009; Khakh and North 2012). Therefore, αβmeATP can be used to 
distinguish the P2X1 and P2X3 receptors from the other P2X receptors, but cannot
be used to uniquely define P2X1 (Jarvis and Khakh 2009; Khakh and North 2012).
Beta, gamma-methylene ATP (βγ-meATP) is equipotent to αβmeATP at P2X1, 
approximately 30-fold to 50-fold less potent at P2X3, and > 100-fold less potent at
P2X2, P2X4, P2X5 and P2X7, indicating βγ-meATP can be used as a selective 
agonist for P2X1 (North 2002; Gever, Cockayne et al. 2006). BzATP is also an
effective agonist at the P2X1 receptor with an EC50 of 0.003 μM when the 
receptor-mediated Ca2+ entry was measured, approximately 100-fold more potent
than αβmeATP (Bianchi, Lynch et al. 1999; Khakh and North 2012). Diadenosine 
polyphosphates such as Ap4A are also reported to be more selective agonists for
P2X1 over P2X2, P2X3 and P2X4 (Wildman, Brown et al. 1999).
To the date, the P2X1 receptor subunit has been reported to participate in the
formation of three heteromeric receptors: P2X1/2, P2X1/4 and P2X1/5 (Jarvis and
Khakh 2009). The P2X1/2 receptor is reported to be activated by ATP (EC50 ≈ 0.5 
μM), 2-MeSATP (EC50 ≈ 0.07 μM), αβmeATP (EC50 ≈ 0.1 μM) and BzATP (EC50 ≈ 
0.003 μM). The heteromeric P2X1/4 receptor can be activated by ATP (EC50 ≈ 
10μM) and αβmeATP (EC50 ≈ 10 μM). Similar to the P2X1 receptor, the 
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heteromeric P2X1/5 receptor can be evoked by ATP (EC50 ≈ 1 μM), 2-MeSATP 
(EC50 ≈ 1 μM) and αβmeATP (EC50 ≈ 3 μM). 
Antagonists
Several analogs of suramin (such as NF023, NF279 and NF449) are developed with
improved potency and selectivity at the P2X1 receptor (Jiang 2012). NF023 was
shown to have a half-maximal inhibitory concentration (IC50) of 210-240 nM, less
potent at the P2X2 (IC50 > 50 μM), P2X3 (9 < IC50 < 29 μM) and P2X4 (IC50 >> 100
μM) receptors (Soto, Lambrecht et al. 1999). NF279 inhibits the P2X1 receptors 
with an IC50 of 19-50 nM, and much less potent at the P2X2 (IC50 ≈ 0.8 μM), P2X3 
(IC50 ≈ 1.6 μM), P2X4 (IC50 > 300 μM) and P2X7 (IC50 ≈ 2.8 μM) receptors 
(Klapperstuck, Buttner et al. 2000; Rettinger, Schmalzing et al. 2000). NF449 has
the greater potency, with an IC50 of 0.3 nM (Kassack, Braun et al. 2004; Rettinger,
Braun et al. 2005). NF449 can inhibit the heteromeric P2X1/2 receptors with an IC50
of 0.7 nM.
Numerous PPADS analogs with increased potency and selectivity for the P2X
receptor have been identified, such as MRS2220, PPNDS, diinosine pentaphosphate
(IP5I) (Jacobson, Kim et al. 1998; King, Liu et al. 1999; Lambrecht, Rettinger et al.
2000; North 2002; Gever, Cockayne et al. 2006). Particularly, IP5I is highly potent
and selective for P2X1 with an IC50 of 3 nM, and much less potent for P2X3 (IC50 ≈ 
2.8 μM) and P2X2 (IC50 > 300 μM), and inactive at the other P2X receptors (King, 
Liu et al. 1999; Khakh and North 2012). Finally, RO-1 or RO-0437626 has been
described as a selective drug-like human P2X1 receptor antagonist with an IC50 of 3
μM in calcium entry assays, and > 30-fold less potent at the human P2X2 and P2X3 
receptors (IC50 > 100 μM) (Jaime-Figueroa, Greenhouse et al. 2005; Ford, Gever et 
al. 2006).
The P2X1 receptors are also inhibited by 2′,3′-O-(2,4,6-trinitrophenyl)-ATP 
(TNP-ATP) (IC50 ≈ 0.006 μM) and Brilliant blue G (BBG) (IC50 > 5 μM) (Khakh, 
Burnstock et al. 2001; North 2002). TNP-ATP is a highly potent antagonist for the
heteromeric P2X1/4 receptor with an IC50 of 0.5 μM, and the heteromeric P2X1/5 
receptor with an IC50 of 0.4 μM (Jarvis and Khakh 2009).   
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1.3.2.2 P2X2 subunit-containing receptors
The P2X2 receptor is expressed in the central nervous system (CNS), smooth
muscles, retina, chromaffin cells, autonomic and sensory ganglia (King, Housley et
al. 1998; Burnstock and Knight 2004; Studeny, Torabi et al. 2005; Puthussery and
Fletcher 2006). It has possible roles in mediating facilitation of synaptic
transmission in hippocampal interneurons (Khakh, Gittermann et al. 2003),
ventilatory responses to hypoxia in the carotid body (Rong, Gourine et al. 2003),
and proliferation of glial cells differentiated from P19 murine embryonic carcinoma
cells . The heteromeric P2X2/3 receptor is expressed in sensory neurons,
sympathetic ganglion cells, and they are necessary for the initiation of sensory
signalling in the pathways subserving taste, chemoreception, visceral distension, and
neuropathic pain (Dunn, Zhong et al. 2001; Jiang, Kim et al. 2003; McGaraughty,
Wismer et al. 2003; Surprenant and North 2009). The heteromeric P2X2/5 receptor
is expressed in peripheral and central neurons, and display functional properties
including pore dilatation, membrane blebbing, and phosphatidylserine exposure
(Compan, Ulmann et al. 2012). The heteromeric P2X2/6 receptor is expressed in
respiratory neurons in the brain (Schwindt, Trujillo et al. 2011).
Agonists
ATP, adenosine-5′-(γ-thio)-triphosphate (ATPγS) and 2-MeSATP are reported to be 
the agonists for the P2X2 receptor, while BzATP is a less potent and partial agonist
(Evans, Lewis et al. 1995; Bianchi, Lynch et al. 1999; Lynch, Touma et al. 1999).
αβmeATP, βγ-meATP, ADP, and UTP are inactive up to 100-300 μM (Evans, 
Lewis et al. 1995; Bianchi, Lynch et al. 1999; Lynch, Touma et al. 1999). The
agonists for the heteromeric P2X1/2 receptor are described in section 1.3.2.1. The
heteromeric P2X2/3 receptor is reported to be potently activated by ATP (EC50 ≈ 0.7 
μM), BzATP (EC50 ≈ 0.8 μM), 2-MeSATP (EC50 ≈ 1 μM), and αβmeATP (EC50 ≈ 5 
μM). While a recent study has showed that the P2X2 and P2X5 subunits interact to 
form a heteromeric P2X2/5 receptor activated by ATP (EC50 ≈ 12 μM), BzATP 
(EC50 ≈ 82 μM) and ATPγS (EC50 ≈ 22 μM) (Compan, Ulmann et al. 2012). The 
heteromeric P2X2/6 receptor is less sensitive to ATP (EC50 ≈ 30 μM), 2-MeSATP 
(EC50 ≈ 35 μM) and αβmeATP (EC50 > 100 μM) (Jarvis and Khakh 2009).   
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Antagonists
PPADS (IC50 ≈ 1 μM), TNP-ATP (IC50 ≈ 1 μM) and BBG (IC50 ≈ 1.4 μM) have 
similar potency of antagonizing ATP-evoked currents mediated by human or rat
P2X2 receptors, while suramin is less potent (IC50 ≈ 8-10 μM) than these antagonists 
(Evans, Lewis et al. 1995; Bianchi, Lynch et al. 1999; Khakh, Burnstock et al. 2001).
PSB-1011 has been identified to be a P2X2 antagonist with a high selectivity over
the P2X1, P2X3, P2X4 and P2X7 receptors (Baqi, Hausmann et al. 2011). Moreover,
NF770 and NF778 are potent P2X2 antagonists generated by structural modification
of suramin (Wolf, Rosefort et al. 2011). The heteromeric P2X2/3 receptor is very
potently blocked by TNP-ATP (IC50 ≈ 0.007 μM) as well as PPADS and suramin 
(Jarvis and Khakh 2009). The P2X2/3 receptors is also potently inhibited by
A-317491 with an IC50 of 0.1 μM (Jarvis, Burgard et al. 2002; Neelands, Burgard et 
al. 2003), and by RO-3 with an IC50 of ~ 2 μM (Jarvis and Khakh 2009). The 
heteromeric P2X2/5 receptor is potently inhibited by 1 μM TNP-ATP (Compan, 
Ulmann et al. 2012).
1.3.2.3 P2X3 subunit-containing receptors
The P2X3 receptor is exclusively expressed in sensory neurons and some
sympathetic neurones (Chen, Akopian et al. 1995; Lewis, Neidhart et al. 1995;
Bradbury, Burnstock et al. 1998), where it is involved in the control of bladder
function, taste, chemoreception and neuropathic pain (McGaraughty, Wismer et al.
2003; Burnstock 2006).
Agonists
The P2X3 receptor is highly sensitive to ATP (EC50 ≈ 0.5 μM, 2-MeSATP (EC50 ≈ 
0.3 μM) and αβmeATP (EC50 ≈ 0.8 μM) (Khakh and North 2012). BzATP is the 
most potent agonist for the P2X3 receptors, with an EC50 of 0.08 μM (Khakh and 
North 2012). Overall, ATP, 2-MeSATP, αβmeATP, BzATP, βγ-meATP and Ap4A 
have been reported to be less potent at the P2X3 receptor as compared to the P2X1
receptor (Khakh and North 2012). The heteromeric P2X2/3 receptor is described in
section 1.3.2.2.
- 23 -
Antagonists
Suramin, PPADS, IP5I and TNP-ATP are antagonists at the P2X3 receptor (Khakh
and North 2012). Particularly, TNP-ATP is a completive potent P2X3 antagonist
with an IC50 of 1 nM (Khakh and North 2012). A-317491 was the first competitive
and selective P2X3 receptor antagonist (IC50 ≈ 20 nM) with drug-like properties 
(Jarvis, Burgard et al. 2002; Neelands, Burgard et al. 2003).
Other potent drug-like P2X3 antagonists have been reported, including RO3 (Gever,
Cockayne et al. 2006), RO4 (or AF353) (Gever, Soto et al. 2010), RO5 (or AF-792)
(Kaan, Yip et al. 2010), RO-51 (Jahangir, Alam et al. 2009), RO-85
(Brotherton-Pleiss, Dillon et al. 2010), MK-3901 (Gum, Wakefield et al. 2012) and
AF-219 (Gum, Wakefield et al. 2012; Ochoa-Cortes, Linan-Rico et al. 2014).
Specially, AF-219 has an IC50 of 30 nM and has been advanced into clinical studies
(Ford 2012; Gum, Wakefield et al. 2012; Ford and Undem 2013; Ochoa-Cortes,
Linan-Rico et al. 2014).
1.3.2.4 P2X4 subunit-containing receptors
The P2X4 receptor has a wide distribution in the CNS, epithelia of ducted glands
and airways, smooth muscle of bladder, gastrointestinal tract, uterus, arteries, and fat
cells (Bo, Kim et al. 2003). It is engaged in the regulation of capillary diameter,
development of vascular inflammation and neuropathic pain (Coull, Beggs et al.
2005; Qureshi, Paramasivam et al. 2007). Mice lacking the P2X4 receptor are
hypertensive and have smaller-diameter arteries (Surprenant and North 2009). The
P2X4/6 receptor is expressed in hippocampal CA1 neurons (Khakh, Proctor et al.
1999).
Agonists
The homomeric P2X4 receptor is activated by ATP and 2-MeSATP with a similar
EC50 of ~ 10 μM, whereas αβmeATP and βγ-meATP are much less potent at the 
P2X4 receptor (Garcia-Guzman, Soto et al. 1997). The heteromeric P2X1/4 receptor
is described in section 1.3.2.1. The heteromeric P2X4/6 receptor can be activated by
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ATP (EC50 ≈ 6 μM), 2-MeSATP (EC50 ≈ 7 μM) and αβmeATP (EC50 ≈ 12 μM) 
(Jarvis and Khakh 2009).
Antagonists
The P2X4 receptor is inhibited by TNP-ATP (IC50 ≈ 15 μM) and BBG (IC50 ≈ 
3-10 μM), but insensitive to suramin and PPADS (Khakh, Burnstock et al. 2001; 
Gum, Wakefield et al. 2012; North and Jarvis 2013). 5-BDBD has been reported to
be a potent P2X4 antagonist that blocks the P2X4 receptor-mediated currents (IC50 ≈ 
0.50 μM) (Casati, Frascoli et al. 2011). Furthermore, PSB-12062 is reported as a 
potent and selective antagonist for the P2X4 receptor (IC50 ≈ 0.9-1.8 μM) and almost 
35-fold less potent at the P2X1, P2X2, P2X3, and P2X7 receptors
(Hernandez-Olmos, Abdelrahman et al. 2012). Suramin and PPADS are antagonists
at the P2X4/6 receptor (Khakh and North 2012).
1.3.2.5 P2X5 subunit-containing receptors
The P2X5 receptor is localized in neurons in the CNS, bladder, thymus, spinal cord,
cardiac muscle, skeletal muscle, skin, eye, and epithelia (Ryten, Dunn et al. 2002;
Burnstock and Knight 2004; Nawazish-i-Husain Syed and Kennedy 2012). In an in
vivo wound-healing study, the P2X5 receptor protein expression, as measured by
immunochemistry, was reported to be significantly increased in keratinocytes of the
regenerating epidermis (Greig, James et al. 2003). Particularly, the P2X5 receptor
expression was reported to be increased in migratory keratinocytes at the wound
edge, which indicates that the P2X5 receptor might be involved in cell migration.
Agonists and antagonists
The P2X5 receptor can be activated by ATP (EC50 ≈ 10 μM) and 2-MeSATP (EC50
≈ 10 μM), and blocked by suramin (IC50 ≈ 40 μM) and PPADS (IC50 ≈ 3 μM) (Gever, 
Cockayne et al. 2006; Khakh and North 2012). The heteromeric P2X1/5 and P2X2/5
receptors are described in section 1.3.2.1 and section 1.3.2.2, respectively.
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1.3.2.6 P2X6 subunit-containing receptors
The P2X6 protein is expressed in the CNS and spinal cord (Burnstock and Knight
2004), and is possibly involved in depolarization of medial habenula, medial
vestibular and locus coeruleus neurons (Edwards, Gibb et al. 1992; Chessell, Michel
et al. 1997; Sansum, Chessell et al. 1998). However, it is generally thought that the
P2X6 subunit is incapable of forming functional homomeric receptors (Gever,
Cockayne et al. 2006; Khakh and North 2012). However, the P2X6 subunit can
interact with other P2X subunits to form heteromeric P2X receptors including the
P2X2/6 and P2X4/6 receptors as described in section 1.3.2.2 and section 1.3.2.4,
respectively.
1.3.2.7 P2X7 receptor
The P2X7 receptor is present in CNS, peripheral nervous system (PNS), pancreas,
skin, the immune system, and bone (Collo, Neidhart et al. 1997; Ke, Qi et al. 2003;
Burnstock and Knight 2004; Burnstock 2011), but not neuronal cells (Sim, Young et
al. 2004). They are involved in the release of proinﬂammatory cytokines from 
macrophages and neuropathic chronic pain (Solle, Labasi et al. 2001; Chessell,
Hatcher et al. 2005; Surprenant and North 2009). Some studies also have shown that
the P2X7 receptor could promote cell proliferation, as shown in human
neuroblastoma cells (Raffaghello, Chiozzi et al. 2006), microglial cells (Bianco,
Ceruti et al. 2006; Monif, Reid et al. 2009; Sanz, Chiozzi et al. 2009), and mouse
Neuro-2a (N2a) neuroblastoma cells (Wu, Lin et al. 2009). Additionally, activation
of the P2X7 receptor in osteoblasts enhances bone formation (Panupinthu, Rogers et
al. 2008; Li, Meyer et al. 2009), whereas activation of the P2X7 receptor in
osteoclasts results in apoptosis and bone resorption (Korcok, Raimundo et al. 2004).
Agonists
Among the P2X receptors, the P2X7 receptor is least sensitive to activation by ATP
(EC50 ≈ 100 μM) and 2-MeSATP (EC50 ≈ 100 μM) (Gever, Cockayne et al. 2006; 
Khakh and North 2012). BzATP exhibits greater potency (EC50 ≈ 20 μM) than ATP, 
2-MeSATP, ATPγS (EC50 ≈ 20 μM) and αβmeATP (EC50 > 300 μM) (Gever, 
Cockayne et al. 2006; Jarvis and Khakh 2009; Khakh and North 2012), but it is
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worth pointing out BzATP is also a full or partial agonist at the P2X1, P2X2, P2X3
and P2X4 receptors as described above.
Antagonists
Earlier studies have identified several potent P2X7 antagonists, such as BBG (Jiang,
Mackenzie et al. 2000) and KN-62 (Gargett and Wiley 1997). These compounds
exhibit striking species differences, for example, BBG with IC50 of ~270 nM for the
human P2X7 receptor and IC50 of ~10 nM for the rat P2X7 receptor; KN-62 with an
IC50 of ~40-130 nM for the human P2X7 receptor and an IC50 of ~86 nM for the
rhesus macaque monkey P2X7 receptor (Bradley et al., 2011). Recently, a variety of
as drug-like, potent and selective P2X7 receptor antagonists have been developed
based on tetrazole/triazole (for example, A-438079 with an IC50 of ~126-500 nM,
A-839977 with an IC50 of ~20-150 nM, A-740003 with an IC50 of ~18-40 nM,
A-759029 with an IC50 of ~32-40 nM and A-804598 with an IC50 of ~9-11 nM),
cyclic imides (such as AZ11645373 with an IC50 of ~5-20 nM), adamantine
amides (such as AZ10606120 with an IC50 < 10 nM for human P2X7 receptors and >
10-1000 nM for rat P2X7 receptors) and 6-azauracil derivatives (such as CE-224535)
(Jiang 2012). To date, P2X7 antagonists AZD9056 and CE-224535 have been tested
in clinical trials (Guile, Alcaraz et al. 2009; Elsby, Fox et al. 2011; Keystone, Wang
et al. 2012; Stock, Bloom et al. 2012). AZD9056 is a potent (IC50 of 10-13 nM) and
high selective antagonist at the human P2X7 receptor (> 1000-fold) compared to the
other P2X receptor subtypes, but it has little affinity for the mouse or rat P2X7
receptors (Keystone, Wang et al. 2012). CE-224535 is also a potent antagonist with
an IC50 of 2-13 nM, and is highly selective for the P2X7 receptor at least 500-fold
relative to the P2X1 and P2Y1 receptors (Stock, Bloom et al. 2012). But both
compounds AZD9056 and CE-224535 failed to bring about significant therapeutic
benefits (Guile, Alcaraz et al. 2009; Elsby, Fox et al. 2011; Keystone, Wang et al.
2012; Stock, Bloom et al. 2012).
1.3.3 P2Y receptors
The P2Y receptors are widely expressed in neurons, muscle cells and many
non-excitable cells (cells lacking the ability to fire action potentials) (Burnstock,
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Fredholm et al. 2010). Eight mammalian P2Y receptors have been identified: P2Y1,
P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14. The P2Y receptor proteins
consist of 308 to 377 amino acid residues. They have seven transmembrane domains
(7TM) with short extracellular N and intracellular C termini as shown in Figure 1.2
(Webb, Simon et al. 1994; Khakh and North 2006).
In contrast to the P2X receptors at which ATP is the only physiological activator as
discussed above, the P2Y receptors are sensitive to activation by a variety of
nucleotides: ATP (P2Y1, P2Y2, P2Y11), ADP (P2Y1, P2Y12, P2Y13), UTP (P2Y2,
P2Y4), UDP (P2Y6, P2Y14) and UDP-glucose (P2Y14) (Burnstock 2006;
Burnstock 2009). The responses mediated by the P2Y receptors are usually longer
than those by the P2X receptors because they are coupled to G-proteins and involve
generation of second messengers. The P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11
receptors are coupled to Gq/11 proteins to activate PLC, which leads to hydrolysis of
phosphatidylinositol 4,5-bisphosphate (PIP2) and subsequent generation of IP3 and
1,2-diacylglycerol (DAG). Diffusible IP3 binds to the IP3 receptors (IP3R) in the
membrane of endoplasmic reticulum (ER) to cause Ca2+ release from the ER, as
shown in Figure 1.2 and Figure 1.4 (Berridge 1993; Fahrner, Muik et al. 2009). The
P2Y12, P2Y13, and P2Y14 are coupled to Gi to inhibit adenylyl cyclase (AC) to
reduce the intracellular levels of cyclic adenosine monophosphate (cAMP) (Khakh
and North 2006; Park, Hoover et al. 2009; Burnstock, Fredholm et al. 2010). The
P2Y11 receptor is also coupled to Gs to stimulate AC to increase the cAMP levels
(Torres, Zambon et al. 2002).
Like the P2X receptors, the P2Y receptors are also inhibited by suramin (P2Y1,
P2Y2, P2Y6, P2Y11, P2Y12, P2Y13) and PPADS (P2Y1, P2Y4, P2Y6, P2Y13)
(von Kugelgen 2006). The distribution, agonists and antagonists of the P2Y
receptors are summarized in Table 1.3 and are discussed below.
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Table 1.3 Main distribution, agonists and antagonists of P2Y receptors.
Receptor Main distribution Agonists Antagonists
P2Y1 Brain, epithelial and endothelial
cells, platelets, immune cells,
osteoclasts
MRS2365 > 2-MeSADP >>
ADP > ATP
MRS2500 > MRS2279 > MRS2179
P2Y2 Neurons, smooth muscle cells,
epithelial and endothelial cells,
osteoblasts, breast cancer cells
2-Thio-UTP > UTP, MRS2698
≥ ATP, INS 365 > INS 37217, 
Ap4A > MRS 2768
AR-C126313 > suramin > Reactive Blue 2, PSB-716
P2Y4 Intestine, epithelial cells,
placenta, spleen and thymus
MRS4062, UTP ≥ ATP  ATP (human) > Reactive Blue 2 > suramin
P2Y6 Airway and intestinal epithelial
cells, placenta, T cells, thymus
MRS2693 > UDPβS, 
PBS0474, UDP > UTP >>
ATP
MRS2578 > Reactive Blue 2, PPADS
P2Y11 Macrophage, neurons, smooth
muscle cells, spleen, intestine,
granulocytes
ATPγS > AR-C67085 > 
BzATP ≥ ATP, NF546  
NF157 > suramin > Reactive Blue 2
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Receptor Main distribution Agonists Antagonists
P2Y12 Platelets, glial cells, smooth
muscle cells, endothelial cells,
and chromaffin cells
ADP ~ 2-MeSADP > ATP AR-C69931MX > AR-C67085, AZD6140, INS49266,
INS50589
P2Y13 Spleen, placenta, brain, lymph
nodes, bone marrow,
osteoblasts, monocytes
2-MeSADP, ADP > ATP >
2-MeSATP
AR-C69931MX > AR-C67085 > MRS2211
P2Y14 Placenta, brain regions, adipose
tissue, stomach, intestine, bone
marrow, immune system
MRS2802, MRS2690 >
UDP-glucose ≥ 
UDP-galactose,
UDP-glucosamine
UDP
[Modified and updated from (von Kugelgen 2006; Burnstock 2009; von Kugelgen and Harden 2011; Burnstock 2013)]
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1.3.3.1 P2Y1 receptor
The P2Y1 expression has been detected at the mRNA level in various tissues and
cells, including brain, epithelial and endothelial cells, platelets, immune cells,
osteoclasts (Burnstock 2013). Activation of the P2Y1 receptor by ADP stimulates
osteoclast activity and bone resorption (Hoebertz, Arnett et al. 2003).
Agonists and antagonists
ATP is a partial agonist for the P2Y1 receptor and ADP is the most potent
physiological agonist (EC50 ≈ 7.9 μM) (Bodor, Waldo et al. 2004), and UTP, UDP, 
CTP, and GTP are all inactive. Moreover, 2-MeSADP is more potent at the P2Y1
receptor (EC50 ≈ 6.3 nM) than ADP. Particularly, MRS2365 (the N-methanocarba 
analogue of 2-MeSADP) represents a highly potent and selective agonist for the
P2Y1 receptor with an EC50 of 0.4 nM, but exhibits no activity at the P2Y12 and
only very low agonist activity at the P2Y13 receptor (at concentrations up to 1μM) 
(Chhatriwala, Ravi et al. 2004). MRS2179 (IC50 ≈ 0.3 μM) (Nandanan, Camaioni et 
al. 1999), MRS2279 (IC50 ≈ 7.9 nM) (Kim, Ohno et al. 2003), and MRS2500 (IC50 ≈ 
1 nM) (Kim, Ohno et al. 2003) represent the potent and selective antagonists at the
P2Y1 receptor.
1.3.3.2 P2Y2 receptor
The P2Y2 receptor is expressed in many cells including neurons, smooth muscle
cells, epithelial and endothelial cells, osteoblasts, breast cancer cells (Hoebertz,
Arnett et al. 2003; Burnstock 2009; Burnstock 2013; Chadet, Jelassi et al. 2014).
Activation of the P2Y2 receptors in osteoblasts by ATP and UTP inhibits bone
growth and mineralization (Hoebertz, Arnett et al. 2003). It is also reported that
activation of the P2Y2 receptor increases MCF-7 breast cancer cells migration
(Chadet, Jelassi et al. 2014).
Agonists and antagonists
ATP (EC50 ≈ 79.4 nM), UTP (EC50 ≈ 7.9 nM), diadenosine tetraphosphate (Ap4A, 
EC50 ≈ 0.79 μM) and -thiophosphate (UTPS, EC50 ≈ 0.25 μM) are full agonists at 
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the P2Y2 receptor, whereas ADP and UDP are much less potent (von Kugelgen
2006; Burnstock 2009; von Kugelgen and Harden 2011). To date, there are several
potent P2Y2 receptor agonists, such as MRS2698 (EC50 ≈ 8 nM) (Ivanov, Ko et al. 
2007) and selective agonists, such as MRS2768 (EC50 ≈ 1.89 μM) (Ko, Carter et al. 
2008). 2-ThioUTP is a potent and selective agonist at the human P2Y2 (hP2Y2)
receptor with an EC50 of 0.035 μM, and it is much less potent at the hP2Y4 and 
hP2Y6 receptors with an EC50 of 0.35 and 1.5 μM, respectively (El-Tayeb, Qi et al. 
2006; Ko, Carter et al. 2008). Additionally, Up4U (INS365, Diquafosol, EC50 ≈ 0.1 
μM) and dCp4U (INS37217, Denufosol, EC50 ≈ 0.22 μM) are drug-like agonists for 
the P2Y2 receptor. The P2Y2 receptor-mediated responses can be blocked by
suramin (IC50 ≈ 50.0 μM), but not by PPADS (von Kugelgen 2006; Burnstock 2009; 
von Kugelgen and Harden 2011). AR-C126313 (IC50 ≈ 1 μM) (Jacobson, Costanzi 
et al. 2004), Reactive Blue 2 (IC50 < ~100 μM) and PSB-716 (IC50 ≈ 10 μM) have 
been reported to be effective antagonists for the P2Y2 receptor (Burnstock 2009;
Jacobson, Balasubramanian et al. 2012; Burnstock 2014).
1.3.3.3 P2Y4 receptor
The P2Y4 receptor is distributed in intestine, epithelial cells, placenta, spleen and
thymus (Burnstock 2009; Burnstock 2013). The P2Y4 receptor has a role in
mediating the regulation of chloride secretion by UTP in the jejuna epithelium
(Robaye, Ghanem et al. 2003; Burnstock, Fredholm et al. 2010).
Agonists and antagonists
UTP is the most potent native agonist at the P2Y4 receptor (EC50 ≈ 2.5 μM for 
human), while ADP and UDP are inactive (von Kugelgen 2006; Burnstock 2009;
von Kugelgen and Harden 2011). MRS4062 is a potent and selective agonist at the
P2Y4 receptor with an EC50 of 23 nM, while it inhibits at the P2Y2 and P2Y6
receptors with an IC50 of 640 and 740 nM, respectively (Jacobson, Balasubramanian
et al. 2012). There is no selective antagonist for the P2Y4 receptor. ATP acts as an
antagonist at the human (IC50 ≈ 39.8 μM), but not the rat, P2Y4 receptors. Suramin 
is a weak P2Y4 receptor antagonist (IC50 < 100 μM). Reactive Blue 2 is a potent 
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antagonist for the rat P2Y4 receptor, but only partially blocks the human P2Y4
receptor (IC50 < 100 μM) (Burnstock 2009; Burnstock 2013).    
1.3.3.4 P2Y6 receptor
The P2Y6 receptor is expressed in airway and intestinal epithelial cells, placenta, T
cells and thymus (Burnstock 2009; Burnstock 2013). It is involved in UDP-induced
release of IL-6 and inflammatory protein-2 from macrophages, and production of
inositol phosphate (Robaye, Ghanem et al. 2003; Burnstock, Fredholm et al. 2010).
Agonists and antagonists
ATP, ADP and their 2-methylthio derivatives are inactive at the P2Y6 receptor.
UDP and UTP activate the P2Y6 receptor; UDP is approximately 100-fold more
potent (EC50 ≈ 0.32 μM) than UTP (Nicholas, Lazarowski et al. 1996; von Kugelgen 
2006; von Kugelgen and Harden 2011). Uridine β-thiodiphosphate (UDPβS) (EC50 ≈ 
0.05 μM) and Up3U (EC50 ≈ 0.25 μM) are more metabolically stable and selective 
agonists at the P2Y6 receptor than UDP (Hou, Harden et al. 2002; Ivanov, Ko et al.
2007). INS48823 is also a potent agonist with an EC50 of ~125 nM (Korcok,
Raimundo et al. 2005). MRS2693 (5-iodo-UDP) is a selective agonist with an EC50
of ~15 nM (Besada, Shin et al. 2006). PSB0474 is a potent and selective agonist
with an EC50 of 70 nM at the P2Y6 receptor and much less potent at the P2Y2 (EC50 >
1 μM) and P2Y4 receptors (EC50 > 10 μM) (El-Tayeb, Qi et al. 2006).  
P2Y6 receptor-mediated responses can be inhibited by Reactive Blue 2 and PPADS
(von Kugelgen 2006; Burnstock 2009; von Kugelgen and Harden 2011). To date,
MRS2578 has been shown to be a non-competitive antagonist (IC50 ≈ 39.8 nM) for 
the P2Y6 receptor (Mamedova, Joshi et al. 2004).
1.3.3.5 P2Y11 receptor
The P2Y11 receptor is expressed in macrophage, neurons, smooth muscle cells,
spleen, intestine and granulocytes (Burnstock 2013; Sakaki, Tsukimoto et al. 2013)
and is involved in macrophage activation (Sakaki, Tsukimoto et al. 2013),
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neuropathic pain (Barragan-Iglesias, Pineda-Farias et al. 2014), neutrophil apoptosis
(Vaughan, Stokes et al. 2007), and relaxations of smooth muscle cells (King and
Townsend-Nicholson 2008).
Agonists and antagonists
ATP is the native agonist at the P2Y11 receptor (EC50 ≈ 15.8 μM for human P2Y11). 
ATPS and BzATP are more potent agonists than ATP, with EC50 of ~ 3.1μM and 
~7.9 μM, respectively (Communi, Robaye et al. 1999). AR-C67085 is a potent 
agonist at the P2Y11 receptor with EC50 of ~8.9 μM (Communi, Robaye et al. 1999), 
but acts as an antagonist at the P2Y12 receptor) (Burnstock 2009; Burnstock 2013).
NF546 has been shown to be a selective agonist for the P2Y11 receptor (EC50 ≈ 53.7 
μM) over the other P2Y receptors, including P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12 
receptors (Meis, Hamacher et al. 2010). P2Y11receptor-mediated responses can be
blocked by Reactive Blue 2 (IC50 < ~100 μM), but not by PPADS (Nicholas, 
Lazarowski et al. 1996; von Kugelgen 2006; von Kugelgen and Harden 2011).
Suramin acts as a more potent antagonist at the human P2Y11 receptor (IC50 ≈ 15.8 
μM) than the human P2Y1 receptor (von Kugelgen 2006; Burnstock 2009; von 
Kugelgen and Harden 2011). NF157, derived from suramin, has been reported to be
a potent and selective antagonist for the P2Y11 receptor (IC50 ≈ 0.46 μM) (Ullmann, 
Meis et al. 2005).
1.3.3.6 P2Y12 receptor
The P2Y12 receptor is present in platelets, glial cells, smooth muscle cells,
endothelial cells, and chromaffin cells (Burnstock 2009; Burnstock 2013). They are
involved in the inhibition of platelet aggregation by ADP, resistance to arterial
thrombosis, and prolonged bleeding time (Burnstock 2009; Burnstock, Fredholm et al.
2010). Moreover, an in vivo study showed that the P2Y12 receptor activated by ADP
stimulates migration of microglial cells to the injury area at the early stages of the
response to local CNS injury (Sharon, Levesque et al. 2006).
Agonists and antagonists
ADP is the native agonist at the P2Y12 receptor (EC50 ≈ 63 nM for human P2Y12), 
at which ATP is inactive. 2-MeSADP is also a potent agonist with an EC50 of ~ 12.6
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nM, similar to ADP. Currently, AR-C69931MX and AR-C67085 are two potent
drug-like antagonists for the P2Y12 receptor with an IC50 of ~ 0.4 nM and ~30 μM, 
respectively (Springthorpe, Bailey et al. 2007). AZD6140 is a potent antagonist at
P2Y12 receptor with an IC50 of ~ 12.6 nM (Springthorpe, Bailey et al. 2007; Ye,
Chen et al. 2008). Other antagonists of the P2Y12 receptor include INS49266 (an
ADP derivative with an IC50 of ~ 52 nM) and INS50589 (an AMP derivative with an
IC50 of ~ 11 nM) (Douglass, deCamp et al. 2008).
1.3.3.7 P2Y13 receptor
The P2Y13 receptor is distributed in spleen, placenta, brain, lymph nodes, bone
marrow, osteoblasts, and monocytes (Burnstock 2009; Burnstock, Fredholm et al.
2010). It is involved in mediating osteogenic responses to mechanical stimulation by
regulating ATP metabolism in osteoblasts (Wang, Rumney et al. 2013). Moreover,
the P2Y13 receptor contributes to the balance of osteoblast and adipocytes
differentiation of BM-MSCs (Biver, Wang et al. 2013).
Agonists and antagonists
The P2Y13 receptor can be activated by ADP, 2-MeSADP and ATP, with EC50 of
~12.6 nM, 12.6 nM and 0.25 μM, respectively at the human P2Y13 receptor for 
human (Jacobson and Boeynaems 2010; Burnstock 2014). ADP is more potent than
ATP, and 3-5 folds more potent than 2-MeSADP at the rat P2Y13 receptor. The
P2Y13 receptor can be inhibited by ARC69931MX (IC50 ≈ 4.0 nM) and ARC67085 
(IC50 ≈ 0.2 μM). A derivative of PPADS, MRS2211, has been shown to be a 
selective antagonist for the P2Y13 receptor with an IC50 of ~1.1 μM (> 20-fold more 
selective over the P2Y1 and P2Y12 receptors) (Kim, Lee et al. 2005).
1.3.3.8 P2Y14 receptor
The P2Y14 receptor is widely expressed in placenta, brain regions, adipose tissue,
stomach, intestine, bone marrow, and immune system (Lee, Cheng et al. 2003;
Moore, Murdock et al. 2003; Burnstock 2009; Kobayashi, Yamanaka et al. 2012;
Kobayashi, Yamanaka et al. 2013). It is involved in the recruitment of macrophages
to liver, local inflammation, induction of insulin resistance, neuropathic pain and
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chemoattractant functions (Lee, Cheng et al. 2003; Moore, Murdock et al. 2003;
Burnstock 2009; Kobayashi, Yamanaka et al. 2012; Kobayashi, Yamanaka et al.
2013).
Agonists and antagonists
The P2Y14 receptor can be activated by UDP-glucose, UDP-galactose,
UDP-glucuronic acid, and UDP-N-acetylglucosamine (Burnstock 2009; Burnstock,
Fredholm et al. 2010). MRS2690 is a 7-fold more potent agonist (EC50 ≈ 0.049 μM) 
at the P2Y14 receptor than UDP-glucose (EC50 ≈ 0.35 μM), and is inactive at the 
P2Y2 receptor (Ko, Fricks et al. 2007). Moreover, MRS2802 is shown to fully
activate the human P2Y14 receptor with an EC50 of 0.063 μM, but it is inactive at 
the P2Y6 receptor (Das, Ko et al. 2010). To the date, a study has shown that UDP
acts an antagonist at the P2Y14 receptor with an IC50 of ~50 nM (Fricks, Maddileti
et al. 2008).
1.3.4 Store-operated calcium channels
As discussed above in section 1.3.3, activation of several P2Y receptors leads to
cause Ca2+ release from the ER store (Figure 1.4) (Berridge 1993; Berridge,
Bootman et al. 2003). Subsequently, the depletion of the Ca2+ store activates
Ca2+ entry through the plasma membrane, a process commonly referred to as
store-operated Ca2+ (SOC) entry (Lewis and Cahalan 1989; Zweifach and Lewis
1993). While, the Ca2+ currents passing through the plasma membrane via the SOC
channels is well characterized electrophysiologically, termed Ca2+ release-activated
Ca2+ (CRAC) currents (Hoth and Penner 1992; Hoth and Penner 1993).
Experimentally, the depletion of the ER Ca2+ store can be evoked by reagents such
as thapsigargin (TG, a sarco/endoplasmic Ca2+-ATPase (SERCA) pump inhibitor),
ionomycin (a Ca2+ ionophore), EGTA and TPEN (Ca2+ chelators) (Parekh and
Putney 2005; Lewis 2011).
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Figure 1.3 The structural features of Stim1 and Orai1.
(A) Stim1 is a single-transmembrane protein. The N terminus is directed to the
lumen of the ER and contains an EF-hand domain, a Ca2+ sensor, followed by a
sterile α-motif (SAM, a protein interaction domain) and the transmembrane (TM) 
domain. In the C terminus, within the coiled-coil domain, there is a Stim-Orai
activating region (SOAR) involved in activation of the Orai1 channels, followed by
a fast inactivation (FI) domain, a regulatory domain (potential phosphorylation sites
that regulate Stim1 function) and a lysine-rich domain (K-rich, that may contribute
to Stim1 localization in near-membrane puncta (see Figure1.4) by interacting with
the plasma membrane acidic lipids). (B) The single Orai1 channel subunit contains
four transmembrane domains (TM1-4) with the α-helical TM1 lining the 
ion-conducting pore. An arginine/lysine-rich (R/K-rich) region in the N-terminus
and the coiled-coil in the C-terminus are involved in coupling Orai1 to Stim1
(Putney 2010; Lewis 2011).
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Figure 1.4 Store-operated Ca2+ entry (SOCE) pathways.
As depicted, SOCE is mediated by multiple sequential steps: (1) Binding of a variety
of physiological agonists to their specific G-protein-coupled receptors results in
activation of phospholipase C (PLC) leading to generation of the second messengers
IP3, and 1,2-diacylglycerol (DAG). (2) Diffusible IP3 binds to the IP3 receptors in
the membrane of the ER to cause Ca2+ release and subsequent store depletion (SD).
(3) The Ca2+ store depletion is sensed by the ER-resident Stim1 proteins. (4)
Dissociation of Ca2+ from Stim1 results in Stim1 oligomerization into punctate
structures and translocation to the junctional ER regions in close apposition with the
plasma membrane. (5) Physical interactions between the C-terminus of Stim1 and C-
and N-termini of plasma membrane Orai1 protein results in Ca2+ entry.
Ca2+-permeable TRPC channels have been also proposed to act as SOC channels
and are regulated by electrostatic interactions with Stim1 (Trebak, Zhang et al.
2013).
- 38 -
The SOCE pathway has been known for decades but our understanding at a
molecular level remained elusive until the identification of ER Ca2+-sensing protein
Stim1 (stromal interaction molecule 1) in 2005 (Liou, Kim et al. 2005; Zhang, Yu et
al. 2005) and plasma membrane protein Orai1 or Ca2+ release-activated Ca2+
modulator 1 (CRACM1) in 2006 (Feske, Prakriya et al. 2005; Feske, Gwack et al.
2006). So far, the ER Ca2+-sensing protein family comprises Stim1 and Stim2
(Dziadek and Johnstone 2007), while the Orai protein family consists of Orai1,
Orai2 and Orai3 (Yeromin, Zhang et al. 2006; Dziadek and Johnstone 2007). The
Stim proteins are single transmembrane proteins (Fig. 1.3A) that are localized in the
ER; their N-termini are directed to the lumen of the ER and contain an EF-hand Ca2+
binding domain. The Orai proteins consist of four transmembrane domains
(TM1–TM4) with both C and N-termini residing in the cytoplasm (Fig.1.3B)
(Fahrner, Muik et al. 2009). As illustrated in Figure 1.4, the depletion of the ER
Ca2+ store causes Ca2+ to dissociate from Stim1, which results in Stim1 aggregation
and movement to the closely apposed ER-plasma membrane junctions to physically
interact with and thereby activate the Orai1 channels that mediate Ca2+ entry
(Fahrner, Muik et al. 2009).
Besides the Orai proteins as the primary SOCs, a number of earlier studies suggested
that the canonical transient receptor potential (TRPC) channels also act as SOC
channels (Yuan, Kim et al. 2009; Lee, Yuan et al. 2010; Yuan, Lee et al. 2012).
TRPC channels belong to the mammalian transient receptor potential (TRP) channel
family with 28 members that contain other 5 subfamilies: TRPA (ankyrin-like),
TRPM (melastatin), TRPML (mucolipin), TRPP (polycystin), and TRPV (vanilloid)
(Ramsey, Delling et al. 2006). They are non-selective cation channels and are
composed of six transmembrane domains (S1-S6) with a pore loop between the S5
and S6 (Ramsey, Delling et al. 2006). The TRP channels play an important role in
mediating vision, taste, olfaction, hearing, touch and temperature (Venkatachalam
and Montell 2007; Latorre, Zaelzer et al. 2009; Huynh, Cohen et al. 2014; Premkumar
2014). The TRPC channels are Ca2+-permeable and activated though PLC-coupled
receptor activation, which indicates their possible roles in mediating the SOCE
pathway (Ramsey, Delling et al. 2006; Trebak, Zhang et al. 2013). There is evidence
to suggest that the TRPC1 (Ambudkar, Ong et al. 2007; Yuan, Zeng et al. 2007;
Cheng, Liu et al. 2008; Zeng, Yuan et al. 2008; Yuan, Kim et al. 2009; Dragoni,
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Laforenza et al. 2014), TRPC4 (Zeng, Yuan et al. 2008; Sours-Brothers, Ding et al.
2009) and TRPC5 (Ma, Peng et al. 2008) channels interact with Stim1. While the
TRPC3 and TRPC6 do not interact directly with Stim1 (Ambudkar, Ong et al. 2007;
Yuan, Zeng et al. 2007; Cheng, Liu et al. 2008; Zeng, Yuan et al. 2008; Yuan, Kim
et al. 2009; Dragoni, Laforenza et al. 2014), they are regulated by Stim1 due to
Stim1-dependent heteromultimerization of TRPC1/TRPC3 and TRPC4/TRPC6
(Ambudkar, Ong et al. 2007; Yuan, Zeng et al. 2007; Cheng, Liu et al. 2008; Zeng,
Yuan et al. 2008; Yuan, Kim et al. 2009; Dragoni, Laforenza et al. 2014). Recent
studies have further shown that Stim1 facilitates formation of the Orai1/TRPC1
complex to mediate the SOC activity (Cheng, Liu et al. 2008; Liao, Erxleben et al.
2008; Lee, Yuan et al. 2010). Moreover, it has been reported that knockdown of
TRPC1 by short hairpin RNA (shRNA) (Li, Chen et al. 2012) or TRPC5 by small
interfering RNA (siRNA) (Shin, Hong et al. 2010) reduced the SOCE in neural
progenitor cells (NPCs), indicating TRPC1 or TRPC5 as a molecular constituent of
the SOC channels. Despite these studies, whether TRPC channels are involved in the
SOCE is still debated (DeHaven, Jones et al. 2009; Lewis 2011).
It is now clear that the SOC channels not only mediate replenishment of the ER
Ca2+ stores but also are coupled to downstream signalling pathways and
transcription factors including c-fos and Nuclear Factor for Activated T cells (NFAT)
(Trebak, Zhang et al. 2013; Xie, Xu et al. 2014). Described below are the main
distribution and function, activators and inhibitors of the SOC channels.
1.3.4.1 Distribution and function
The SOC channels are now known to be present in almost all cells, including
neurons, skeletal muscles and non-excitable cells (Parekh and Putney 2005; Lewis
2011). Recent studies have revealed that Stim and Orai play important roles in the
immune system, skeletal muscles, platelets, sweat glands, teeth and breast
cancer cells (Lewis 2011; Trebak, Zhang et al. 2013). For example, previous studies
reported that Stim1 and Orai1 were involved in cell migration and metastasis of
breast cancer cells (Yang, Zhang et al. 2009; Hu, Qin et al. 2011). Orai3
channel-mediated SOCE has been also recently shown to be expressed in estrogen
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receptor α-expressing (ERα(+)) breast cancer cells and to mediate cell tumorigenesis 
(Motiani, Zhang et al. 2013).
1.3.4.2 Activation
As mentioned above, the SOC channels are activated following the Ca2+ store
depletion by activation of the IP3 receptors, blockade of the SERCA pumps (e.g.
TG, cyclopiazonic acid (CPA)) and use of a Ca2+ ionophore (e.g. ionomycin)
(Putney 2010; Lewis 2011). Experimentally, 2-aminoethyldiphenyl borinate
(2-APB) is widely considered as a small-molecular-weight activator for the SOC
channels (DeHaven, Smyth et al. 2008; Putney 2010; Lewis 2011). 2-APB at low
concentrations (3-20 μM) potentiates, but at high concentrations (≥30 μM) inhibits 
TG-mediated SOCE (DeHaven, Smyth et al. 2008; Putney 2010). Moreover, 2-APB
is potent in activating the Orai1 channel at concentrations less than or equal to 20
μM in cells co-expressing Orai1 and Stim1, and less potent in activating the Orai2 
channel in cells co-expressing Orai2 and Stim1 (Lis, Peinelt et al. 2007; DeHaven,
Smyth et al. 2008). Interestingly, 2-APB at higher concentrations (> 50 μM) can 
evoke sustained currents in cells co-expressing Orai3 and Stim1 (Lis, Peinelt et al.
2007; DeHaven, Smyth et al. 2008). Furthermore, 2-APB can directly activate Orai3
without store depletion or co-expression of Stim1 (Lis, Peinelt et al. 2007; DeHaven,
Smyth et al. 2008; Schindl, Bergsmann et al. 2008; Zhang, Kozak et al. 2008).
Currently, one direct activator of the SOC channels is a peptide derived from the
Orai-interacting domain of Stim1 (Putney 2010), which directly forms punctuate
structures that move to the ER-plasma membrane junctions and activate the Orai
channels without depletion of the Ca2+ store (Park, Hoover et al. 2009).
1.3.4.3 Inhibition
Experimentally, the SOC channels can be inhibited by La3+ and Gd3+ (Putney 2010;
Dragoni, Laforenza et al. 2014). But, La3+ can also block voltage-gated sodium
channels and Gd3+ is well known as an inhibitor of mechanosensitive ion channels
(Tanaka, Tamba et al. 2002). Up to date, a number of agents (such as BTP-2, 2-APB,
DPB162-AE, DPB163-AE, Synta66) are reported to block the SOC channels. BTP2
(YM-58483) has been shown to block the SOC channels with an IC50 of ~10 nM,
and displays ~31-fold greater selectivity over the voltage-dependent Ca2+ channels
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(Zitt, Strauss et al. 2004; Ohga, Takezawa et al. 2008). Previous studies showed that
2-APB inhibited puncta formation of Stim1 at the plasma membrane, and
subsequently blocked the SOC channels (DeHaven, Smyth et al. 2008; Peinelt, Lis
et al. 2008). Additionally, 2-APB has been also reported to inhibit Orai1- and
Orai2-mediated Ca2+ entry at high concentrations (≥ 50 μM) (Lis, Peinelt et al. 2007; 
DeHaven, Smyth et al. 2008). Two 2-APB analogues, DPB162-AE and
DPB163-AE, have recently been reported; they are more potent and selective
inhibitors for the Orai1 and Orai2 channels as compared to 2-APB (Goto, Suzuki et
al. 2010). Synta66 (GSK1349571A) has been reported as a potent inhibitor of
TG-induced SOCE (Li, Cubbon et al. 2011; Li, McKeown et al. 2011).
1.4 Extracellular ATP-evoked Ca2+ Signalling in Stem Cells
Several studies have shown that stem cell types release ATP constitutively, such as
embryonic stem cells, hematopoietic stem cells, BM-MSCs, AT-MSCs, and
DP-MSCs (Coppi, Pugliese et al. 2007; Burnstock and Ulrich 2011; Sun, Junger et
al. 2013). Furthermore, it has been proposed that ATP is released via
hemi-gap-junction channels in hBM-MSCs (Kawano, Otsu et al. 2006).
As described below, studies have provided increasing evidence to support the
expression of the P2X, P2Y and SOC channels in stem cells. There is also emergent
evidence to suggest the importance of ATP-induced purinergic signalling in stem
cell functions (Coppi, Pugliese et al. 2007; Pedata, Melani et al. 2007; Burnstock
and Ulrich 2011). A better understanding of ATP-induced purinergic signalling is
interesting and potentially important in facilitating usage of stem cells for cell
therapies and tissue regeneration.
1.4.1 Expression and function of the P2X receptors
Studies using RT-PCR, Western blotting and Ca2+ imaging show the expression of
P2X1, P2X2, P2X3, P2X4, P2X6 and P2X7 receptors in undifferentiated pluripotent
P19 murine embryonic carcinoma cells (Resende, Majumder et al. 2007; Resende,
Britto et al. 2008; Yuahasi, Demasi et al. 2012). Additionally, the results from Ca2+
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imaging suggests that P2X4 receptor is the major receptor responsible for
ATP-induced Ca2+ entry in undifferentiated P19 cells (Resende, Britto et al. 2008).
RT-PCR analysis showed that all P2X receptors were expressed in human CD34+
HSCs (Lemoli, Ferrari et al. 2004). The protein expression of P2X7 receptor in
human CD34+ HSCs was confirmed by Western blotting (Lemoli, Ferrari et al.
2004).
Expression of the P2X receptors in MSCs from several tissues (such as bone marrow,
adipose tissue, skin biopsies) has been examined in recent studies. It has been shown
that ATP-induced inward currents in BM-MSCs using patch-clamp recording
(Coppi, Pugliese et al. 2007). It was also demonstrated that ATP increased
intracellular Ca2+ levels in BM-MSCs (Ichikawa and Gemba 2009). More recent
studies have reported that mRNAs for all the P2X receptors except P2X2 are
expressed in BM-MSCs using RT-PCR (Ferrari, Gulinelli et al. 2011). In particular,
it has been further demonstrated by Western blotting that the protein expression of
P2X1, P2X4 and P2X7 receptors in BM-MSCs (Ferrari, Gulinelli et al. 2011; Sun,
Junger et al. 2013). Up to date, the expression of the P2X receptors in dental pulp
MSCs is still unknown, which will be one of the objectives of my study.
1.4.2 Roles of the P2X receptors
To date, a number of in vitro studies have shown that the P2X receptors play
important roles in stem cell proliferation, migration, differentiation (Burnstock and
Ulrich 2011; Glaser, Cappellari et al. 2012; Ulrich, Abbracchio et al. 2012; Scarfi
2014). The main proposed functional roles of ATP-sensitive P2 purinergic receptors
in stem cells are summarized in Table 1.4, and will be discussed further in the next
section.
1.4.2.1 Proliferation
A previous study demonstrated that ATP (10 μM) decreased by about 9% 
hBM-MSC proliferation using an Automated Coulter Counter (Coppi, Pugliese et al.
2007). In agreement, another study showed that treatment with ATP (1 mM) induced
down-regulation of the genes required for cell proliferation in hBM-MSCs using
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Affymetrix HG-U133 Plus 2 GeneChip array, and inhibited cell proliferation
(Ferrari, Gulinelli et al. 2011).
It has been reported that stimulation of murine bone marrow-derived hematopoietic
stem cells/progenitor cells with ATP at high concentrations (>1 mM) inhibited cell
growth by driving cell death through the P2X7 receptors (Yoon, Lee et al. 2007).
However, an early study showed using the 5-bromo-2-deoxyuridine (BrdU)
incorporation assay that ATP (100 μM) up-regulated cell proliferation of P19 
embryonic carcinoma cells, which was inhibited by PPADS (10 μM) (Resende, 
Britto et al. 2008). Similar results were reported by a more recent study, cell
proliferation of mouse embryonic stem cells was inhibited by the specific P2X7
inhibitors KN62 (10 μM) and A438079 (1 μM) (Glaser, de Oliveira et al. 2014). 
Therefore, studies suggest that the P2X7 receptor might be involved in the
regulation of the stem cell proliferation by ATP, with the effects being
concentration-dependent.
1.4.2.2 Migration
There is evidence to suggest that the P2X receptors, such as P2X5, are involved in
the modulation of cell migration (Greig, James et al. 2003). A recent study using
Affymetrix HG-U133 Plus 2 GeneChip array has shown that genes required for cell
migration were up-regulated in hBM-MSCs after treatment with ATP (1 mM)
(Ferrari, Gulinelli et al. 2011). Moreover, ATP (1 mM) significantly enhanced cell
migration of hBM-MSCs using a transwell assay. However, whether the P2X
receptors are involved in ATP-induced BM-MSC migration is still unknown.
1.4.2.3 Differentiation
ATP has also been reported to modulate stem cell differentiation. ATP (0.1-100 μM) 
increased the ALP activity, osteocalcin (OC) protein production, and formation of
bone nodules assessed by Alizarin Red staining in hBM-MSCs, which was inhibited
by reducing P2X7 receptor expression with P2X7-siRNA and/or inhibiting the P2X7
receptor using selective antagonist KN62 (0.1 μM) (Sun, Junger et al. 2013), 
indicating that ATP activates the P2X7 receptor and downstream signalling
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pathways to increase the osteogenic differentiation of MSCs. In addition,
knockdown of the P2X7 receptor expression was reported to induce neuronal
differentiation of Neuro-2a cells (Wu, Lin et al. 2009). Similarly, a more recent
study has reported that suppression of the P2X7 receptor activity by KN62 (10 μM) 
enhanced neuronal differentiation of embryonic stem cells (Glaser, de Oliveira et al.
2014). These studies suggest that the P2X7 receptor is involved in the regulation of
stem cell differentiation by ATP.
1.4.3 Expression and function of the P2Y receptors
As discussed above, the P2Y receptors are expressed in many cells (Table 1.3).
Studies were carried out to examine the expression of the P2Y receptors in MSCs
from several tissues, such as adipose tissue, skin biopsies and bone marrow (Riddle,
Taylor et al. 2007; Ichikawa and Gemba 2009; Ferrari, Gulinelli et al. 2011;
Fruscione, Scarfi et al. 2011; Zippel, Limbach et al. 2012). Ferrari et al showed the
mRNA expression of all the P2Y receptors in hBM-MSCs (Ferrari, Gulinelli et al.
2011). Studies further confirmed that the protein expression of the P2Y1, P2Y2 and
P2Y11 receptors in the hBM-MSCs by immunostaining and Western blotting
(Ichikawa and Gemba 2009).
The P2Y receptors are also expressed in other type of stem cells, such as P19
embryonic carcinoma cells, HSCs and hepatocellular carcinoma cells (as cancer
stem cells) (Sainz and Heeschen 2013). The protein expression of the P2Y1, P2Y2,
P2Y4, and P2Y6 receptors was detected in undifferentiated P19 embryonic
carcinoma cells by immunostaining or Western blotting (Resende, Majumder et al.
2007). The mRNA expression of the P2Y1 and P2Y2 receptors was observed in
HSCs by RT-PCR analysis, and the protein expression of the P2Y1 receptor was
confirmed by Western blotting (Lemoli, Ferrari et al. 2004). Hepatocellular
carcinoma cells were shown to express the P2Y2 and P2Y4 receptors by RT-PCR
and Western blotting (Xie, Xu et al. 2014).
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Table 1.4 Proposed function of ATP-sensitive P2 purinergic receptors in stem cells.
Receptors Cells Proposed functional roles References
P2X7 ESCs Cell proliferation Glaser, de Oliveira et al. 2014
Inhibition of neuronal differentiation Glaser, de Oliveira et al. 2014
HSCs Active cell death at high ATP concentrations Yoon, Lee et al. 2007
BM-MSCs ATP-increased osteogenic differentiation Sun, Junger et al. 2013
Neuro-2a cells Inhibition of Neuronal differentiation Wu, Lin et al. 2009
P2Y1 ESCs ATP-increased cell proliferation Resende, Britto et al. 2008
ATP-induced neuronal differentiation Resende, Britto et al. 2008
HSCs ATP-increased cell proliferation Lemoli, Ferrari et al. 2004
BM-MSCs Inhibition of cell proliferation Coppi, Pugliese et al. 2007
ATP-increased adipogenic differentiation Ciciarello, Zini et al. 2013
AT-MSCs Osteogenic differentiation Zippel, Limbach et al. 2012
Cancer stem cells ATP-increased cell proliferation Xie, Xu et al. 2014
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Receptors Cells Proposed function References
P2Y2 ESCs ATP-induced cell proliferation Resende, Britto et al. 2008
ATP-induced neuronal differentiation Resende, Britto et al. 2008
HSCs ATP-increased cell proliferation Lemoli, Ferrari et al. 2004
UTP-mediated cell migration Lemoli, Ferrari et al. 2004
BM-MSCs NAD+-mediated cell migration Fruscione, Scarfi et al. 2011
AT-MSCs Osteogenic differentiation Zippel, Limbach et al. 2012
Cancer stem cells ATP-increased cell proliferation Xie, Xu et al. 2014
ATP-mediated cell migration Xie, Xu et al. 2014
P2Y11 AT-MSCs Adipogenic differentiation Zippel, Limbach et al. 2012
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1.4.4 Roles of the P2Y receptors
To date, several studies have shown that the ATP-sensitive P2Y receptors (P2Y1,
P2Y2 and P2Y11) play important roles in stem cell proliferation, migration and
differentiation (Table 1.4) (Burnstock and Ulrich 2011; Glaser, Cappellari et al.
2012; Scarfi 2014).
1.4.4.1 Proliferation
In an earlier study, BM-MSC proliferation was increased by ~26% by the P2
receptor generic antagonist PPADS (30 μM) and ~12% by MRS2179 (10 μM), a 
selective P2Y1 receptor antagonist (Coppi, Pugliese et al. 2007). In contrast, cell
proliferation of undifferentiated P19 mouse embryonic carcinoma cells was reported
to be increased by ATP (100 μM), ADP (100 μM) and UTP (100 μM) using the 
BrdU-incorporation assay (Resende, Britto et al. 2008). Moreover, ATP or
ADP-induced increase in cell proliferation was blocked by suramin (30 μM) and 
PPADS (10 μM), while UTP-induced cell proliferation was inhibited by suramin (30 
μM) but not PPADS (10 μM). Since the P2Y11 receptor was not expressed in these 
cells (Resende, Majumder et al. 2007), the P2Y1 and P2Y2 receptors are thought to
be involved in ATP-induced cell proliferation (Resende, Britto et al. 2008).
Additionally, the P2Y1 and P2Y2 receptors were reported to be involved in cell
proliferation of adult human (CD34+) HSCs stimulated by ATP (1-100 nM) (Lemoli,
Ferrari et al. 2004). Knocking down the P2Y2 receptor inhibited (10 μM) 
ATP-induced cell proliferation of hepatocellular carcinoma cells as assessed by
MTT (methylthiazoltetrazolium) and BrdU-incorporation assays (Xie, Xu et al.
2014). These studies suggested that the P2Y1 and P2Y2 receptors are involved in
the regulation of stem cell proliferation by ATP.
1.4.4.2 Migration
ATP has been reported to modulate hBM-MSC migration (Ferrari, Gulinelli et al.
2011). UTP at 10 μM was also reported to increase cell migration of CD34+ HSCs
using the transwell assays (Lemoli, Ferrari et al. 2004). Since the P2Y4 receptor was
not expressed in CD34+ HSCs, the P2Y2 receptor is mainly involved in
UTP-mediated cell migration (Lemoli, Ferrari et al. 2004). As shown using both
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wound-healing and transwell migration assays, ATP at 20 μM induced cell 
migration of hepatocellular carcinoma cells, which was also inhibited by the P2Y2
receptor specific shRNA (Xie, Xu et al. 2014). The group of Fruscione (Fruscione,
Scarfi et al. 2011) demonstrated that knockdown of the P2Y11 receptor with siRNA
inhibited cell migration of hBM-MSCs induced by extracellular NAD+. In summary,
these studies indicate that the ATP-sensitive P2Y2 and P2Y11 receptors are
involved in the regulation of stem cell migration.
1.4.4.3 Differentiation
During neuronal differentiation of P19 EC cells, ATP (100 μM) increased gene 
mRNA and protein expression of nestin (a marker for neural progenitors) and
neuron-speciﬁc enolase (a marker for neurons) by RT-PCR and Western blotting 
analysis respectively (Resende, Britto et al. 2008). Additionally, ATP-induced Ca2+
increase can be blocked by suramin (30 μM) and PPADS (10 μM). Due to the fact 
that P19 cells express the P2Y1 and P2Y2 not P2Y11 receptors, the P2Y1 and P2Y2
receptors are possibly involved in ATP-induced neuronal differentiation (Resende,
Britto et al. 2008). Expression of the P2Y1 and P2Y2 receptors is down-regulated in
osteogenic differentiation, while the P2Y11 is significantly up-regulated in
adipogenic differentiation of AT-MSCs (Zippel, Limbach et al. 2012; Scarfi 2014).
Recently, preincubation with 1 mM ATP for 24 hr improved lipid droplets formation
and the expression level of PPARγ (an adipogenic master gene) in hBM-MSCs 
during adipogenic differentiation (Ciciarello, Zini et al. 2013). Such ATP-dependent
PPARγ expression was decreased by MRS 2279 (a P2Y1 specific antagonist), not by   
MRS2768 (a P2Y2 agonist) (Ciciarello, Zini et al. 2013). These studies suggested
that the P2Y1 and P2Y2 receptors might be involved in the regulation of stem cell
neuronal differentiation and osteogenic differentiation, whereas the P2Y1 and
P2Y11 receptors have a role in adipogenic differentiation.
1.4.5 Expression and function of the SOC channels
An early study reported that Ca2+ entry through activation of SOC channels by
depletion the ER store with Ca2+-ATPase blockers 10 μM CPA or 1 μM TG in 
hBM-MSCs (Kawano, Shoji et al. 2002). Recently, it has been shown that (20 μM) 
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ATP-induced Ca2+ entry was inhibited by 2-APB (30 μM) and specific shRNA for 
Stim1 in human hepatocellular carcinoma cells (Xie, Xu et al. 2014). Moreover, the
SOC entry was inhibited by knockdown of STIM1, Orai1 or TRPC1 in adult neural
progenitor cells (Li, Chen et al. 2012). In previous studies, five TRPC proteins
(TRPC1, TRPC3, TRPC4, TRPC5, and TRPC6) were shown to be expressed in
embryonic central nervous system by Western blotting (Strubing, Krapivinsky et al.
2003) and in neural progenitor cells by real-time RT-PCR analysis (Shin, Hong et al.
2010; Li, Chen et al. 2012).
1.4.6 Roles of the SOC channels
1.4.6.1 Proliferation
It has been demonstrated that the SOC channels inhibitor, 2-APB (30 μM) and 
knockdown of Stim1 expression using shRNA inhibited cell proliferation of
hepatocellular carcinoma cells induced by ATP (10 μM) in the MTT 
(methylthiazoltetrazolium) and BrdU-incorporation assays (Xie, Xu et al. 2014).
Another recent study has also shown that knockdown of Stim1, Orai1 by siRNA or
TRPC1 by shRNA inhibited cell proliferation in adult neural progenitor cells using
the BrdU-incorporation assay (Li, Chen et al. 2012). These studies suggest that the
SOC channels are involved in the regulation of stem cell proliferation by ATP.
1.4.6.2 Migration
In a previous study, 2APB (30 μM) and knockdown of Stim1 were shown to inhibit 
cell migration of hepatocellular carcinoma cells induced by ATP (20 μM) using 
wound healing and transwell migration assays (Xie, Xu et al. 2014), suggesting that
the SOC channels are involved in the regulation of stem cell migration by ATP.
1.4.6.3 Differentiation
To date, the role of the SOC channels has not been well defined in the differentiation
of stem cells. A real-time RT-PCR analysis showed that the mRNA expression of
TRPC1 and TRPC4 was down-regulated, while the mRNA expression of TRPC3,
TRPC5, and TRPC6 was up-regulated during the neuronal differentiation of NPCs
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(Shin, Hong et al. 2010). Particularly, the expression level of TRPC5 in
differentiated neuronal cells was up-regulated by about 43-folds as compared to that
in NPCs. Moreover, knockdown of TRPC5 by siRNA inhibited TG-stimulated SOC
entry and induced NPCs to express nestin but not MAP2 (a mature neural cell
marker) during neuronal differentiation, indicating that TRPC5 acts as a SOC
channel and plays a key role in neuronal differentiation (Shin, Hong et al. 2010).
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1.5 Aim and Objectives
As discussed above, there is strong evidence to support the great promise of using
MSCs for tissue engineering and cell therapies. On the other hand, our understanding
of the extracellular signalling molecules and intrinsic mechanisms that determine or
regulate the MSCs functions is limited. ATP is an extracellular signalling molecule
activating the P2X and P2Y receptors on the cell surface. P2X receptors are
Ca2+-permeable channels, and ATP-sensitive P2Y receptors are coupled to
downstream signalling pathways that induce intracellular Ca2+ release from the ER,
and depletion of the ER Ca2+ store in turn activates the SOC channels to mediate Ca2+
entry. It has well established these signalling molecules are important in mediating
extracellular ATP-induced Ca2+ signalling mechanisms that determine functions of
both excitable and non-excitable functional cells. However, our understanding of such
signalling mechanisms in stem cells is just emerging but remains piecemeal.
Therefore, the overall aim of the study presented in this thesis is to gain a better
understanding of the ATP-induced effects on DP-MSC functions and the underlying
molecular signalling mechanisms. The primary objectives of this study are as follows:
1. To isolate and characterize human dental pulp MSCs from different
donors (chapter 3).
2. To determine the effects of extracellular ATP on cell proliferation,
migration and differentiation (chapter 3).
3. To investigate the expression of ATP-sensitive P2X and P2Y receptors
and their roles in mediating ATP-induced Ca2+ signalling (chapter 4).
4. To investigate the expression of the SOC channels and their roles in
contributing ATP-induced Ca2+ signalling (chapter 5).
5. To determine the roles of P2X and P2Y receptors and SOC channels in the
regulation by extracellular ATP of MSC proliferation, migration, differentiation
(chapter 6).
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Chapter 2
Materials and Methods
2.1 Materials
2.1.1 General materials
General chemicals or reagents are summarized in Table 2.1 and were purchased
from Sigma unless otherwise indicated.
2.1.2 Solutions
Solutions are summarized in Table 2.2 and they were prepared with distilled water.
Solutions for cell culture were sterilized by syringe filter (0.22 µm) or autoclaving.
2.2 Methods
2.2.1 Cell isolation and culture
Human MSCs were isolated from dental pulp of teeth (human molars) which were
obtained from the Leeds Dental Institute Dental Clinic. The project has been
approved by the Dental Research Ethics Committee (280211/LJ/60). The teeth from
four donors (9, 21 and 32 years old, all female; 22 years old, male) were immersed
in 70% (v:v) ethanol for 5 minutes. After removing the connective tissues by scalpel
under sterile conditions, teeth were cracked into several parts (Figure 3.1). Pulp
tissues were removed from the pulp chamber of the teeth and placed in a drop of
phosphate-buffered saline (PBS) (Invitrogen/GIBCO) in a sterile Petri dish. The
pulp tissues were minced into approximately 0.5 x 0.5 x 1 mm3 sized pieces using a
sterile scalpel and transferred to a 15-ml tube with 2 ml of PBS containing 5 mg/ml
collagenase P (Worthington Biochem, Freehold, NJ) for 45-60 minutes at 37°C and
5% CO2 according to the size of the pulp pieces. Through the incubation the tube
was removed and the contents were gently pipetted every 15 minutes. The reaction
was stopped by adding 7 ml of DMEM with 10% heat-inactivated fetal bovine
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serum (FBS) (Invitrogen) when pulp pieces were totally dispersed in the solutions.
The cell suspension was then centrifuged at 200 x g for 10 minutes. The cell pellet
was resuspended in 5 ml of Dulbecco's modified Eagle's medium (DMEM)
(Invitrogen) supplemented with 20% (v: v) FBS, 2 mM L-glutamine, 100 units/ml
penicillin and 100 µg/ml streptomycin (Biofluids, Rockville, MD). Single-cell
suspension was obtained by passing the cells through a 70-µm cell strainer (BD
FalconTM California, USA). The cells were seeded into a T-25 (25 cm2) plastic tissue
culture flask (BD Biosciences) and incubated in a humidified 5% CO2 and 37°C air
incubator (Heraeus HERAcell 240) with medium changes every 3-4 days until 90%
confluency was reached. Cell growth was monitored everyday by examining under a
light microscope (Olympus LH50A). The mesenchymal stromal cells were isolated
based on their ability to adhere to the plastic surface of the culture flasks, while
other non-adherent cells were removed by changing the growth medium. The
adherent cells were grown to 90% confluency and were defined as passage zero (P0)
cells. Later passages were named accordingly. All cell handling was carried out in a
tissue culture hood (Wolf labortorories Aura-B6).
2.2.2 Cell subculture
When the cells reached around 90% confluency, they were subcultured as follows.
Taking a T-75 (75cm2) flask as an example, after aspiration of the media, the cell
monolayer was washed with 4 ml of PBS. Then 4 ml of 0.25% trypsin-EDTA
solution (Invitrogen/GIBCO) was added to cover the cells and incubated at 37°C for
5-7 minutes to allow the cells to be dislodged from the bottom of the flask. Mixed
with the same volume of growth medium, the detached cells were gently suspended.
The detached cells were pelleted down by centrifuging at 1000 rotation per minute
(rpm) for 5 minutes. The supernatant was aspirated and the cell pellet was
resuspended in 3 ml of DMEM supplemented with 10% FBS. The number of cells
per ml of the suspension was determined by a haemocytometer and seeded onto T25
or T75 fresh culture flasks (Greiner™) at a concentration of 1×104 cells/cm2. Cell
growth medium was replaced every 3-4 days until 90% confluency was reached.
Cells within the fifth passage were used throughout the study.
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Table 2.1 General chemical and reagents used.
Chemicals Supplier
Ethanol VWR International Poole, UK.
Phosphate-buffered saline (PBS) Invitrogen, USA.
Collagenase P Worthington Biochem, Freehold, NJ
Dulbecco’s modified Eagle’s medium (DMEM) Invitrogen, USA.
Foetal bovine serum (FBS) Invitrogen, USA.
L-glutamine Sigma-Aldrich Ltd., UK.
Penicillin-streptomycin Sigma-Aldrich Ltd., UK.
10× Trypsin-EDTA Invitrogen, USA.
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Ltd., UK.
Sodium chloride Fisher scientific, UK.
Potassium chloride Fisher scientific, UK.
Calcium chloride solution Sigma-Aldrich Ltd., USA
Magnesium chloride solution Sigma-Aldrich Ltd., USA
N-(2-hydroxyethyl) piperazine-N’-(2-ethanulfonic
acid) (HEPES)
Fisher scientific, UK.
Glucose Fisher scientific, UK.
Ethylene diamine tetraacetic acid (EDTA) Sigma-Aldrich Ltd., USA
Pluronic acid F-127 Invitrogen, USA.
Sodium hydroxide Sigma-Aldrich Ltd., UK.
Agarose Sigma-Aldrich Ltd., UK.
EtBr Sigma-Aldrich Ltd., UK.
OPTI-MEM medium Invitrogen, USA.
SYBR Green I Stain Invitrogen, USA.
ATP Sigma-Aldrich Ltd., UK.
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αβmeATP Sigma-Aldrich Ltd., UK. 
BzATP Sigma-Aldrich Ltd., UK.
ADP Sigma-Aldrich Ltd., UK.
UTP Sigma-Aldrich Ltd., UK.
MRS4062 Tocris bioscience, UK
UDP Sigma-Aldrich Ltd., UK.
PPADS Tocris bioscience, UK
5-BDBD Tocris bioscience, UK
AZ11645373 Sigma-Aldrich Ltd., UK.
Thapsigargin (TG) Sigma-Aldrich Ltd., UK.
2-APB Sigma-Aldrich Ltd., UK.
CGS15943 Tocris bioscience, UK
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Table 2.2 Solutions and culture media used in the present study.
For cell culture
Primary cell culture medium
(only for Passage 0)
DMEM supplemented with 20% (v:v) FBS, 2 mM
L-glutamine, 100 units/ml penicillin and 100
µg/ml streptomycin
Cell growth basal medium
(BM)
DMEM was supplemented with 10% (v:v) FBS
For FLEXstation
Extracellular Ca2+-containing
solution (SBS) (in mM)
NaCl 147, KCl 2, CaCl2 1.5 (or 7.5),
MgCl2 1, HEPES 10 and glucose 13, pH 7.3
Extracellular Ca2+-free
solution (in mM)
NaCl 147, KCl 2, MgCl2 1, HEPES 10, glucose
13 and EDTA 1. 147, pH 7.3
SBS-Fura-2/AM 2 μM Fura-2/AM and 0.1% pluronic acid in SBS 
For DNA preparation
10 mg/ml EtBr Dissolved in TE buffer made of 10 mM Tris pH8.0,
and 1 mM EDTA pH8.0
TAE buffer 40 mM Tris-Oac, 0.114% (v:v) glacical acetic acid,
and 1 mM EDTA pH8.0
2% DNA agarose gel 2% (w:v) agarose dissolved in TAE buffer with
EtBr (10 mg/ml)
6× DNA gel loading buffer 0.25% (w:v) bromopenol blue and 40% (w:v)
sucrose, stored at 4°C
Other
SYBR Green staining solution 0.1% SYBR Green I Stain in DMSO
Note: solutions which were generally used are summarized in this table, and some
solutions which are not included are specified where they were applied.
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2.2.3 Preparation of frozen cells
To prepare frozen cell stocks, cells were grown to reach a >90% confluency in T-75
flasks, and dislodged as described in section 2.2.2. The detached cells from each
flask were then collected and resuspended in 1 ml of solution containing 90% FBS
and 10% (v:v) DMSO, and were transferred into 2-ml cryostat vials. The vials were
frozen at -80°C overnight and, on the next day were transferred into a liquid
nitrogen cryostat.
2.2.4 Thawing and restoring frozen cells
Vials containing frozen cells were removed from a liquid nitrogen cryostat and
quickly thawed by incubation at 37°C. The thawed cell suspension was transferred
into a T-25 flask containing 5 ml of DMEM supplemented with 10% FBS. After
incubation for 24 hours to allow the cells to attach the bottom of the flask, the
growth medium was replaced with fresh basal growth medium. Cells were
maintained at 37°C until they became confluent.
2.2.5 Colony-forming test
To assess the colony-forming capability, single cells were seeded into 6-well tissue
culture plates (1×103 cells/well) and maintained in growth basal medium for 7 or 14
days with the medium changed every 3-4 days. At the end of 7 or 14 days, the cells
were washed with PBS and fixed with 10% neutral buffered formalin (Sigma, UK)
at room temperature for at least 30 minutes. The cells were then stained in Harris
Hematoxylin staining solutions (VWR International) at room temperature for 2
minutes. The cells nuclei were stained blue-violet after extensively washing with
distilled water to remove the staining solution. An aggregate of more than 50 cells in
a small field was scored as one colony, and more than 100 cells in a large field as
two colonies (Osathanon, Nowwarote et al. 2011). Colony-forming capability was
determined by the number of colonies relative to the total number of seeded cells in
each well (Ferrari, Gulinelli et al. 2011).
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2.2.6 Flow cytometry
To confirm that hDP-MSCs maintain their phenotypic characteristics after growth in
culture, cells were subjected to flow cytometry analysis. Cells were harvested as
described in section 2.2.2 and suspended in 1 ml of flow cytometry staining buffer
(PBS containing 0.5% (w:v) BSA and 2 mM EDTA) at a concentration of 1 × 107
cells/ml. The cell suspension was treated with 1mg/ml Fc receptor blocking solution
(TruStain FcXTM, Biolegend) at room temperature for 10 minutes. The cell
suspension (1 × 106 cells) was transferred to 1.5-ml eppendorf tube and incubated at
4°C for 30 minutes with primary mouse anti-human antibodies: CD105-fluorescein
isothiocyanate (FITC) (Biolegend), CD90-FITC (Biolegend), CD73-phycoerythrin
(PE) (Biolegend), CD45-FITC (Biolegend), CD34-FITC (Biolegend), CD14-FITC
(Biolegend), Isotype Control-FITC (Biolegend), Isotype Control-PE (Biolegend)
and STRO-1 (Santa Cruz Biotechnology). After washing, cells were centrifuged at
2000 rpm for 5 minutes and resuspended in 400 μl of flow cytometry staining buffer. 
The cells labelled with the anti-STRO-1 antibody were then incubated with a
secondary FITC-conjugated goat anti-mouse antibody (Invitrogen) at 4°C for 30
minutes in the dark and resuspended in 400 μl of flow cytometry staining buffer 
again after washing and centrifugation. Flow cytometry was performed using a
FACSCalibur (BD Biosciences, San Diego, USA) and ten thousand events were
recorded for each sample. The data were analyzed with Cell Quest software (BD
Biosciences).
2.2.7 Osteogenic differentiation
Cells were harvested as described in section 2.2.2 and were seeded into 24-well
plates with 4 × 104 cells/well. After incubation for 48 hours, cells were cultured for 2
weeks in osteogenic differentiation medium (ODM) containing 100 nM
dexamethasone (Sigma-Aldrich) and 0.05 µM ascorbate-2-phosphate (Wako
Chemicals, Richmond, VA, USA) in basal growth medium (BM). ATP from 0 µM
to 300 µM was added into the culture medium and, in some experiments, after
pretreatment with antagonists or inhibitors (CGS15943, AZ11645373, PPADS and
2-APB) for 30 minutes. The medium was replaced every 3 days. In some
experiments, cells were transfected with siRNA for 48 hours and then cultured in
BM or ODM, and transfected again with siRNA for 24 hours after 7 days during
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osteogenesis and then cultured in BM or ODM. After 14 days, osteogenic
differentiation was assessed using ALP staining (Sigma-Aldich, Fluka Chemie AG,
Buchs, Switzerland), or determining the DNA content and ALP activity.
CGS15943, PPADS and 5-BDBD were prepared as 10 mM stock solutions
in DMSO and were diluted in the culture medium to indicated final concentrations.
All the other agonists or antagonists stock solutions were made in water or culture
medium.
2.2.8 ALP staining assay
After 14 days in BM or ODM as described section 2.2.7, cells in each well were
washed with PBS and fixed in 98% ethanol in a cold room for 10 minutes. Then,
ethanol was removed and replaced by 4% (v:v) α-naphthol in distilled water 
containing 24 mg/ml of Fast violet. The cells were incubated at room temperature
for 1 hour. After washing with distilled water, cells expressing ALP were stained in
red and were visualized under a light microscope.
2.2.9 DNA content determination
After 14 days in BM or ODM as described section 2.2.7, cells were washed twice
with PBS and 200 μl of PBS containing 0.01% (v:v) Triton X-100 was added into 
each well. Cells were collected using a cell scraper and cells were lysed by
freezing-thawing at -20 C. The cell lysates were transferred to eppendroff tubes and
centrifuged at 2000 rpm for 5 minutes to remove cellular debris. The resulting cell
lysate (20 μl) for each condition was transferred into 8 wells in a flat, clear bottom 
96-well plate (Greiner Bio-One) which was used to determine the DNA content as
well as the ALP activity. For each well, 80 μl of TE buffer (Tris-EDTA buffer, 
containing 10 mM Tris-HCl and 1 mM EDTA, pH 8.0, Sigma) was added to make
up a total volume of 100 μl. DNA standard solutions in 100 μl containing 0, 0.04, 
0.2, 1, 1.5, 2 μg/ml were transferred into 3 wells for each condition in the same 
96-well plate. Then, an equivalent volume (100 μl) of PicoGreen (Molecular 
Probes®, Invitrogen, Leiden), diluted at 1:200 in TE, was added into each well
including the DNA standards and incubated for 5 minutes in the dark. The
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fluorescence was measured using a fluorescence micro-plate reader (Varioskan™)
with the excitation wavelength of 480 nm and the emission wavelength of 520 nm.
The standard curves were constructed between the absorption values and DNA
concentrations, and was linear (R2 ≈ 0.99860, n/N = 2/6). The DNA content (μg/ml) 
in the cell lysates was calculated from the standard curves.
2.2.10 ALP activity assay
The cell lysates (20 μl) prepared as described section 2.2.9 was also used to 
determine the ALP activity. The total volume was made up to 100 μl using 
p-Nitrophenol phosphate substrate (80 μl). An equivalent volume (100 μl) of ALP 
standard solutions ranging from 0, 10, 50, 100, 200 nmol/ml were transferred to 3
wells for each concentration in the same 96-well plate. The plate was incubated in
the dark at 37°C for 60 minutes. The reaction was stopped by adding 100 μl of 1 M 
NaOH to each well including the standards. The optical density of the yellow
product, para-nitrophenol, was determined by a VersaMax Microplate Reader
(Varioskan™) at the wavelength of 405 nm. The standard curves were determined
between the absorption values and ALP concentrations and were linear (R2 ≈ 
0.99587, n/N = 2/6). The ALP concentration (nmol/ml) in each well was calculated
from the standard curve. The ALP activity was expressed as the ALP amount (nmol)
per μg DNA in each sample. 
2.2.11 Adipogenic differentiation
Cells were harvested as described in section 2.2.2 and were seeded onto glass
coverslips (BD Biosciences) in 24-well plates with 4 × 104 cells/well. After 48
hours, cells were cultured for 3 weeks in adipogenic differentiation medium (ADM)
containing 0.5 mM isobutyl-methylxanthine (IBMX-Sigma-Aldrich), 10 µM
dexamethasone (Sigma-Aldrich, Fluka Chemie AG, Buchs, Switzerland), 10 µg/ml
insulin (Invitrogen/GIBCO), and 200 µM indomethacin (Sigma-Aldrich) in BM.
Cells were treated with ATP from 0 µM to 30 µM alone or after pretreatment with
antagonists or inhibitors (CGS15943, AZ11645373, PPADS and 2-APB). The
medium was replaced every 3 days. In some experiments, cells were transfected
with siRNA for 48 hours and then cultured in ADM. Cells were transfected again
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with siRNA for 24 hours after 9 days during induction of adipogenesis and then
cultured in ADM. After 3 weeks, cells were stained with Oil Red O for detection of
the fat droplets in adipocytes.
2.2.12 Oil red O staining
Oil red O staining was conducted as described by Perry (Perry, Zhou et al. 2008).
After 3 weeks in BM or ADM as described section 2.2.11, cells were washed with
PBS and fixed with 4% paraformaldehyde (PFA) at room temperature for at least 30
minutes. The cells were then washed with distilled water twice and incubate with
60% isopropanol in distilled water at room temperature for 5 minutes. After that,
cells were stained for 15 minutes with 0.3% Oil red O, which was prepared by
mixing 3 ml of 0.5% Oil red O (5mg/ml in isopropanol, Sigma) with 2 ml of
distilled water and extensively washed with distilled water to remove the staining
solution. The fat droplets were stained in red. For counting the cell number, cells
were also stained by Harris Hematoxylin solution at room temperature for 2 minutes
and nuclei were stained in blue-violet after extensively washing with distilled water
to remove the staining solution. Stained cells were visualized under an Olympus
inverted microscope and imaged five different fields in each well using a digital
camera (Olympus 7 megapixel camera). Adipogenic differentiation was determined
by the number of Oil red O-stained cells relative to the total number of cells in the
same area. To distain cells, stained cells in each well were incubated with 100 μl of 
isopropanol and rotated at room temperature for 15 minutes to distain red colour
from the fat droplets. The distained isopropanol solutions (80 μl) were transferred 
into a flat, clear bottom 96-well plate (Greiner Bio-One) and determined by a
VersaMax Microplate Reader (Varioskan™) at the wavelength of 510 nm (Basseri,
Lhotak et al. 2009; Xu, De Becker et al. 2010). The distained cells were washed
with distilled water and the DNA content was determined as described section 2.2.9.
Adipogenic differentiation was expressed as the OD510 value per μg/ml DNA in each 
sample.
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2.2.13 Chondrogenic differentiation
Monolayer cells
Cells were harvested as described in section 2.2.2 and were seeded in 24-well plates
with 4 × 104 cells/well for monolayer cell cultures. After 48 hours, cells were
cultured for 3 weeks in chondrogenic differentiation medium (CDM) containing 0.1
µM dexamethasone (Sigma, UK), 10 ng/mL TGF-β3, 50 µg/mL ascorbic acid 
2-phosphate (Sigma, UK) and 1 insulin-transferrin-selenium supplement (ITS,
Sigma) in BM. The medium was replaced every 3 days. After 3 weeks, monolayer
cells were stained by Alcian blue staining.
Cell pellets
The cell suspension harvested as described in section 2.2.2 were also centrifuged in
14ml BD Falcon round bottom test tubes at 1100 rpm for 5 min to obtain cell pellets
(1 × 106 cells/tube) for three-dimensional (3D) cell culture. Cell pellets were
cultured in BM for 24 hours and then were encouraged to float freely for 48 hours
by gentle shaking. Cell pellets were then cultured in CDM or BM for 3 weeks with
the medium changed every 3 days. After 3 weeks, cell pellets were paraffin
embedded, sectioned and stained with Alcian blue/Sirius red staining for the
identification of glycosaminoglycans (GAG) and collagenous matrix.
2.2.14 Alcian blue staining for monolayer cells
Alcian blue dye stains sulfated proteoglycan in cartilage tissues to indicate cell
chondrogenesis. Monolayer cells were washed with PBS and fixed with 10% neutral
buffered formalin (Sigma, UK) at room temperature for at least 30 minutes. The
cells were then washed with distilled water twice and incubate in 1% Alcian blue
solution (in 3% acetic acid; Sigma) at room temperature for 30 minutes. After that,
cells were washed with distilled water to remove the staining solution. Acid
mucosubstances were stained in blue. In order to determine the total number of cells
in each well, cells were stained with 1:100 (v:v) SYBR Green diluted in staining
solution/water for 15 minutes in the dark. The nuclei were stained in green. Stained
cells were visualized and imaged five different areas in each well under an Olympus
inverted fluorescence microscope (Olympus IX51) using a digital camera (Olympus
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7 megapixel camera). Chondrogenic differentiation was determined by comparing
the density of blue colour, normalized by the total number of cells in each image.
2.2.15 Alcian blue/Sirius red staining for cell pellets
After 3 weeks, cell pellets were washed with PBS twice and fixed with 10% neutral
buffered formalin (Sigma, UK) and a drop of 0.1% Nuclear Fast Red solution
(0.1 g nuclear fast red in 100 ml of 5% aluminum sulphate in distilled water; Sigma)
for at least 24 hours at room temperature before processing. Cell pellets were then
placed in the embedding cassettes (Simport, Canada) with a metal lid and were
processed in a tissue processor (Tissue-Tek VIP) for a 16-hour program. The
processor is an automated machine which dehydrates the samples through a series of
treatments with ethanol (50%, 70%, 90%, 100%, 100%, and 100%) for 1 hour each
treatment, xylene (100%, 100%, and 100%) for 1.5 hour each time, and molten
paraffin wax four times at 65°C. For embedding, the cell pellets were transferred
onto a metal tissue-holding tray and fully covered with additional hot wax (65°C).
The embedding cassette was then placed on top of the tray following addition of hot
wax to the brim of the tray. After that, the tray was placed on the cold plate for
overnight to make the wax completely solidified. Samples were then sectioned at 5
µm thickness using N35 blades (Surgipath, UK) on an Ultra microtome (Jung
Biocut, UK) and the slices were placed and floated in water at 40°C. These slices
were attached on to poly-L-lysine-coated slides (VWR, UK), after a drop of 20%
ethanol was placed on the slice. The slides were incubated at 37°C for at least 16
hours for histological examination.
Paraffin embedded slices were de-waxed in xylene for 5 minutes, and were
immerged in absolute alcohol twice for 5 minutes each time. After washing under
tap water, the slices were stained with a mixed solution containing Weigarts
haematoxylin A (Fisher scientific, UK) and B (Fisher scientific, UK) in a ratio of 1:1
for 10 minutes and rinsed with tap water for 10 minutes. Slides were stained with
1% Alcian blue in 3% acetic acid (Sigma) for 10 minutes, and washed with tap
water for 1 minute, and were stained with 1% aqueous phosphomolybdic acid in
distilled water (Fluka, UK) for 20 minutes and then washed in tap water for 1
minute. Sections were then stained with 0.1% Sirius red in saturated picric acid
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(Fluka, UK) for 60 minutes. The sections were dehydrated through absolute alcohol
twice for 5 minutes each time and immersed in xylene twice for 1 minute each time
before mounting in dibutyl phthalate xylene (DPX). Stained slices were then
visualized under an Olympus inverted light microscope (Olympus LH50A). Alcian
blue binds to proteoglycans while the Sirius red stain binds to collagen types I, II
and III (Lee, Choi et al. 2006).
2.2.16 Cell proliferation assays
The proliferation capacity of cells was measured using a XTT cell viability assay kit
(Biotium). Cells were seeded at 5,000 cells/well into 4-6 wells of flat, clear bottom
96-well plates (Greiner Bio-One) for each condition. After 48 hours, the culture
medium was replaced with fresh medium and cells were incubated with ATP at
concentrations from 0, 0.3, 3, 30 to 300 µM in 5% CO2 at 37°C for 72 hours in BM.
The medium was replaced every 24 hours.
For the XTT cell viability assay, the activated-XTT solution was prepared by adding
the activation reagent to the XTT solution (v:v = 1:50). Cells were washed twice
with PBS and then incubated with 25 µl of the activated-XTT solution in 100 µl BM
for 4 hours in the dark, including 3 control wells containing no cells as blank
absorbance readings. The numbers of living cells were determined by measuring the
absorbance at the wavelength of 475 nm and 650 nm by a spectrophotometer
microplate reader (Varioskan™). The specific absorbance of the sample is expressed
as follows:
Specific Absorbance = A475nm (Test) – A650nm (Test) – A475nm (Blank)
The cell proliferation was also examined by cell counting. In order to estimate the
numbers of cells in 4-6 wells for each condition in the 96-well plates (Greiner
Bio-One), cells with 98 µl/ well BM were treated with 2 µl/ well of SYBR Green
staining solution (see Table 2.2) for 15 minutes in the dark. Stained cells were
imaged at the same two areas of each well and counted by IncuCyte (Essen
BioScience).
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2.2.17 Cell migration assays
Cells were seeded at 40,000 cells/well in 96-well plates (Thermo Scientific) and
incubated in a tissue incubator with 5% CO2 at 37°C. After 48 hours, the 96-pin
Wound Maker (Essen BioScience) was used to produce the wounds in all wells of a
96-well plate by gently removing cells from the confluent monolayer using an array
of 96 pins. Cells were then washed with PBS twice to remove the detached cells and
cultured in BM, before plates were placed in the IncuCyte. ATP at concentrations
from 0, 3, 30 to 300 µM was added into 4-6 wells for each condition, or after cells
were pretreated with antagonists or inhibitors (CGS15943, AZ11645373, PPADS
and 2-APB) for 30 minutes. In order to count the number of cells migrating into the
wound area in each well, cells in 98 µl/well BM were treated with 2 µl/well SYBR
Green staining solution (see Table 2.2) for 15 minutes in the dark at 24, 48 or 72
hours. Cells in each well were imaged by IncuCyte. Cell migration was determined
by counting the number of cells migrating into the wound area relative to the cell
density in the adjacent and healthy area in each well. The values obtained were
expressed as percentage of relative cell migration.
Cell migration was more closely examined by measuring the width of the wound
area that is reduced as cells migrate into the wound area. The 96-well cell migration
software (Essen BioScience) was set to scan the wells to measure the wound width
every hour. The wound width by obtained automatically using the cell migration
software is the average distance from 924 random lines of resolution between the
edges of the scratch wound within an image, and the migration distance at a given
time is the difference between the initial wound width (at time 0) and wound width
at that time (24 hours, as illustrated in Figure 3.6A). The migration distance was
collected every hour and the migration time courses were obtained. The areas coved
by the time course curves are calculated and the migration is expressed as
percentage of the area for control cells (no treatment with ATP).
2.2.18 Measurements of the intracellular Ca2+ levels
The changes in the intracellular Ca2+ levels ([Ca2+]i) were measured using both
single cell Ca2+ imaging and FLEXstation. Cell suspension was harvested as
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described in section 2.2.2. Cells were then seeded on type I collagen-coated
coverslips placed in 24-well plates (Greiner Bio-one) at a density of 2× 103 cells/cm2
for single cell Ca2+ imaging and in 96-well assay plates (black and µclear, Greiner
Bio-one GmbH,) at 40,000 cells/well for FLEXstation.
After 48 hours, cells were washed with PBS and incubated with 4 μM Fura-2/AM 
(Molecular Probes) and 0.4% pluronic acid in standard bath solution (SBS, see
Table 2.2) at 37°C for 1 hour in the dark. Then, the cells were extensively washed
twice in SBS in the dark. After incubation at 37°C for 30 minutes in SBS, cells were
washed and replaced with fresh SBS or extracellular Ca2+-free solution (see Table
2.2). Both extracellular Ca2+-containing and Ca2+-free solutions were adjusted to pH
7.4 with 4 M NaOH. All agonists or antagonists stock solutions were diluted in the
extracellular solutions to the indicated final concentrations. Cells were pretreated
with antagonists or inhibitors (PPADS, 5-BDBD, AZ11645373, 2-APB and Synta66)
before treatment with ATP. Synta66 (GSK1349571A) was obtained as a gift from
Prof David J. Beech (University of Leeds).
For single cell Ca2+ imaging, a coverslip with cells were placed in a chamber which
was fixed onto the microscope (Axiovert S100 TV, Zeiss). Cells were perfused with
the SBS or extracellular Ca2+-free solution. Individual cells in one field were
selected to be measured as well as the background region. After the recording
started, images were acquired by exciting the cells at 340 nm and 380 nm every 10
seconds.
For the FLEXstation experiments, a 96-well U-bottomed compound plate (Greiner
Bio-one) was prepared in advance with the correct layout, concentrations, and
volumes of solutions (up to 250 μl each well). Then the cell assay plate, the 
compound plate and pipette tips were loaded into the FLEXstation (FLEXstation II
384, Molecular Devices), setting up and running the experiments using FLEXstation
software Softmax Pro (Molecular Devices). The FLEXstation uses tips to transfer
compounds from the compound plate to designated wells in the cell assay plate. 40
or 50 µl of compounds at 5 working concentrations were added to wells (for cells
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containing 160 µl or 200 µl of 1 working concentrations) in the assay plate (final
volume each well is 200 µl or 250 µl). ATP or other P2 receptor agonists were
applied after 60 seconds to establish the baseline. In the experiments examining P2
receptor antagonists, cells were treated for 300 seconds before agonist application.
Intracellular Ca2+ levels were monitored by measuring the ratio of fluorescence
intensity at emission of 510 nm alternatively excited by 340 nm and 380 nm
(F340/F380).
Data analysis was carried out using OriginPro 8.0. The receptor agonist
concentration–response curve was least squared fit to the Hill equation:
ΔF340/F380 = ΔF340/F380 max/ (1 + (EC50/ [agonist])nH)
Where ΔF340/F380 is the change in the ratio of fluorescent intensities (F340/F380)
induced by the receptor agonist, ΔF340/F380max is the maximal change, EC50 is the
receptor agonist concentration evoking half of the maximal change, and nH is the
Hill coefficient.
2.2.19 Real-time reverse transcription polymerase chain reaction
(RT-PCR)
RNA was extracted from one T75 flask of cells for each condition. RNA extraction
was carried out using the TRI reagents (Sigma) as follows. 75% ethanol solution
was prepared using RNase-free water and cooled on ice. After removing the growth
medium, cells were washed once in PBS, and treated with 1 ml of TRI reagent. The
cell lysates were transferred to a 1.5-ml eppendorf and left on ice for 5 min. After
adding 100 μl of bromochloropropane (BCP, Sigma) and vortexing thoroughly, cell 
lysates were left at room temperature for 15 minutes before centrifuging at 13,000
rpm at 4°C for 15 minutes. The top RNA-containing aqueous layer was carefully
transferred into a fresh eppendorf, without disturbing the DNA in the middle white
layer or protein in the bottom pink layer. After mixing thoroughly with an equal
volume of ice cold isopropanol thoroughly for 15 minutes on ice, the RNA sample
was centrifuged at 13,000 rpm at 4°C for 20 minutes. After the supernatant was
removed, 750 μl of 75% ethanol solution was added. Followed by vortexing 
thoroughly and centrifuged at 13,000 rpm at 4°C for 5 minutes, ethanol was
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removed. After air dried for about 5 minutes or all the ethanol was removed, the
white and shiny RNA pellet was resuspended in 10 μl of RNase-free water. The 
RNA samples were subjected to DNase digestion or stored at -80°C.
DNase digestion of the RNA samples to remove the DNA contamination was
performed as follows. The digestion was assembled by adding 3 μl of RQ1 
RNase-free DNase enzyme and 1.3 μl of RQ1 RNase-free DNase 10× Reaction 
Buffer (Ambion) into10 μl of the RNA sample and the mix was incubated at 37°C 
for 1 hour. After brief centrifugation using a bench centrifuge, 3 μl of Stop Reagent 
was added and left on ice for 2 minutes. Then the samples were subjected to the
Ribogreen assay or were stored at -80°C after centrifugation for 1 minute.
The Ribogreen assay was carried out as follows to determine the RNA
concentration. 10 μl of Ribogreen solutions (Invitrogen) (dilute at 1:200 in TE 
buffer) were mixed with 10 μl of the RNA sample (dilute at 1:100 in TE buffer) or 
TE buffer alone as blank control in capillaries. After centrifugation using the Light
Cycler centrifuge, capillaries were loaded in the Light Cycler for F1 readings
through running Real Time Fluorimeter by Light Cycler 3 computer program. The
RNA concentration in the samples was estimated according to the following
equation:
RNA concentration (μg/μl) = 0.2 × [(Ribogreen F1 reading – blank control) 
+0.2607]/15.96
The RNA was reverse-transcribed into cDNA in a total reaction volume of 20 μl 
containing 0.6 μg of RNA sample and 4 μl of High Capacity RNA-to-cDNA Master 
Mix (Applied Biosysytems). The same procedure was used for preparing No RT
control with Master Mix without reverse transcriptase (Applied Biosysytems).
Reverse transcription was performed using a Mastercycler Gradient PCR machine
(Eppendorf) with the following parameters (one cycle): 25°C for 5 minutes, 42°C
for 30 minutes, 85°C for 5 minutes and holding at 4°C.
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The cDNA samples were amplified using PCR and primers specific to the target
genes as shown in Table 2.3. The PCR reaction samples in 5 μl were made in the 
dark, containing 0.5 μl of the cDNA sample, 2.9 μl of H2O, 0.6 μl of 4 mM MgCl2,
0.5 μl of SYBR Green (Applied Biosystems), 0.25 μl of 0.5 μM forward primers and 
0.25 μl of 0.5 μM reverse primers. The PCR protocols were composed of 95°C for 
10 minutes, 45 cycles of 95°C for 10 seconds, 60°C for 6 seconds (55°C for Orai1,
Orai2, Orai3, Stim1 and Stim2) and 72°C for 16 seconds, and a final melting step
from 65°C to 95°C before the samples were maintained at 4°C (Li, Cubbon et al.
2011). The minimal cycle threshold values (Ct) were calculated from each of the
quadruplicate reactions and the mean was obtained. The mRNA expression level for
the gene under investigation was normalized to that of β-actin based on the 
following equation (Livak and Schmittgen 2001):
Normalized expression =  (Ctsample - Ctβ-actin)
The difference in the relative gene expression fold after gene knockdown with
siRNA (Time x), was calculated using the 2-ΔΔCt method (Livak and Schmittgen
2001) relative to the gene expression level (Time 0, untreated control). The mean
fold change in the expression of the target gene at each time point was calculated
using following equation: ΔΔCt = [(Ctsample - Ctβ-actin)Time x - (Ctsample - Ctβ-actin)Time 0].
The PCR products were analyzed by electrophoresis on 2% agarose gels. To prepare
an agarose gel, the required amount of agarose was dissolved in TAE
electrophoresis buffer by heating using a microwave oven until the solution
appeared clear. After the agarose gel solution was cooled down to 50-60 °C,
ethidium bromide (EtBr) (10 mg/ml) (Sigma) with the final concentration of 0.5
μg/ml was added into agarose gel solution and mixed by gently swirling. The gel 
tray was prepared and the prepared agarose gel solution was poured carefully into it.
The well-forming gel comb was inserted into the tray after removing air bubbles.
The gel tray was left at room temperature for 1 hour for polymerisation of the
agarose. Then, the comb was carefully removed from the gel and the tray was
transferred into the gel tank covered with TAE buffer. Samples were prepared for
gel loading by mixing 10 μl of PCR products with 2 μl of 6 gel loading buffer
(Biolabs). The PCR samples were then transferred into the well of the gel merged in
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running buffer in the tank. 0.5 μl of 100 bp DNA ladder (500 μg/ml, Biolabs) was 
mixed with 1 μl of 6 loading buffer and 4.5 μl of RNase-free water, and loaded 
along side with the PCR samples. The electrophoresis was run at 70 V for 60
minutes at room temperature. The DNA in the gel was visualized under the UV
trans-illuminator. Gel images were captured with a Biorad Molecular Imager Gel
Doc XR+ System (Biorad) and analyzed with Quantity Ome 1-D Analysis Software
(Biorad). The size of PCR products was estimated based on the DNA ladders.
2.2.20 Transfection with siRNA
Cells were harvested as described in section 2.2.2 and seeded in 96-well plates for
measurements of intracellular Ca2+ levels and migration tests, in 24-well plates for
differentiation tests, or in 6-well plates for measurements of gene expression using
RT-PCR. After 24 hours, cells were transfected with siRNA directed against targets
or a negative siControl 1# (Ambion) (Table 2.4). For each transfection, 4 µl of
siRNA (20 μM stock prepared in nuclease-free water) (Ambion) and 4 µl of 
Lipofectamine™ 2000 (Invitrogen) was separately diluted in 200 µl of OPTI-MEM
medium, and was incubated for 5 minutes at room temperature. Diluted siRNA and
Lipofectamine™ 2000 were mixed gently with a total volume of 400 µl and
incubated for 20 minutes at room temperature. Cells in each well of 96-well plates
were covered by 100 µl of the mixed transfection solution, 400 µl for cells in each
well of 24-well plates, or 1 ml for cells in each well of 6-well plates. Cells were
cultured for 48-72 hours before they were used in experiments. During the
osteogenesis and adipogenesis study, cells were transfected twice with siRNA (see
section 2.2.7 and 2.2.11).
2.2.21 Data analysis
All data are presented as mean ± standard error of mean (S.E.M.), where
appropriate, with n indicating the number of independent experiments
and N indicating the number of wells of cells or cells from all preparations.
Statistical analysis was performed using Student’s unpaired t-test and one-way
ANOVA (with Tukey post hoc test) by Origin software (Origin Lab Corporation,
Northampton, MA, USA), with p < 0.05 being indicative of significance.
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Table 2.3 Primers used for PCR.
Primer Sequence (5’-3’) Expected Size
P2X1 forward primer TTTCATCGTGACCCCGAAGCAG 633
P2X1 reverse primer TCAAAGCGAATCCCAAACACC
P2X2 forward primer ACCTGCCCCGAGAGCATAAG 426
P2X2 reverse primer AATGACCCCGATGACACCACCC
P2X3 forward primer CACCTCGGTCTTTGTCATCATCAC 695
P2X3 reverse primer TGTTGAACTTGCCAGCATTCC
P2X4 forward primer ACAGCAACGGAGTCTCAACAGG 561
P2X4 reverse primer CCTTCCCAAACACAATGATGTCG
P2X5 forward primer AACCTGATTGTGACCCCCAACC 683
P2X5 reverse primer TCGCAGAAGAAAGCACCCTTGC
P2X6 forward primer GGTGACCACTTCCTTGTGACG 476
P2X6 reverse primer CCCAGTGAACTCTGATGCCTACAG
P2X7 forward primer TGCGATGGACTTCACAGATTTG 465
P2X7 reverse primer TGCCCTTCACTCTTCGGAAAC
β-Actin forward primer TTGAGACCTTCAACACCC 300
β-Actin reverse primer TCTCTTGCTCGAAGTCC  
P2Y1 forward primer CCGGCTGTCTACATCTTGGT 152
P2Y1 reverse primer GGCAGAGTCAGCACGTACAA
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Primer Sequence (5’-3’) Expected Size
P2Y2 forward primer CCACCTGCCTTCTCACTAGC 163
P2Y2 reverse primer TGGGAAATCTCAAGGACTGG
P2Y4 forward primer TGCCTGGTCACTCTTGTTTG 205
P2Y4 reverse primer GTACTCGGCAGTCAGCTTCC
P2Y6 forward primer CGACCACATGAGCTCCTACA 198
P2Y6 reverse primer GAGCTTCTGGGTCCTGTGAG
P2Y11 forward primer AGGGCAAAGTGATGTTCCAC 175
P2Y11 reverse primer CCCTCCAGGCTCTTCTTTCT
Orai1 forward primer GCACAATCTCAACTCGG 300
Orai1 reverse primer GCGAAGACGATAAAGATCAG
Orai2 forward primer GCTGAGCTTAACGTGCCTATC 406
Orai2 reverse primer GGAGTTCAGGTTGTGGATGTT
Orai3 forward primer CAAGGCATTGGTCTAGC 298
Orai3 reverse primer AATTCAGTGTCAGAAGAGC
Stim1 forward primer CTCTCTTGACTCGCCA 276
Stim1 reverse primer GCTTAGCAAGGTTGATCT
Stim2 forward primer TGGACCTCTAACACGC 351
Stim2 reverse primer GCATACTGACGTCTACTCAA
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Table 2.4 siRNAs used.
siRNA Sense (5’-3’) Ambion Catalogue No.
siP2X7 GCUUUGCUCUGGUGAGUGAtt S9959
siP2Y1 GCCCUGAUCUUCUACUACUtt S9962
siP2Y11 CACCCUAGGUGUUGCUGGAtt S194676
siOrai1 GGGAAGAGGAUUUUUAUAAtt 34616
siOrai2 GACCAAAGUUUUCCUCUUGtt 131489
siOrai3 CAUCCACAACCUCAACUCUtt S41088
siStim1 GCAGAGUUUUGCCGAAUUGtt 138791
siStim2 GGAACGACACUUCCCAGGAtt 133273
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Chapter 3
Effect of ATP on Cell Proliferation, Migration and Differentiation
of Human Dental Pulp Mesenchymal Stem Cells
3.1 Introduction
Human DP-MSCs provide a promising stem cell source that can have possible
clinical applications as cell therapy for regenerative medicine and dental tissue
engineering due to the fact that they are easily available from teeth after extraction
with very low morbidity and little ethical issues (Batouli, Miura et al. 2003; Yen and
Sharpe 2006; Otaki, Ueshima et al. 2007). A clear understanding of extracellular
signalling molecule and intrinsic mechanism that regulating proliferation, migration
and differentiation of hDP-MSCs is expected to support better use in clinical
applications. It has been demonstrated that hMSCs are strongly influenced by
extracellular signalling molecules such as growth factors and extracellular matrix
protein (Shi and Li 2008; Biver, Wang et al. 2013; Biver, Thouverey et al. 2014). As
a signalling molecule, extracellular ATP has been shown to play a significant role in
a diversity of cell functions, including proliferation, migration and differentiation in
BM-MSCs (Coppi, Pugliese et al. 2007; Ferrari, Gulinelli et al. 2011; Sun, Junger et
al. 2013), embryonic stem cells (Resende, Britto et al. 2008), hematopoietic stem
cells (Lemoli, Ferrari et al. 2004), and neuronal progenitor stem cells (Wu, Lin et al.
2009). However, to date, the effects of extracellular ATP on such function of
hDP-MSCs were unknown.
Therefore, the aim of the study described in this chapter was to investigate the
effects of extracellular ATP on proliferation, migration and differentiation of
hMSCs from dental pulp. The study started with characterization of hMSCs isolated
from dental pulp in order to determine whether such cell preparations meet the
minimal criteria for hMSCs (Dominici, Le Blanc et al. 2006), including plastic
adherence, colony formation, specific surface marker expression and multipotent
differentiation potential. Then, the effects of extracellular ATP on their proliferation,
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migration, osteogenic differentiation and adipogenic differentiation under
established in vitro differentiation conditions were determined.
3.2 Results
3.2.1 Isolation and characterization of cells
3.2.1.1 Isolation of cells from human dental pulp
Human MSCs were isolated from dental pulp tissues from 4 donors: 9F (9 years old,
female), 21F (21 years old, female), 32F (32 years old, female) and 22M (22 years
old, male). The donors frequently used in this study were female due to they were
isolated earlier than the male donor. Figure 3.1A illustrates the dental pulp tissues in
the pulp chamber from the donor 21F. Figure 3.1B shows one single cell adhering to
the plastic bottom of a tissue culture flask following 4 days of culture. The cells
(Passage [P] 0) proliferated and formed small colonies, called colony-forming units
after incubation for 14 days (Figure 3.1C). Most of the cells exhibited the
fibroblast-like and spindle-shaped morphology. These primary cells were
subcultured when reaching 90% confluency. During their later passages (Passage 4),
a majority of cells maintained such morphology (Figure 3.1D).
3.2.1.2 Formation of colony-forming units
The colony-forming unit-fibroblast (CFU-F) assay has been used as an important
assay for the quality of MSCs to determine the incidence of clonogenic cell
preparations (stem-like cells) after they are plated at a low density (Huang, Gronthos
et al. 2009; Vemuri, Chase et al. 2011). P4 cultured cells were seeded at a low cell
density (1×103 cells/well) in 6-well plates and the colony-forming efficiency was
evaluated after 7 days. These cells became adherent onto the plastic surface and
grew to form colonies that were composed of ≥ 50 cells identified upon staining in 
blue using Harris hematoxylin solution. The cells in the colonies, displayed typical
fibroblast-like morphology and alignments in a similar direction (Figure 3.1E-G).
Figure 2.1E and F show typical one single colony (Figure 3.1E) and two adjacent
colonies (Figure 3.1F). There was 31.2 ± 1.2 colonies per 1000 cells from the donor
9F after 7 days in culture (Figure 3.1G). The ability to form CFU-F was also
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examined for cells after storage at -80°C. There were 32.4 ± 1.8 colonies after 14
days in culture (Figure 3.1H). Similarly, there were 29.2 ± 1.4 colonies per 1000
cells after storage at -80°C from the donor 22M after 14 days in culture (Figure
3.1I). These results suggest that these cells from dental pulp were able to self-renew
and form new cell population.
3.2.1.3 Expression of MSC positive and negative markers
To further characterize these cell preparations from the dental pulp, flow cytometry
analysis was performed using well-known MSC positive and negative cell surface
markers (Dominici, Le Blanc et al. 2006). A typical set of flow cytometry
histograms from the donor 9F are shown in Figure 3.2, and the results from all 4
donors (9F, 21F, 22M and 32F) are summarized in Table 3.1. These cells exhibited
strong expression of positive MSCs markers, such as CD105, CD90 and CD73, but
no or very weak expression of negative MSC markers, such as hematopoietic
lineage markers CD45, CD34, CD14. Furthermore, a substantial proportion of cells
(27.5 ± 9.5%) also expressed STRO-1 (Table 3.1).
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Figure 3.1 Isolation, morphology and colony-forming units of hDP-MSCs.
(A) Representative human dental pulp (white arrow, 21F). (B) Single primary
hDP-MSC (P0) cultured for 4 days after treatment with collagenase P. (C)
Representative primary hDP-MSCs (P0) cultured for 14 days. (D) Typical cultured
hDP-MSCs (P4) cultured for 7 days. (E-I) Representative images are showing one
(E) or two colonies (F) formed by hDP-MSCs (P4, 9F) after 7 days in culture. The
number (open circle) and the average number (solid circle) of colony-forming unit
per 1000 P4 cells prepared from the donor 9F after 7 days (G, N = 5) and 14 days (H,
N = 6), and from the donor 22M after 14 days (I, N = 6) are shown.
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Figure 3.2 Flow cytometry analysis of expression of cell-surface markers in
hDP-MSCs.
(A) Isotype control-FITC, CD105-FITC (98.5%), CD90-FITC (99.9%), CD45-FITC
(1.3%), CD34-FITC (1.5%), and CD14-FITC (9.4%). (B) Isotype control-PE,
CD73-PE (99.9%); (C) STRO-1-FITC (11.3%). P4 cells from the donor 9F were
used.
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Table 3.1 Summary of expression of cell surface markers in hDP-MSCs from four
donors.
Donors
Markers
9 Female
(%)
21 Female
(%)
22 Male
(%)
32 Female
(%)
Mean
(%)
N
CD105 93.4 (2)a 40.9 (2) 60.1 51.9(4)a 59.6±7.0 9
CD90 99.9 (2)a 99.1 99.4 99.8 99.6±0.2 5
CD73 99.9 (2)a 98.6 99.8 93.4 98.3±1.3 5
CD45 1.2 (2)a 1.4 4.2 6.4 2.9±1.1 5
CD34 1.2 (2)a 0.9 12.5 0.4 3.2±2.3 5
CD14 8.1 (2)a 10.1 (2)a 3.6 8.9 (2)a 8.2±1.3 7
STRO-1 11.3 28.3 53.8 16.6 27.5±9.5 4
aNote: mean values from two or four independent experiments.
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3.2.1.4 Osteogenic, adipogenic and chondrogenic differentiation
To evaluate the multipotent differentiation capacity of these cells, they were induced
using well-established in vitro osteogenic, adipogenic and chondrogenic
differentiation media (Koyama, Okubo et al. 2009; Karaoz, Dogan et al. 2010).
Representative results are shown in Figure 3.3. The osteogenic differentiation was
examined by ALP staining. The cells cultured under osteogenic conditions displayed
more extensive ALP staining as compared to the control cells or cells cultured under
basal medium (Figure 3.3A-D), demonstrating osteogenic differentiation. The ALP
expression was quantified by the ALP activity assay (see details in the section 2.2.10
in chapter 2).
To examine adipogenic differentiation, the cells were stained by Oil red O staining
(Figure 3.3F-H). Red lipid droplets were discerned in cells cultured in adipogenic
differentiation medium (ADM), but not in cells cultured in basal medium (BM). In
addition, the cells cultured in ADM proliferated more slowly, and exhibited
dramatic changes in their morphologies from a fibroblast-like shape to oval-like
adipocyte one. These observations indicate differentiation into adipocytes.
To test chondrogenic differentiation, cells cultured in a monolayer were analyzed
using Alcian blue staining (Figure 3.3I-L), and cells cultured in pellets by Alcian
blue/Sirius red staining (Figure 3.3M-O). The monolayer cells were also stained by
SYBR Green nucleus staining (Figure 3.3I and K). The cells cultured in
chondrogenic differentiation medium had similar or less cell density as compared
with the cells in basal medium (Figure 3.3I and K), but alcian blue staining of the
cells cultured in chondrogenic differentiation medium (Figure 3.3L) was stronger as
compared to that of the cells in basal medium (Figure 3.3J). Pellets cultured in the
chondrogenic differentiation medium (Figure 3.3O) also showed stronger blue
staining of proteoglycans by Alcian blue and less red staining of collagenous matrix
formation by Sirius red compared to those in basal medium (Figure 3.3N),
suggesting that the cells differentiated into chondrocytes.
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3.2.2 Effects of extracellular ATP on cell proliferation
To examine the influence of extracellular ATP on cell proliferation, cells were
cultured without or with ATP in different concentrations (0.3 μM, 3 μM, 30 μM and 
300 μM) in BM for 72 hours and the number of cells was determined using the XTT 
assay. Cells from the donor 9F cultured in the absence and presence of ATP after 48
or 72 hours significantly increased in number compared with cells cultured for 24
and 48 hours (Figure 3.4A). However, there was no significant difference in
percentage of cell proliferation among the different culture conditions (Figure 3.4B).
The exception was that the cell proliferation was slightly reduced with ATP at 300
μM at 48 hours (Figure 3.4B). Similar results were found for cells from the donor 
21F (Figure 3.4C) and the donor 32F (Figure 3.4D). Overall, the results from all 3
donors show that ATP at the concentrations examined did not have any significant
effect on cell proliferation (Figure 3.4E).
Such findings were observed using cell counting after SYBR Green staining of cells
from the donor 9F. Figure 3.5A-C shows representative phase-contrast SYBR Green
staining and merged images captured using IncuCyte. Typical SYBR Green staining
images of cells cultured without or with ATP from 3 μM to 300 μM at 24, 48, 72 
hours as shown in Figure 3.5D. The number of cells as indicated in the Figure 3.5D
was counted and the results are presented in Figure 3.5E. The results show that the
number of cells without or with ATP at 48 or 72 hours increased as compared to that
at 24 hours (Figure 3.5E). However, there was no significant difference in cells
cultured under the basal medium and basal medium containing different
concentrations of ATP at 24, 48 and 72 hours (Figure 3.5F).
3.2.3 Effects of extracellular ATP on cell migration
To assess whether extracellular ATP affected cell migration, scratch wound healing
assays were performed. Cells were stained by SYBR Green and captured by
IncuCyte 24 hours after wounds were introduced, and the number of cells migrating
into the wound area was counted in each image and corrected by the average cell
density in the adjacent and healthy areas on both sides, resulting in the relative cell
density (%) in the wound area (Figure 3.6A). Representative SYBR Green staining
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images of cells cultured without or with ATP from 3 μM to 300 μM in the wound 
areas are shown in Figure 3.6B. The average relative cell density (%) is presented in
Figure 3.6C, and the results after normalized to cells in the basal medium are shown
in Figure 3.6D. While there was no difference in the migration between cells
cultured in basal conditions and cells exposed to ATP at 3 μM (Figure 3.6D). ATP at 
30 μM and 300 μM significantly increased the cell migration. Similar results were 
observed for cells from the donor 21F (Figure 3.6E) and the donor 32F (Figure
3.6F). The mean data from all 3 donors are shown in Figure 3.6G.
The wound areas are reduced or narrowed as cells migrate into and fill the wound
areas (Figure 3.7A). The time course of migrated distance was measured using
IncuCyte in the absence of ATP or in the presence of ATP at 3 μM and 30 μM for 
cells from the donor 9F are shown Figure 3.7 B. The migration areas at 24, 36 and
48 hours were calculated (see section-2.2.17 in chapter 2) and shown in Figure 3.7C,
and further expressed as percentage of the migration area in the basal medium
(Figure 3.7D). ATP at 3 μM did not change the cell migration area, whereas ATP at 
30 μM significantly increased the cell migration at 24, 36 and 48 hours. Similar 
results were obtained for cells from the donor 21F (Figure 3.7E) and the donor 32F
(Figure 3.7F). The mean data from all 3 donors are summarized in Figure 3.7G.
Overall, these results are consistent with those from cell counting and support that
ATP at 30 μM significantly promotes cell migration.    
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Figure 3.3 Differentiation potential of hDP-MSCs.
(A-D) ALP staining of hDP-MSCs (P4, 9F) cultured in the basal medium (A, C) and
osteogenic differentiation medium (B, D). (E-H) Oil red O and Hematoxylin
staining of hDP-MSCs cultured in the basal medium (E, G) and adipogenic
differentiation medium (F, H). (K-J) SYBR Green and Alcian blue staining of
hDP-MSCs cultured in the basal medium (I, J) and chondrogenic differentiation
medium (K, L). (M-O) Alcian blue and Sirius red staining of hDP-MSCs pellets (M,
chondrogenic differentiation medium) cultured in the basal medium (N) and
chondrogenic differentiation medium (O).
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(Figure 3.4)
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Figure 3.4 No effect of ATP on hDP-MSC proliferation by XTT assay.
(A-B) hDP-MSCs (P4, 9F) were cultured in basal medium without or with ATP
from 0.3 µM to 300 µM for 24, 48 and 72 hours. The number of live cells are
determined by the XTT assays and are presented as the OD value (A) and
percentage of those in the basal medium alone (B), N = 6 wells. (C-E) The average
percentage of cell proliferation in hDP-MSCs is shown: (C) 21F, P4, N = 6 wells; (D)
32F, P4, N = 4 wells; (E) 9F, 21F and 32F, n/N = 3/16. *, p < 0.05, **, p < 0.01, ***,
p < 0.001; compared to the control (no ATP). #, p < 0.05, ##, p < 0.01.
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(Figure 3.5)
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Figure 3.5 No effect of ATP on hDP-MSC proliferation by cell counting.
(A-C) Phase-contrast (A) and fluorescent SYBR Green staining (B) images of
hDP-MSCs (9F, P4) under the indicated conditions. The merged images are shown
in (C). (D-E) SYBR Green staining imaging (D) and the cell number per field (E) of
hDP-MSCs cultured in basal medium without or with ATP from 3 µM to 300 µM
for 24 hours, 48 hours and 72 hours. (F) The percentage of cell proliferation in
hDP-MSCs cultured in basal medium alone are shown, N = 4 wells. *, p< 0.05, **,
p< 0.01, ***, p< 0.001; compared to the control (no ATP).
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Figure 3.6 Effects of ATP on hDP-MSC migration by counting cells.
(A) Typical images showing the wound area immediately after being introduced by
scratching and 24 hours later. From left to right, images are phase-contrast at the
start time (0 hour), and phase-contrast and SYBR Green staining at 24 hours. (B)
Typical images showing the wound after 24 hours in the basal medium without or
with ATP from 0.3 µM to 300 µM (P4, 9F). (C-D) The relative density of cells in
the wound area were calculated (C) and expressed as percentage of that in the basal
medium without ATP (D), N = 7 wells. (E-G) The average percentage of hDP-MSC
migration is shown: (E) 21F, P4, N = 5 wells; (F) 32F, P4, N = 5 wells; (G) all three
donors, n/N = 3/17. *, p < 0.05, **, p < 0.01, ***, p < 0.001; compared to the
control (no ATP).
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Figure 3.7 Effects of ATP on hDP-MSC migration determined by real-time
imaging.
(A) Typical images showing the wound at 0 hour and 24 hours later. From left to
right, images are the initial wound at the start time (0 hour), the wound at 24 hours,
and the superimposition view (the white grey indicates the migrated width). (B) The
changes in the migration distance in the basal medium without or with ATP from 3
µM to 30 µM for 72 hours (P4, 9F), N = 5 wells. (C-D) The relative migration area
was calculated (C) and expressed as percentage of that in basal medium without
ATP (D), N = 5 wells. (E-G) The average percentage of cell migration is shown: (E)
21F, P4, N = 5 wells; (F) 32F, P4, N = 5 wells; (G) all three donors, n/N = 3/15. *, p
< 0.05, **, p < 0.01, ***, p < 0.001; compared to the control (no ATP).
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3.2.4 Effects of extracellular ATP on osteogenic differentiation
As mentioned above, the ALP staining was considerably increased in cells cultured
for 14 days in ODM. Treatment with ATP (3 μM and 30 μM) caused a noticeable 
reduction in the ALP staining in cells cultured in both BM and ODM (Figure 3.8A).
To quantitatively evaluate the effect of extracellular ATP on the osteogenic
differentiation, the ALP activity assays were conducted. The DNA content (μg/ml), 
an indicator of the cell number, in BM showed significantly higher than that in
ODM (Figure 3.8B). However, treatment with ATP did not have any significant
effect on the DNA content of cells cultured in both BM and ODM. To minimise the
potential effect of the difference in the cell proliferation, the ALP activity per
microgram of DNA was used to indicate the ability of cells to undergo osteogenic
differentiation. The ALP activity in cells from the donor 9F, before and after
normalized to that in the control cells or cells that were not treated with ATP are
shown in Figure 3.8C-D. The ALP activity in cells in ODM exhibited significantly
higher than that in BM (Figure 3.8C), consistent with the increase in the ALP
staining (Figure 3.8A and Figure 3.3A-D). The ALP activity (%) in cells in both BM
and ODM was significantly decreased by ATP at 30 μM, not at 3 μM. Similar 
inhibition of the ALP activity by ATP were obtained in cells from the donor 21F
(Figure 3.8E) and the donor 32F (Figure 3.8F). The mean data from all 3 donors are
shown in Figure 3.8G. These results support that ATP inhibits osteogenic
differentiation of hDP-MSCs.
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Figure 3.8 Effects of ATP on osteogenic differentiation of hDP-MSCs.
(A) Typical ALP staining of hDP-MSCs (P4, 9F) cultured for 14 days in the basal
medium and osteogenic differentiation medium without or with ATP at 3 µM and 30
µM. (B-D) The DNA content (B) and ALP activity per µg of DNA (C) were
calculated and expressed as percentage of that in the basal medium without ATP
(D), n/N = 3/12. (E-G) The average percentage of the ALP activity in hDP-MSCs is
shown: (E) P4, 21F, N = 4; (F) P4, 32F, N = 4; (G) 9F, 21F and 32F, n/N = 5/20. *,
p < 0.05, **, p < 0.01, ***, p < 0.001; compared to the control (no ATP).
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3.2.5 Effects of extracellular ATP on adipogenic differentiation
To evaluate the influence of extracellular ATP on adipogenic differentiation, cells
were incubated in BM and ADM without or with ATP at 3 μM and 30 μM for 21 
days and were stained with Oil red O to identify the lipid droplets-containing
adipocytes. Lipid droplets were not detected in the cells cultured in BM, but were
clearly visible in a subset of cells cultured in ADM (Figure 3.9A). The number of
adipogenic cells from the donor 9F is shown in Figure 3.9B, and the data expressed
as percentage of the control cells in ADM alone without ATP are shown in Figure
3.9C. ATP alone did not induce adipogenic differentiation of hDP-MSCs cultured in
BM. However, ATP at 30 μM, but not at 3 μM, significantly increased the 
adipogenic differentiation of hDP-MSC in ADM. Similar results were observed in
cells from the donor 21F (Figure 3.9D) and the donor 32F (Figure 3.9E). The mean
data from all 3 donors are shown in Figure 3.9F. Taken together, these results show
that ATP cannot induce but can facilitate the adipogenic differentiation.
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Figure 3.9 Effects of ATP on adipogenic differentiation of hDP-MSCs.
(A) Typical Oil red O staining after cells (P4, 9F) cultured for 21 days in BM and
adipogenic differentiation medium (ADM) with or without ATP at 3 μM or 30 μM. 
Red arrows indicate fat-containing cells or adipocytes. (B) The positively-stained
cells were counted and expressed as the number of adipogenic cells in every 300
cells. (C-F) The average percentage of adipogenic differentiation of hDP-MSCs as
compared to cells without ATP in ADM is shown: (C) P4, 9F, N = 4 wells; (D) P4,
21F, N = 4 wells; (E) P4, 32F, N = 4 wells; (F) 9F, 21F and 32F, n/N = 3/12 wells. *,
p < 0.05, **, p < 0.01, ***, p < 0.001; compared to the control (no ATP).
- 94 -
3.3 Discussion
In this chapter, MSC cells from human dental pulp were isolated as described by
previous studies to isolate MSCs from adipose tissue (Rubio, Garcia-Castro et al.
2005) and placenta (Chang, Kao et al. 2007). Early passages (<5) of these cells were
used to avoid loss of their stem cell characteristics during in vitro culture (Bonab,
Alimoghaddam et al. 2006; Coppi, Pugliese et al. 2007; Ferro, Spelat et al. 2012).
The results show that these cells can form CFU-F, express the positive MSC
markers and no or a very low level of the negative MSC markers, and exhibit
osteogenic, adipogenic and chondrogenic differentiation. In summary, the cells
isolated from human dental pulp meet the criteria for MSCs (Dominici, Le Blanc et
al. 2006).
First of all, these cells were plastic-adherent and grew well on plastic surfaces
(Figure 3.1B and C). The colony-forming efficiency assay demonstrated that a small
subsets of cells was clonogenic (Figure 3.1E-I), as previously reported for the
BM-MSCs (Gronthos, Mankani et al. 2000). The results from the present study also
showed that there was no significant difference in the colony-forming efficiency (~
30 colonies/103 cells) between the donors 9F and 22M (Figure 3.1H and I),
indicating hDP-MSCs from different donors had similar clonogenic capability.
Secondly, Flow cytometry assays showed that these cells expressed a high level of
CD105, CD90 and CD73, and a very low level of CD45, CD34 and CD14 (Table
3.1). However, the prevalence of the CD105 expression observed in the present
study, 59.6 ± 7.0%, was slightly low. The cells with a similar expression level of
CD105 (51.7%) were able to maintain mesenchymal multipotent differentiation
potential and thus can be considered as MSCs (Mark, Kleinsorge et al. 2013). The
expression level of CD14 (8.2 ± 1.3%) was slightly high, but a similar expression
level of CD14 (5-9%) was also observed in hBM-MSCs (Pilz, Braun et al. 2011).
Furthermore, the present study shows the MSC positive marker STRO-1 was
expressed in a substantial number of cells (27.5 ± 9.5%), which was similar to that
reported in BM-MSCs (Mafi, Hindocha et al. 2011). Therefore, the results from flow
cytometry assay indicate that these cells show a similar expression profile of the
surface markers of MSCs (Mark, Kleinsorge et al. 2013). Finally, these cells also
displayed the ability of osteogenic, adipogenic, chondrogenic differentiation using
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well-established in vitro differentiation inducing media and examination methods
(Pittenger, Mackay et al. 1999; Augello and De Bari 2010), indicating that these
cells have multipotent differentiation potential (Figure 3.3). Therefore, the cells
isolated from dental pulp in this study have similar cell properties as MSCs reported
in previous studies and thus termed hDP-MSCs in the rest of this thesis.
The study described in this chapter further examined the effects of extracellular ATP
on several functional properties of hDP-MSCs, including cell proliferation,
migration, adipogenic and osteogenic differentiation. The results from both XTT
assay and cell counting indicate that ATP (0.3-300 μM) did not have any significant 
effect on hDP-MSC proliferation of (Figure 3.4 and 3.5). This is similar with a
previous study that demonstrated that ATP (1-100 μM) had no significant effect on 
hBM-MSC proliferation although ATP at a higher concentration (1 mM) decreased
cell proliferation (Ferrari, Gulinelli et al. 2011). However, another previous study
showed that ATP at low concentration of 10 μM decreased hBM-MSC proliferation 
(Coppi, Pugliese et al. 2007). In contrast, another early study reported that ATP at
25-250 μM increased hBM-MSCs proliferation (Riddle, Taylor et al. 2007). Such 
discrepancies among different studies may arise from different cell preparations,
different durations of ATP treatment and also proliferation assays used.
The present study using wound healing assays demonstrates that hDP-MSC
migration was enhanced by exposure to extracellular ATP at 30- 300 μM for 24-72 
hours (Figure 3.6 and 3.7). ATP at 1 mM was reported to induce hBM-MSC
migration using transwell assays (Ferrari, Gulinelli et al. 2011). Similar to what
observed in the present study, ATP at 20 μM stimulated migration of hepatocellular 
carcinoma cells using both wound healing and transwell migration assays (Xie, Xu
et al. 2014).
The results obtained in the present study also show that extracellular ATP (30 μM) 
significantly decreased the ALP activity in hDP-MSCs cultured in both BM and
ODM (Figure 3.8), suggesting that ATP significantly inhibits or down-regulates the
osteogenic differentiation. However, a previous study reported that pretreatment
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with of ATP (0.1 – 100 μM) for 5 minutes enhanced the ALP activity in hBM-MSCs 
(Sun, Junger et al. 2013). In addition, pretreatment of hBM-MSCs with 1 mM ATP
for 24 hours promoted mineralization as shown by increased Alizarin Red staining
and expression of RUNX2 (runt-related transcription factor 2, an osteoblast-related
gene) (Ciciarello, Zini et al. 2013). In this study, hDP-MSCs were cultured in ODM
along with ATP during the differentiation process. It is possible that the different
results observed by the previous and present studies are due to the different
treatment durations used. In contrast with the inhibitory effects on the osteogenic
differentiation potential, treatment with extracellular ATP (30 μM) increased the 
number of cells containing lipid droplets in hDP-MSCs cultured in ADM, indicating
that extracellular ATP enhances adipogenic differentiation potential (Figure 3.9).
This is consistent with the recent findings that lipid droplets formation and the
expression level of PPARγ are improved during adipogenic differentiation of 
hBM-MSCs after preincubation with 1 mM ATP for 24 hours (Ciciarello, Zini et al.
2013).
In summary, the studies presented in this chapter show that extracellular ATP
promotes hDP-MSC migration, but has no effect on cell proliferation. In addition,
ATP inhibits the osteogenic differentiation potential and by contrast enhances the
adipogenic differentiation potential of hDP-MSCs. The following chapters will
investigate the expression of signalling mechanisms activated by extracellular and
their role in ATP-induced regulation of migration, osteogenesis and adipogenesis of
hDP-MSCs.
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Chapter 4
Expression of P2 Purinergic Receptors in Human Dental Pulp
Mesenchymal Stem Cells
4.1 Introduction
The results presented in chapter 3 have shown that extracellular ATP significantly
promotes cell migration and regulates adipogenic and osteogenic differentiation
potential of hDP-MSCs. It is well established that ATP imposes various effects via
activating P2X and P2Y receptors as discussed in Introduction chapter (see section
1.4.2 and 1.4.4). It has been reported that hBM-MSCs express both P2X and P2Y
receptors (Ferrari, Gulinelli et al. 2011). The mRNA expression for all P2X and P2Y
receptors except P2X2 was observed in hBM-MSCs by real-time RT-PCR, and the
protein expression of the P2X1, P2X4, P2X7, P2Y1, P2Y2 and P2Y11 receptors
were demonstrated by Western blotting (Ferrari, Gulinelli et al. 2011). Other studies
provide evidence to suggest the functional expression of P2Y1 (Coppi, Pugliese et al.
2007) and P2X7 receptors in hBM-MSCs (Sun, Junger et al. 2013). Furthermore,
recent studies suggest ATP via the P2X7 receptor regulates the osteogenic
differentiation of hBM-MSCs (Sun, Junger et al. 2013), and via the P2Y receptors to
regulate adipogenic differentiation (Ciciarello, Zini et al. 2013). However, the
current understanding of the ATP-sensitive P2X and P2Y receptors in hBM-MSCs
remains incomplete and inconsistent, which prevent a clear understanding of the
intrinsic mechanisms that are responsible for the various effects of extracellular ATP
on hMSCs.
Nothing is known regarding the expression of the P2 purinergic receptors in
hDP-MSCs. Therefore, the aim of the study described in this chapter was to
investigate the functional expression of the P2X and P2Y purinergic receptors for
extracellular ATP in hDP-MSCs. Activation of ATP-sensitive P2X and P2Y
receptors lead to increases in the [Ca2+]i, which were measured using single cell Ca2+
imaging and FLEXstation, in a combination of P2 purinergic receptors agonists,
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antagonists and specific siRNAs. Moreover, the mRNA expression of P2X and P2Y
receptors was examined by real-time RT-PCR.
4.2 Results
4.2.1 Ca2+ oscillations and ATP-induced Ca2+ responses in individual
cells
Single cell Ca2+ imaging was firstly used to measure the changes in the [Ca2+]i in
individual cells. In the extracellular Ca2+-containing solutions, 12 out of 40 cells
examined displayed spontaneous Ca2+ oscillations in the absence of exogenous
application of ATP. Examples are shown in Figure 4.1A and B. The average number
of the Ca2+ spike events (ΔF340/F380≥ 0.05) during a period of 10-minute recording 
was about 3 (Figure 4.1C) and the average amplitude was 0.06 (Figure 4.1D).
Cells not exhibiting Ca2+ oscillations were used to study ATP-induced Ca2+
responses. Cells responded with a rapid increase in the [Ca2+]i to application of
extracellular ATP at 100 μM (Figure 4.1E). Such ATP-induced Ca2+ responses were
observed in 16 of 17 cells examined. ATP also induced strong Ca2+ responses in a
majority of individual cells (14 of 15 cells) in the extracellular Ca2+-free solutions
(Figure 4.1F). The peak amplitude of ATP-induced Ca2+ responses was not
significantly different in the extracellular Ca2+-containing and Ca2+-free solutions.
However, the ATP-induced Ca2+ responses in the extracellular Ca2+-containing
solutions were sustained significantly longer than those in the extracellular Ca2+-free
solutions (Figure 4.1G). These results indicate expression of ATP-sensitive P2
receptors in hDP-MSCs.
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Figure 4.1 Spontaneous and ATP-induced Ca2+ responses in single hDP-MSCs.
(A-B) Typical spontaneous Ca2+ oscillations in individual cells (P4, 9F) are shown.
(C-D) Summary of the average number of the Ca2+ spikes (C) and changes in
F340/F380 during a period of 10-minute recording (D), N = 12 out of 40 cells. (E-F)
Changes in the F340/F380 in individual cells treated with ATP at 100 μM in the 
absence (E, N = 14 out of 15 cells) and presence (F, N = 16 out of 17 cells) of
extracellular Ca2+. (G) The average change in the F340/F380 in cells treated with ATP
at 100 μM in the extracellular Ca2+-containing solutions and extracellular Ca2+-free
solutions. *, p< 0.05, compared the amplitude of Ca2+ responses in the extracellular
Ca2+-containing and Ca2+-free solutions at the same time points.
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4.2.2 RT-PCR analysis of mRNA expression of P2 receptors
The mRNA expression of the P2 receptors in hDP-MSCs was examined using
real-time RT-PCR. The primers and PCR protocols were validated using plasmids.
In addition, the mRNA for β-actin was consistently detected. As shown in Figure 4.2 
A and B, the mRNA expression for P2X4, P2X6, P2X7, P2Y1, P2Y4, P2Y6 and
P2Y11 was detected in hDP-MSCs from all three donors examined (Figure 4.2A,
B). The P2Y2 mRNA was detected in hDP-MSCs from one donor (9F) but very
weak or not in hDP-MSCs from other two donors (21F and 32F) (Figure 4.2B). In
contrast, the mRNA expression for P2X1, P2X2, P2X3 and P2X5 was not detected
in hDP-MSCs from all three donors. The mRNA expression levels for each of these
P2 receptors relative to β-actin from two independent preparations, each in 
triplicates (n/N = 2/6) is summarized in Figure 4.2C. There are noticeable variations
in the mRNA expression level among the three donors. The P2Y11 is most abundant
in hDP-MSCs from all three donors.
To further investigate the functional expression of the P2 receptors for extracellular
ATP, the increases in the [Ca2+]i induced by ATP and other known P2 receptor
subtypes selective agonists and the effects of known P2 receptor antagonists on
agonist-induced Ca2+ responses were examined using FLEXstation.
4.2.3 Effects of PPADS on ATP-induced Ca2+ responses
As seen in Figure 4.3A, ATP induced significant Ca2+ responses in the extracellular
Ca2+-containing solutions that reached the maximum after 20-40 seconds and
gradually declined (Figure 4.3A). The maximum Ca2+ responses induced with 300
μM ATP are shown in Figure 4.3B and C. The effect of PPADS, a generic P2 
receptor antagonist (see section 1.3.1), on the ATP-induced Ca2+ responses was
measured. Pre-treatment with PPADS at 10 µM for 30 minutes significantly
inhibited ATP-evoked increases in the [Ca2+]i in hDP-MSCs from all three donors
(Figure 4.3D-G), indicating that ATP-sensitive P2 receptors are functionally
expressed.
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(Figure 4.2)
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Figure 4.2 The mRNA expression of P2 receptors in hDP-MSCs.
(A) Representative images of agarose gel analysis of PCR products. The expression
of P2X4, P2X6 and P2X7 was consistently observed, while the expression of P2X1,
P2X2, P2X3 and P2X5 was not detected. The primers for the latter group of P2X
receptors were validated using plasmids. (B) The expression of P2Y1, P2Y4, P2Y6
and P2Y11 receptors was detected, whereas the P2Y2 expression was detected only
in the donor 9F. (C) The mRNA expression levels of the indicated P2 receptors
relative to that of β-actin are shown (n/N = 2/6). 
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(Figure 4.3)
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Figure 4.3 ATP-induced Ca2+ responses and inhibition by PPADS.
(A-C) Typical Ca2+ responses (A: 9F, 21F, 32F, P4, N = 4 wells for each case), and
summary of the average maximum change in the F340/F380 in cells for each donor (B)
and average maximum changes from all three donors (C). ATP at 300 μM was used. 
(D-F) The effect of PPADS at 10 μM on ATP-induced Ca2+ responses: (D) 9F; (E)
21F; (F) 32F. P4, N = 4 wells for each case. (G) Summary of the average percentage
of inhibition by PPADS in cells (9F, 21F and 32F) (n/N = 5/20). *, p< 0.05, **, p<
0.01, ***, p< 0.001; compared to the control (ATP alone).
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4.2.4 Ca2+ responses to P2X receptor agonists
In the following experiments, the Ca2+ responses induced by P2X receptor subtype
selective agonists, BzATP and αβmeATP were investigated in order to further 
define the P2X receptors expressed in hDP-MSCs. Figure 4.4A-C show the Ca2+
responses to ATP at 300 μM, αβmeATP at 100 μM, and BzATP at 300 μM in the 
presence of extracellular Ca2+. While αβmeATP did not evoke discernible increases 
in the [Ca2+]i (Figure 4.4B), BzATP induced strong Ca2+ responses (Figure 4.4C).
The maximum Ca2+responses induced by BzATP were significantly higher than that
by ATP in hDP-MSCs from all three donors (Figure 4.4D-F).
4.2.5 ATP and BzATP concentration-response relationships
In order to determine the sensitivity to ATP and BzATP, agonist concentration-Ca2+
response relationship curves were constructed. Figure 4.5A shows the Ca2+
responses to ATP at 0.3 µM, 3 µM, 30 µM and 300 µM in hDP-MSCs from the 9F
donor. Figure 4.5B summarizes the ATP concentration-response relationship curve;
fitting the data to the Hill equation yielded an EC50 of 22 µM and Hill coefficient
(nH) of 0.5 (Figure 4.5B). Figure 4.5C shows the Ca2+ responses induced by BzATP
at 10 µM, 30 µM, 100 µM and 300 µM in hDP-MSCs from the 9F donor. The EC50
for BzATP was 87 µM and nH value was1.4 (Figure 4.5D).
4.2.6 Effects of P2X antagonists on ATP-induced Ca2+ responses
To further assess whether the cells express functional P2X4 and P2X7 receptors, the
effects of 5-BDBD and AZ11645373 on ATP-induced Ca2+ responses were
examined. 5-BDBD is a P2X4 selective antagonist with an IC50 of ~0.50 μM (see 
section 1.3.2.4). Pre-treatment with 5-BDBD at 10 µM for 30 minutes before
exposure to ATP produced no significant inhibition on ATP-evoked Ca2+ responses
in hDP-MSCs from all three donors (Figure 4.6A-E), indicating no functional
expression of the P2X4 receptor.
AZ11645373 is a P2X7 selective antagonist with an IC50 of ~5-20 nM for the hP2X7
receptor (see section 1.3.2.7). Pre-treatment with AZ11645373 at 1 µM for 30
minutes caused significant inhibition on ATP-evoked Ca2+ responses in hDP-MSCs
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from all three donors (Figure 4.7A-D). On average, AZ11645373 blocked
ATP-induced Ca2+ responses by 35 ± 5% (Figure 4.7E), indicating that functional
expression of the P2X7 receptor.
4.2.7 Ca2+ responses induced by P2Y receptor agonists
To assess functional expression of the P2Y receptors, the increases in the [Ca2+]i in
response to several P2Y receptor subtype selective agonists were measured. These
experiments were conducted in the extracellular Ca2+-free solutions in order to avoid
the contribution of Ca2+ entry through the P2X receptors as described above and also
the contribution of Ca2+ entry through the SOC channels that are activated as a result
of the P2Y receptor activation (see section 1.3.4 in the Introduction chapter), which
is to be examined in the next chapter. ATP is a full and partial agonist at P2Y1,
P2Y2 and P2Y11, ADP at P2Y1, UTP at P2Y2 and P2Y4, MRS4062 at P2Y4, UDP
at P2Y6, and BzATP at P2Y1 and P2Y11 (see section 1.3.3 in the Introduction
chapter). Figure 4.8A-F show representative Ca2+ responses to ATP, ADP, UTP,
MRS4062, UDP and BzATP all at 100 μM. Figure 4.8G-I summarize the mean 
amplitude of Ca2+ responses in hDP-MSCs from all three donors. Figure 4.8J shows
the mean Ca2+ responses expressed as percentage of the Ca2+ responses induced by
ATP in each of three donors. There was no significant difference in the Ca2+
responses induced by ATP, ADP, UTP and BzATP. In contrast, the Ca2+ responses
induced by MRS4062 were significantly lower than those by ATP.UDP-evoked
responses were very small or undetectable in all three donors (Fig.4.8E and G-J).
These results suggest that the P2Y1, P2Y2, P2Y4 and P2Y11 receptors are
functionally expressed, but the P2Y6 receptor is not or very weakly expressed in
hDP-MSCs.
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Figure 4.4 Ca2+ responses to P2X receptor agonists in hDP-MSCs.
(A-C) Representative Ca2+ responses to ATP at 300 μM (A), αβmeATP at 100 μM 
(B) and BzATP at 300 μM (C) in the presence of extracellular Ca2+. (D-F) The
average change in F340/F380 induced by ATP, αβmeATP and BzATP as shown in 
A-C: (D) 9F; (E) 21F; (F) 32F. P4, N = 4 wells for each case. *, p< 0.05, **, p<
0.01, ***, p< 0.001; compared to ATP.
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Figure 4.5 Agonist concentration-Ca2+ response relationship curves for ATP and
BzATP.
(A) The Ca2+ responses to ATP at 0.3µM, 3 µM, 30 µM and 300 µM in hDP-MSCs
(P4, 9F) in the presence of extracellular Ca2+; N = 4 wells for each case. (B) The
ATP concentration-response relationship curve derived from fitting the data to the
Hill equation (EC50 = 22 µM and nH = 0.5). (C) The Ca2+ responses induced by
BzATP at 10 µM, 30 µM, 100 µM and 300 µM in hDP-MSCs (P4, 9F) in the
presence of extracellular Ca2+. N = 4 wells for each case. (D) The BzATP
concentration-response relationship curve from fitting to the Hill equation (EC50 =
87 µM and nH = 1.4).
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Figure 4.6 No effect of P2X4 receptor antagonist 5-BDBD on ATP-induced Ca2+
responses.
(A) Representative Ca2+ responses to ATP in hDP-MSCs (P4, 21F) pretreated
without or with 5-BDBD at 10 µM. ATP at 300 µM was used. (B-D) Summary of
the average maximum change in F340/F380 in hDP-MSCs: (B) 21F; (C) 9F; (D) 32F.
P4, N = 4 wells for each case. (E) The percentage of inhibition by 5-BDBD in
hDP-MSCs from all three donors, n/N = 3/12 wells. NS, no significant difference
compared to ATP alone.
- 110 -
Figure 4.7 Inhibition of ATP-induced Ca2+ responses by P2X7 receptor antagonist
AZ11645373.
(A) Representative Ca2+ responses to ATP in hDP-MSCs (P4, 21F) pretreated
without or with AZ11645373 at 1 µM. ATP at 300 µM was used. (B-D) Summary
of the average maximum change in the F340/F380 in hDP-MSCs: (B) 21F; (C) 9F; (D)
32F. P4, N = 4 wells for each case. (E) The percentage of inhibition by AZ11645373
in hDP-MSCs from all three donors, n/N = 3/12 wells. *, p< 0.05, **, p< 0.01, ***,
p< 0.001; compared to ATP alone.
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(Figure 4.8)
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Figure 4.8 Ca2+ responses to P2Y receptor agonists in hDP-MSCs.
(A-F) Representative Ca2+ responses to 100 μM ATP (A), ADP (B), UTP (C), 
MRS4062 (D), UDP (E) and BzATP (F) in hDP-MSCs (P4, 9F) in the absence of
extracellular Ca2+. (G-J) Summary of the average change in F340/F380 as shown in
A-F: (G) 9F, P4, N = 4 wells; (H) 21F, P4, N = 4 wells; (I) 32F, P4, N = 4 wells; (J)
all donors, n/N = 3/12 wells. *, p< 0.05, **, p< 0.01, ***, p< 0.001; compared to
ATP.
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4.2.8 The role of P2X7 receptor in ATP-induced Ca2+ responses
The P2X7 mRNA expression and the sensitivity of ATP-induced Ca2+ responses to
AZ11645373 support expression of the P2X7 receptor. In order to provide further
evidence support contribution of the P2X7 receptor in ATP-induced Ca2+ signalling,
Ca2+ responses to ATP or BzATP in cells transfected with P2X7 specific siRNA
(siP2X7) were examined.
In order rule out the potential non-specific effect of scrambled or control siRNA
(siControl), used as a negative control, the Ca2+ responses induced by 300 µM ATP
in untransfected hDP-MSCs and hDP-MSCs transfected with siControl were
examined. There was no significant difference in ATP-induced Ca2+ responses
between untransfected and siControl-transfected cells (Figure 4.9A). Such
observations were made in hDP-MSCs from all three donors (Figure 4.9B-E),
suggesting that transfection with siControl has no discernible specific effect.
The mRNA expression level of the P2X7 receptor in hDP-MSCs transfected with
siControl and siP2X7 was determined by real-time RT-PCR. Compared with cells
treated with siControl, the mRNA expression level of the P2X7 receptor was
reduced by 55 ± 5% using siP2X7 in hDP-MSCs from the donors 21F and 32F (n/N
= 2/6) (Figure 4.10A-B). The reduced P2X7 expression by siRNA resulted in a
significant decrease in ATP-induced Ca2+ responses in hDP-MSCs from all three
donors (Figure 4.10C-F). The average decrease reached 27 ± 4% (n/N = 3/12)
(Figure 4.10G). Treatment with siP2X7 also significantly decreased the Ca2+
responses induced by 300 μM BzATP (Figure 4.10H-K). The BzATP-induced Ca2+
responses were decreased on average by 34 ± 3% (Figure 4.10L). These results
provide further evidence to support that the P2X7 receptor is expressed in
hDP-MSCs and contributes to ATP-induced Ca2+ responses.
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Figure 4.9 Effect of siControl on ATP-induced Ca2+ responses in hDP-MSCs.
(A) Typical ATP-induced Ca2+ responses in untransfected (control) or transfected
hDP-MSCs (P4, 21F) with siControl. (B-D) Summary of the average maximum
change in F340/F380: (B) 21F; (C) 9F; (D) 32F. P4, N = 4 wells for each case. ATP at
300 μM was used. (E) Summary of the average maximum change of the F340/F380 in
all donors, n/N = 3/12 wells. NS, no significant difference compared to the control.
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(Figure 4.10)
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Figure 4.10 Effects of knocking down the P2X7 expression on Ca2+ responses by
ATP and BzATP in hDP-MSCs.
(A) The mRNA expression level of P2X7 relative to that of β-actin in hDP-MSCs 
transfected with siP2X7 and siControl. n/N = 2/6 (21F, P4, N = 3 wells; and 32F, P4,
N = 3 wells). (B) The mRNA expression level of P2X7 receptor in hDP-MSCs
transfected with siP2X7 (n/N = 2/6) as percentage of that in hDP-MSCs transfected
with siControl. (C) Typical ATP-induced Ca2+ responses in hDP-MSCs (9F, N = 4
wells) transfected with siP2X7 and siControl. ATP at 300 μM was used. (D-G) 
Summary of the average maximum change in F340/F380: (D) 9F, P4, N = 4 wells; (E)
21F, P4, N = 4 wells; (F) 32F, P4, N = 4 wells; (G) all donors, n/N = 3/12. (H)
Typical BzATP-induced Ca2+ responses in hDP-MSCs (9F, N = 4 wells) transfected
with siP2X7 and siControl. BzATP at 300 μM was used. (I-G) Summary of the 
average maximum change in F340/F380: (I) 21F, P4, N = 4 wells; (J) 9F, P4, N = 4
wells; (K) 32F, P4, N = 4 wells; (L) all donors, n/N = 3/12. *, p< 0.05, **, p< 0.01,
***, p< 0.001; compared to siControl.
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4.2.9 The role of P2Y1 receptor in ATP-induced Ca2+ responses
The P2Y1 mRNA expression and ADP-induced Ca2+ responses support functional
expression of P2Y1 receptors. To provide further independent evidence to support
the P2Y1 receptor is involved in extracellular ATP-induced Ca2+ signalling, the Ca2+
responses to ATP or ADP in cells transfected with P2Y1 specific siRNA (siP2Y1)
were determined. The mRNA expression level of the P2Y1 receptor in hDP-MSCs
transfected with siControl and siP2Y1 was examined by real-time RT-PCR.
Compared with cells treated with siControl, the mRNA expression level of the P2Y1
receptor was decreased by 81 ± 5% using siP2Y1 (Figure 4.11A-B). The reduced
P2Y1 expression using siP2Y1 resulted in a significant decrease in ADP-induced
Ca2+ responses in hDP-MSCs from all three donors (Figure 4.11C-F). The average
decrease reached 51 ± 9% (Figure 4.11G). Knockdown of the P2Y1 receptor
expression with siP2Y1 also significantly decreased the Ca2+ responses induced by
ATP (Figure 4.12H-K). The average ATP-induced Ca2+ responses were attenuated
by 43 ± 8% (Figure 4.11L). These results provide further strong evidence to support
that the P2Y1 receptor is expressed in hDP-MSCs and contributes to ATP-evoked
Ca2+ responses.
4.2.10 The role of P2Y11 receptor in ATP-induced Ca2+ responses
The P2Y11 mRNA expression and BzATP-induced Ca2+ responses in the
extracellular Ca2+-free solutions support functional expression of the P2Y11 receptor.
In order to investigate further contribution of the P2Y11 receptor in ATP-induced
Ca2+ signalling, Ca2+ responses to ATP in cells transfected with P2Y11 specific
siRNA (siP2Y11) were performed. The mRNA expression levels of the P2Y11
receptor were determined by RT-PCR in cells transfected with siControl and
siP2Y11. Compared with cells treated with siControl, the mRNA expression level of
the P2Y11 receptor was reduced by 51 ± 5% using siP2Y11 (Figure 4.12A-B).
Reduced P2Y11 expression by siP2Y11 resulted in a significant decrease in
ATP-induced Ca2+ responses in cells from all three donors (Figure 4.12C-F). The
average decrease reached 35 ± 6% (Figure 4.12G). These results provide further
evidence to support that P2Y11 receptor is expressed in these cells and contributes
to ATP-evoked Ca2+ responses.
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(Figure 4.11)
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Figure 4.11 Effects of knocking down the P2Y1 expression on the Ca2+ responses
by ADP and ATP in hDP-MSCs.
(A) The mRNA expression level of P2Y1 relative to that of β-actin in hDP-MSC 
from 21F and 32F transfected with siP2Y1 and siControl. 21F, P4, N = 3 wells and
32F, P4, N = 3 wells; n/N = 2/6. (B) The mRNA expression level of P2Y1 receptor
in hDP-MSCs transfected with siP2Y1 (n/N = 2/6) as percentage of that in
hDP-MSCs transfected with siControl. (C) Typical ADP-induced Ca2+ responses in
hDP-MSCs (21F, P4, N = 4 wells) transfected with siP2Y1 and siControl. ADP at
100 μM was used. (D-G) Summary of the average maximum change in F340/F380:
(D) 21F, P4, N = 4 wells; (E) 9F, P4, N = 4 wells; (F) 32F, P4, N = 4 wells; (G) all
donors, n/N = 3/12. (H) Typical ATP-induced Ca2+ responses in hDP-MSCs (32F, N
= 4 wells) transfected with siP2Y1 and siControl. ATP at 300 μM was used. (I-G) 
Summary of the average maximum change in F340/F380: (I) 32F, P4, N = 4 wells; (J)
9F, P4, N = 4 wells; (K) 21F, P4, N = 4 wells; (L) all donors, n/N = 3/12 wells. *, p<
0.05, **, p< 0.01, ***, p< 0.001; compared to siControl.
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Figure 4.12 Effects of knocking down the P2Y11 expression on the Ca2+
responses by ATP in hDP-MSCs.
(A) The r mRNA expression level of P2Y11 relative to that of β-actin in hDP-MSCs 
transfected with siP2Y11 and siControl. 21F, P4, N = 3 wells and 32F, P4, N = 3
wells; n/N = 2/6. (B) The mRNA expression level of P2Y11 receptor in hDP-MSCs
transfected with siP2Y11 (n/N = 2/6) as percentage of that in hDP-MSCs transfected
with siControl. (C) Typical ATP-induced Ca2+ responses in hDP-MSCs (32F, P4, N
= 4 wells) transfected with siP2Y11 and siControl. ATP at 300 μM was used. (D-G) 
Summary of the average maximum change in F340/F380: (D) 32F, P4, N = 4 wells;
(E) 9F, P4, N = 4 wells; (F) 21F, P4, N = 4 wells; (G) all donors, n/N = 3/12. *, p<
0.05, **, p< 0.01, ***, p< 0.001; compared to siControl.
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4.3 Discussion
The results described in this chapter have provided compelling evidence to
demonstrate functional expression of several ATP-sensitive P2 receptors in
hDP-MSCs, including the P2X7, P2Y1 and P2Y11 receptors.
Single cell imaging analyzing the Ca2+ responses in individual cells showed that
~30% cells displayed spontaneous Ca2+ oscillations (Figure 4.1C). Such spontaneous
Ca2+ oscillations were reported in hBM-MSCs by previous studies (Kawano, Shoji et
al. 2002; Kawano, Otsu et al. 2003; Kawano, Otsu et al. 2006). An early study
reported a much higher proportion of cells exhibited spontaneous Ca2+ oscillations in
the presence of extracellular Ca2+ (72%) and in the absence of extracellular Ca2+
(67%) (Kawano, Shoji et al. 2002). The frequencies of the Ca2+ oscillations were
virtually the same in the extracellular Ca2+-containing andCa2+-free solutions.
However, increasing the extracellular Ca2+ concentration significantly enhanced the
amplitude of Ca2+ oscillations without effect on the frequency of Ca2+ oscillations,
indicating that the Ca2+entry across the plasma membrane does not directly determine
the frequency of Ca2+ oscillations but is required to reﬁll the intracellular Ca2+ stores
and increase the intensity of subsequent Ca2+ oscillations. The spontaneous Ca2+
oscillations were prevented by application of TG (1 μM), demonstrating that the Ca2+
oscillations result mainly from Ca2+ release from the ER (Kawano, Shoji et al. 2002).
A later study further demonstrated that hBM-MSCs secreted ATP, and that ATP
release was important in sustaining the spontaneous Ca2+ oscillations. The
spontaneous Ca2+ oscillations were completely blocked by PPADS (100 μM), U73122 
(a PLC blocker; 10 μM) or transfection with an IP3-binding protein (pTRE-IP3
sponge) to buffer the cytosolic IP3 and prevent IP3-induced Ca2+ release, and also
abolished by 2-APB (an IP3 receptor and SOC blocker, 75 μM) (Kawano, Otsu et al. 
2006). The author of these studies have proposed that the Ca2+ oscillations result from
ATP release and subsequent activation of the P2Y receptors leads to activation of
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PLC to generation of IP3, which binds to the IP3 receptors to cause Ca2+ release from
ER and subsequent Ca2+ entry through the plasma membrane to reﬁll the ER store. 
Such mechanisms may also explain the spontaneous Ca2+ oscillations in hDP-MSCs
observed in the present study.
A majority of hDP-MSC responded to extracellular ATP in the extracellular Ca2+-free
solutions with strong and rapid increases in the [Ca2+]i (Figure 4.1E), indicating that
intracellular Ca2+ is released, most likely from the ER store subsequent to activation
of the ATP-sensitive P2Y receptors (Burnstock, Fredholm et al. 2010). The
ATP-induced increases in the [Ca2+]i in the extracellular Ca2+-containing solutions
were significantly prolonged as compared those in the extracellular Ca2+-free
solutions (Figure 4.1G), suggesting that extracellular Ca2+ entry also contributes to
increases in the [Ca2+]i. As discussed in the Introduction chapter (see section 1.3.3),
extracellular ATP can activate two structurally and functional subfamilies of P2
purinergic receptors, P2X and P2Y. All the P2X receptors are activated by ATP and
mediate extracellular Ca2+ entry, while five of the eight P2Y receptors, P2Y1, P2Y2,
P2Y4, P2Y6 and P2Y11, are coupled to the PLC-IP3 signalling that can mobilize the
intracellular Ca2+ release from the ER, and three of them are sensitive to ATP, P2Y1,
P2Y2 and P2Y11. The results from real-time RT-PCR in the present study show the
mRNA expression of the P2X4, P2X6, P2X7, P2Y1, P2Y4, P2Y6 and P2Y11
receptors in hDP-MSCs (Figure 4.2A-B). The P2Y2 mRNA expression was detected
in only the 9F donor and at a low level. There was no detectable mRNA expression of
the P2X1, P2X2, P2X3 and P2X5 receptors (Figure 4.2A-B). A previous study using
RT-PCR detected the mRNA expression of all PX and P2Y receptors except P2X2 in
hBM-MSCs (Ferrari, Gulinelli et al. 2011). Taken together, the present and previous
studies are consistent in showing the mRNA expression of the P2X4, P2X6 and P2X7
and P2Y1, P2Y4, P2Y6 and P2Y11 and lack of the P2X2 mRNA expression in
hDP-MSCs and hBM-MSCs. The two studies also indicate difference in MSCs from
two different origins in terms of the mRNA expression for the P2X1, P2X3, P2X5 and
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P2Y2 receptors.
A functional characterization of the P2 receptors expression in hDP-MSCs cells was
further carried out to examine the functional expression of these receptors by
monitoring the changes in the [Ca2+]i in response to ATP and other receptor subtype
selective agonists and the effects of generic and receptor selective antagonists. First of
all, ATP evoked a strong increase in the in the [Ca2+]i in the presence of extracellular
Ca2+ (Figure 4.3A-C). ATP-induced responses were significantly inhibited by PPADS
(Figure 4.3 D-G), supporting the expression of ATP-sensitive P2 receptors.
The mRNA expression of P2X1, P2X2, P2X3 and P2X5 was undetected (Figure
4.2B). There was no discernible response to αβmeATP up to 100 µM (Figure 4.4B, 
D-F). This is consistent with lack of mRNA expression of P2X1 and P2X3. Taken
together, these results support no functional expression of the P2X1 and P2X3
receptors. ATP-evoked Ca2+ responses were not inhibited by 5-BDBD at 10 µM
(Figure 4.6A-E) that is a potent and selective antagonist at the P2X4 receptor and
shows no activity at other P2 receptors (Casati, Frascoli et al. 2011), suggesting no
expression of the functional P2X4 receptor despite that the P2X4 mRNA expression
was consistently detected in these cells from all three donors (Figure 4.2A).
BzATP is more potent than ATP for the P2X7 receptor but equipotent with or less
potent than ATP for other P2X receptors (North and Surprenant 2000) (see section
1.3.2.7). BzATP evoked greater responses than ATP at the same concentration (300
µM) in the extracellular Ca2+-containing solutions (Figure 4.4D-F). In addition,
ATP-evoked responses were substantially reduced by AZ11645373 (Figure 4.7A-E),
a hP2X7 receptor selective antagonist (Stokes, Jiang et al. 2006; Jiang 2012).
Furthermore, down-regulation of the P2X7 expression using siRNA resulted in a
significant reduction in the Ca2+ responses induced by ATP (Figure 4.10C-G) and
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BzATP (Figure 4.10H-L). Taken together, these results provided consistent evidence
to support expression of the functional P2X7 receptor in hDP-MSCs. Consistently,
several studies have shown the expression of P2X7 receptor in hBM-MSCs, using
RT-PCR, Western blotting and immunofluorescent staining (Sun, Junger et al. 2013),
and using KN-62 to show significant inhibition of ATP-induced Ca2+ responses
(Ferrari, Gulinelli et al. 2011). Therefore, the P2X7 receptor is expressed in MSCs
from dental pulp and bone morrow, and contributes in mediating ATP-induced Ca2+
signalling.
The present study also provided strong evidence for functional expression of several
P2Y receptors in hDP-MSCs. Activation of the P2Y1-like receptors can lead to
intracellular Ca2+ release; ADP acts as an agonist at the P2Y1 receptor, while UTP
activates the P2Y2 and P2Y4 receptors, MRS4062 is a selective agonist for the P2Y4
receptor, UDP for the P2Y6 receptor, and BzATP for the P2Y11 receptor (see section
1.3.3 in the Introductory chapter). In hDP-MSCs, ATP, ADP, UTP, MRS4062 and
BzATP evoked considerable Ca2+ responses in the extracellular Ca2+-free solution,
whereas UDP induced very low or undetectable responses (Figure 4.8A-J). These
results taken together with the results from RT-PCR (Figure 4.2C), suggest that
hDP-MSC mainly functionally express the P2Y1, P2Y4 and P2Y11 receptors, but not
the P2Y2 and P2Y6 receptors. Therefore, ATP-induced intracellular Ca2+ release are
mainly mediated by the P2Y1 or/and P2Y11 receptor in hDP-MSCs. Transfection
with siP2Y1 significantly decreased Ca2+ responses evoked by ATP as well as by
ADP (Figure 4.11C-L), while transfection with siP2Y11 reduced ATP-evoked Ca2+
responses (Figure 4.12C-G), confirming functional expression of the P2Y1 and
P2Y11 receptors. These results provide compelling evidence to indicate that a
significant contribution of the P2Y1 and P2Y11 in ATP-induced Ca2+ signalling in
hDP-MSCs. The expression of ATP-sensitive P2Y receptors in BM-MSCs from
human and rabbit was examined in several studies. The protein expression of the
P2Y1, P2Y2 and P2Y11receptors were demonstrated in hBM-MSCs by
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immunostaining and Western blotting (Ichikawa and Gemba 2009). Activation of the
P2Y1 receptor has been implicated in ATP-induced outward K+ currents (Coppi,
Pugliese et al. 2007) and spontaneous Ca2+ oscillations (Kawano, Otsu et al. 2006).
However, another study suggests expression of the P2Y11 but not the P2Y1 receptor
using immunofluorescent staining (Riddle, Taylor et al. 2007).
In conclusion, the results from the experiments presented in this chapter show that the
P2X7, P2Y1 and P2Y11 receptors are functionally expressed and contribute to
extracellular ATP-induced Ca2+ signalling in hDP-MSCs.
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Chapter 5
Expression of Stim/Orai SOC Channels in Human Dental Pulp
Mesenchymal Stem Cells
5.1 Introduction
The results described in chapter 4 provide evidence to show that ATP-sensitive P2Y1
and P2Y11 receptors are functionally expressed in hDP-MSCs and contribute in
ATP-evoked Ca2+ signalling by inducing Ca2+ release from the ER store. As discussed
in the Introduction chapter (see section 1.3.4), Ca2+ release from the ER can activate
the SOC channels on the cell surface that mediate extracellular Ca2+ entry into the cell
in order to reﬁll the Ca2+ store in the ER (McHale, Hollywood et al. 2006). Previous
studies have reported that such Ca2+ entry is mediated through the SOC channels upon
depletion of the ER Ca2+ store in stem cells (Yanagida, Shoji et al. 2004), including
BM-MSCs (Kawano, Shoji et al. 2002), but the molecular components forming the
SOC channels remain elusive. Recent studies have shown that Ca2+ entry through the
SOC channels plays a significant role in the proliferation, migration and
differentiation of stem cells (Shin, Hong et al. 2010; Li, Chen et al. 2012; Xie, Xu et
al. 2014).
Therefore, the aim of the study described in this chapter was to investigate expression
of the SOC channels and their contribution in ATP-induced Ca2+ signalling
mechanism in hDP-MSCs. The changes in the [Ca2+]i in hDP-MSCs were measured
using single cell Ca2+ imaging and FLEXstation. The mRNA expression level of the
SOC channel components was examined by real-time RT-PCR. Finally, the role of the
SOC channels in ATP-induced Ca2+ signalling was evaluated using SOC channel
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inhibitors to suppress the channel function and specific siRNA to reduce the
expression of the SOC channels.
5.2 Results
5.2.1 Single cell Ca2+ responses to TG and ATP
To investigate the functional expression of the SOC channels in individual
hDP-MSCs, single cell Ca2+ imaging was carried out using in combination with the
widely used Ca2+ add-back protocols; pretreatment of cells with TG depleted the Ca2+
store in the ER in the extracellular Ca2+-free solutions and thereby activated the SOC
channels, and the Ca2+entry through the activated SOC channels were measured by
adding Ca2+ back to the extracellular solution.
In hDP-MSCs pre-treated with 1 μM TG for 30 minutes in the absence of 
extracellular Ca2+, addition of extracellular Ca2+ resulted in a strong increase in the
[Ca2+]i in all individual cells (N = 18 in 18 cells), whereas a small increase in the
[Ca2+]i was observed in control cells or DMSO-treated cells (N = 15 in 15 cells)
(Figure 5.1A-D), indicating emptying the Ca2+ store in the ER induces robust SOCE
in all individual cells.
Experiments were also conducted to examine ATP-induced SOCE. Treatment with
100 μM ATP evoked intracellular Ca2+ release, as shown by a transient increase in the
[Ca2+]i in the absence of extracellular Ca2+ solutions. There were robust increases in
the [Ca2+]i upon addition of Ca2+ into the extracellular solutions, after ATP was
washed (Figure 5.1E). These results from single cell Ca2+ imaging suggest that the
SOC channels are functionally expressed in hDP-MSCs that can be activated by ATP
via activation of the P2Y receptors
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Figure 5.1 Single cell Ca2+ responses to TG and ATP in hDP-MSCs.
(A-B) Typical Ca2+ responses in single hDP-MSC (P4, 9F) without (A, N = 15 in 15
cells) and with pretreatment with TG at 1 μM (B, N = 18 in 18 cells). (C) Summary of 
the average change in F340/F380 in individual cells. (D) Summary of the average
maximum change in F340/F380 after Ca2+ add-back in the control cells and cells
pretreated with TG. (E-F) Typical Ca2+ responses (E, N = 19 in 19 cells) and the
average change in F340/F380 (F) in cells treated with ATP at 100 μM in the absence of 
extracellular Ca2+ and after Ca2+ add-back. (G) Summary of the average maximum
change in F340/F380 in cells treated with ATP after Ca2+ add-back. *, p < 0.05; **, p <
0.01; ***, p < 0.001; compared to the control.
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5.2.2 mRNA expression levels of SOC channel component proteins
As discussed in the Introduction chapter (see section 1.3.4), Orai and Stim proteins
have been identified as the key components of the SOC channels. Therefore, the
expression of Orai and Stim in hDP-MSCs was examined using real-time RT-PCR.
As shown in Figure 5.2A, the mRNA transcripts for Orai1, Orai2, Orai3, Stim1 and
Stim2 were detected in hDP-MSCs from all three donors. The mRNA expression
level relative to β-actin is summarized in Figure 5.2 B. In hDP-MSCs from all three 
donors, Orai3 showed the highest expression level among three Orai genes, and the
expression level for Stim1 and Stim2 was similar.
5.3.3 Effects of extracellular Ca2+ on constitutively active Ca2+-permeable
conductance
Removal of the extracellular Ca2+ and subsequent addition of Ca2+ back into the
extracellular solutions revealed a constitutively active Ca2+ conductance in
hDP-MSCs (Figure 5.1A). To better understand this Ca2+ conductance, changes in the
[Ca2+]i upon addition of various concentrations of extracellular Ca2+ were measured
using FLEXstation (Figure 5.3A). The [Ca2+]i was rapidly increased as the
extracellular Ca2+ concentration was increased from 0 mM to 0.03, 0.1, 0.3, 1, 3, 5
mM (Figure 5.3B). These results support the Ca2+ entry take place through such
constitutively active Ca2+-permeable conductance in cells.
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Figure 5.2 The mRNA expression of the SOC channels in hDP-MSCs.
(A) Representative images of agarose gel analysis of PCR products. The expression of Orai1, Orai2, Orai3, and Stim1, Stim2 was consistently
observed. (B) Summary of the mRNA expression level relative to β-actin for Orai1, Orai2, Orai3, and Stim1, Stim2 in hDP-MSCs for each of 
the three donors (P4; 9F, 21F and 32F) from two independent experiments, each in triplicate (n/N = 2/6).
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5.3.4 Effects of 2-APB on the constitutively active Ca2+-permeable
conductance
Further experiments were conducted to characterize the constitutively active
Ca2+-permeable conductance by determining the effect of 2-APB. Figure 5.3C
illustrates the Ca2+ responses in the absence of extracellular Ca2+ and subsequent
addition of extracellular Ca2+ in hDP-MSCs pretreated with 2-APB at different
concentrations for 10 minutes. As summarized in Figure 5.3D, 2-APB from 1 µM to
30 µM did not significantly alter the [Ca2+]i, but it at 50 µM and 100 µM induced
detectable intracellular Ca2+ release. Pretreatment with 2-APB at 1 µM and 5µM did
not significantly inhibit the increases in the [Ca2+]i upon addition of extracellular
Ca2+, but it at high concentrations from 10 µM to 100 µM significantly blocked such
increases, with 100 µM resulting in a complete inhibition (Figure 5.3D). These results
show that 2-APB at concentrations of 10-100 µM cause a concentration-dependent
inhibition of the constitutively active Ca2+-permeable conductance. In addition, these
results show 2-APB at high concentrations (50-100 µM) can induce intracellular Ca2+
release.
5.3.5 Effects of Synta66 on the constitutively active Ca2+-permeable
conductance
Synta66 is a selective SOC channel inhibitor (Putney 2010; Li, Cubbon et al. 2011;
van Kruchten, Braun et al. 2012). The effect of Synta66 on the constitutively active
Ca2+-permeable conductance was also examined. As shown in Figure 5.3E and F,
Synta66 from 1 µM to 10 µM did not significantly change the [Ca2+]i in the
extracellular Ca2+-free solutions, suggesting no Ca2+ release. It also did not
significantly inhibit the increases on the [Ca2+]i after addition of extracellular Ca2+,
suggesting Synta66 at the concentrations (1-10 µM) examined have no effect on the
constitutively active Ca2+-permeable conductance.
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(Figure 5.3)
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Figure 5.3 Characterization of the constitutively active Ca2+ conductance.
(A) Typical Ca2+ responses in hDP-MSCs (P4, 9F) after addition of Ca2+ from 0.03
mM to 5 mM into the extracellular Ca2+-free solution. (B) Summary of the average
change in F340/F380 in cells shown in (A). N = 4 wells (C) The Ca2+ responses in the
absence of extracellular Ca2+ and subsequent addition of extracellular Ca2+ in control
cells (9F) and cells treated with 2-APB at 1, 5, 10, 30, 50 and 100 µM. (D) Summary
of the average maximum change in F340/F380 in control cells (9F, P4, n/N = 3/12 wells)
and cells treated with 2-APB in the extracellular Ca2+-free solution and after addition
of Ca2+. (E) The Ca2+ responses in control cells (9F) without and with treatment with
Synta66 (S66) at 1, 3 and 10 µM. (F) Summary of the average maximum change in
F340/F380 in control cells (9F, P4, n/N = 3/12 wells) and cells treated with Synta66 in
the extracellular Ca2+-free solution and after addition of Ca2+. *, p < 0.05; **, p < 0.01;
***, p < 0.001; compared to the control.
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5.3.6 Ca2+ responses in TG-treated cells
To further investigate the functional expression of the SOC channels in hDP-MSCs,
[Ca2+]i in cells treated without and with TG were measured. As expected, treatment
with TG at 1 µM induced significant Ca2+ release in the absence of extracellular Ca2+
solutions (Figure 5.4A and B). Subsequent addition of extracellular Ca2+ resulted in
increases in the [Ca2+]i (Figure 5.4A and B), which are much greater in TG-treated
cells than in control cells without treatment with TG. These results indicate that TG
induces extracellular Ca2+ entry through the SOC channels in hDP-MSCs.
5.3.7 Effects of 2-APB on TG-induced Ca2+ responses
The effects of 2-APB on TG-induced Ca2+ responses were investigated. As described
in Figure 5.3D, 2-APB at 1 µM and 5 µM had no effect on the Ca2+ responses
mediated by the constitutively active Ca2+-permeable conductance in control cells
without treatment with TG. 2-APB at these concentrations also did not affect
TG-induced Ca2+ release in the extracellular Ca2+-free solutions (Figure 5.4C-D).
However, 2-APB at 5 µM significantly reduced the increases in the [Ca2+]i following
addition of extracellular Ca2+ in TG-treated cells (Figure 5.4C-D). TG-induced Ca2+
responses were obtained by subtracting the contribution of the constitutively active
Ca2+-permeable conductance in the matched control cells. 2-APB at 5 µM had no
significant effect on the peak amplitude of TG-induced Ca2+ responses but
significantly inhibited the sustained Ca2+ responses at the end of the experiments that
is, measured at 210 seconds after addition of extracellular Ca2+ (Figure 5.4E). These
results provide further evidence to support functional expression of the SOC channels
in hDP-MSCs.
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(Figure 5.4)
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Figure 5.4 The SOC channel-mediated Ca2+ responses in hDP-MSCs.
(A) Typical Ca2+ responses in the absence of extracellular Ca2+ and subsequent
addition of extracellular Ca2+ in hDP-MSCs (P4, 9F) without and with pretreatment
with TG at 1 μM. (B) Summary of the average change in F340/F380 in cells shown in
(A). *, p< 0.05; **, p< 0.01; ***, p < 0.001; compared to the control. (C) The effects
of 2-APB at 1 and 5 μM on Ca2+ responses to in control cells (without TG) and
TG-treated hDP-MSCs. (D) Summary of the average change in F340/F380 in
hDP-MSCs in the extracellular Ca2+-free solution and after addition of Ca2+. (E) The
peak amplitude (Peak) of TG-induced Ca2+ responses and sustained Ca2+ responses
(Sustained) at 210 seconds after addition of extracellular Ca2+ in control cells or cells
pretreated with 2-APB. 9F, P4, n/N = 3/12 wells. *, p< 0.05; **, p< 0.01; ***, p <
0.001; compared to the control (no 2-APB). (F) The effect of Synta66 at 1, 3, 10 μM 
on the Ca2+ responses in TG-treated hDP-MSCs. (G) Summary of the average change
in F340/F380 in hDP-MSCs in the extracellular Ca2+-free solution and after addition of
Ca2+. (H) The peak amplitude (Peak) of TG-induced Ca2+ responses and sustained
Ca2+ responses (Sustained) at 210 seconds after addition of extracellular Ca2+ in
control cells and cells pretreated with Synta66. 9F, P4, n/N = 3/12 wells. *, p < 0.05;
**, p < 0.01; ***, p < 0.001; compared to the control (no Synta66).
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5.3.8 Effects of Synta66 on TG-induced Ca2+ responses
The effects of Synta66 on TG-induced responses were examined. As shown in Figure
5.4F-G, while Synta66 at 1-10 µM did not change TG-induced intracellular Ca2+
release in the extracellular Ca2+-free solutions, it at 3 µM and 10 µM significantly
reduced the increases in the [Ca2+]i after addition of extracellular Ca2+, that is, the
extracellular Ca2+ entry in TG-treated cells. Synta66 at 10 µM significantly inhibited
both the peak and sustained amplitude of TG-induced Ca2+ entry (Figure 5.4H),
supporting that the SOC channels are functionally expressed in hDP-MSCs.
5.3.9 Effects of 2-APB on ATP-induced Ca2+ responses
To investigate whether the SOC channels were involved in extracellular ATP
induced-Ca2+ signalling, the effects of 2-APB on ATP-induced Ca2+ responses in the
extracellular Ca2+-containing solutions were measured using FLEXstation.
The typical Ca2+ responses activated by 300 µM ATP in hDP-MSCs pretreated with
2-APB are shown in Figure 5.5A. Pre-treatment with 2-APB at 5 µM for 30 minutes
significantly inhibited ATP-evoked Ca2+ responses in hDP-MSCs from three donors
(Figure 5.5B-D), with an average inhibition of 37.5 ± 3.1% (Figure 5.5E). These
results support that the SOC channels are involved in ATP-induced Ca2+ signalling
5.3.10 Effects of Synta66 on ATP-induced Ca2+ responses
The effects of Synta66 on ATP-activated Ca2+ responses were also examined. As
shown in Figure 5.6A, pre-treatment with Synta66 at 10 µM for 30 minutes
significantly reduced the amplitude of the sustained Ca2+ responses induced by 300
µM ATP without effect on the peak amplitude in hDP-MSCs from all three donors
(Figure 5.6B-D). The average inhibition was 58.3 ± 6.2% at 240 seconds after
treatment with ATP (Figure 5.6E).
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These results, taken together with the inhibition by 2-APB described above show that
the extracellular Ca2+ entry mediated by the SOC channels contribute to ATP-induced
Ca2+ signalling.
5.3.11 Effects of reducing Stim and Orai expression using siRNA on
ATP-induced Ca2+ responses
As shown above using RT-PCR, Stim1, Stim2, Orai1, Orai2 and Orai3 are expressed
in hDP-MSCs. In order to identify which of these SOC channel proteins are important
in forming the SOC channels mediating extracellular ATP-induced Ca2+ signalling,
TG-induced Ca2+ responses in hDP-MSCs transfected with siRNA that specifically
reduce the expression of each of these proteins (Li, Cubbon et al. 2011) were
examined using the Ca2+ add-back protocols. In order to rule out the potential
non-specific effect of transfection, the Ca2+ responses to TG in untransfected cells and
siControl-transfected cells were compared. Cells transfected with siControl resulted in
no significant difference in TG-induced Ca2+ release and extracellular Ca2+ entry
(Figure 5.7A-C). Moreover, transfection with siControl had no significant effect on
extracellular Ca2+ entry through constitutively active Ca2+-permeable conductance
(Figure 5.7D-F). Such observations suggest that transfection with siControl has no
non-specific effect.
Figure 5.8 shows the mRNA expression level in hDP-MSCs transfected with
siControl or siRNA for Stim1, Stim2, Orai1, Orai2 and Orai3. Treatment with specific
siRNA resulted in a significant reduction in the mRNA expression level for Stim1 (68
± 7%), Stim2 (38 ± 7%), Orai1 (55 ± 4%), Orai2 (66 ± 4%) and Orai3 (41 ± 5%).
Figure 5.9A-B show the typical Ca2+ responses following addition of extracellular
Ca2+ in control hDP-MSCs (Figure 5.9A) and cells pretreated with TG (Figure 5.9B).
Figure 5.9C-E summarizes the Ca2+ entry in control cells and TG-treated cells, and
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the TG-induced Ca2+ entry in hDP-MSCs from each of the three donors. Figure 5.9F
shows the Ca2+ responses in cells transfected with indicated siRNA presented as the
percentage of those from cells transfected with siControl. The results show that
siRNA for Orai1, Orai2, Orai3, Stim1 and Stim2 had no significant effect in the Ca2+
entry through constitutively active Ca2+-permeable conductance. Knockdown in the
expression of Orai1, Orai2, Orai3 and Stim1 and Stim2 by siRNA resulted in
significant inhibition, but to various degrees, on the Ca2+ entry in TG-treated cells
from three donors (Figure 5.9F). In contrast, the reduced expression of Stim2 had no
significant effect on TG-induced Ca2+ entry (Figure 5.9 F). These results suggest
Orai1, Orai2, Orai3 and Stim1 contribute significantly to formation of the SOC
channels.
The effects of treatments with siRNA on ATP-induced Ca2+ responses were also
examined. Representative Ca2+ responses induced by ATP at 300 µM are shown in
Figure 5.10A. The results in cells from all three donors are summarized in Figure
5.10B-D. Treatment with Orai1, Orai2, Orai3 and Stim1 but not with Stim2
significantly attenuated ATP-induced Ca2+ responses in hDP-MSCs from two of the
three donors (9F and 32F) (Figure 5.10B-C). ATP-induced Ca2+ responses in
hDP-MSCs from the third donor (21F) was significantly reduced by treatment with
siStim1 (Figure 5.10D). On average, the ATP-induced Ca2+ responses were attenuated
by siRNA for Orai1 (36.2 ± 6.4%), Orai2 (28.0 ± 6.0%), Orai3 (42.2 ± 5.7%) and
Stim1 (48.7 ± 9.2%) while siRNA for Stim2 had no significant effect (Figure 5.10E).
These results are consistent with the effects of TG-induced Ca2+ entry and, taken
together, support involvement of all three Orai and Stim1 proteins in ATP-induced
Ca2+ responses in hDP-MSCs from two of three donors.
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Figure 5.5 Effects of 2-APB on ATP-induced Ca2+ responses in hDP-MSCs.
(A) ATP-induced Ca2+ responses in cells (P4, 21F) treated without and with 2-APB at
5 μM. (B-D) Summary of the average maximum changes in F340/F380 in cells: (B) 21F;
(C) 9F; (D) 32F. P4, N = 4 wells for each case. ATP at 300 μM was used. (E) The 
percentages of inhibition by 2-APB in cells (P4; 9F, 21F and 32F) compared to the
control. *, p < 0.05; **, p < 0.01; ***, p < 0.001; compared to the control.
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Figure 5.6 Effects of Synta66 on ATP-induced Ca2+ responses in hDP-MSCs.
(A) ATP-induced Ca2+ responses in hDP-MSCs (P4, 9F) with or without pretreated
with Synta66 (S66) at 10 μM. (B-D) Summary of the average peak amplitude (Peak) 
of Ca2+ responses and sustained Ca2+ responses (Sustained) at the end of recording
(240 seconds after addition of 300 μM ATP): (B) 9F; (C) 21F; (D) 32F. P4, N = 4 
wells for each case. (E) The percentage of inhibition by Synta66 of ATP-induced Ca2+
responses in hDP-MSCs (9F, 21F and 32F). *, p< 0.05; **, p< 0.01; ***, p< 0.001;
compared to the control.
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Figure 5.7 Effects of transfection with siControl on Ca2+ responses in hDP-MSCs
without or with TG treatment.
(A-B) Typical Ca2+ responses to TG in untransfected (A, control) and
siControl-transfected hDP-MSCs (P4, 9F) (B) in the absence of extracellular Ca2+ and
subsequent addition of extracellular Ca2+. (C) Summary of the average maximum
change in F340/F380 in cells treated with TG in the absence of extracellular Ca2+ and
after addition of extracellular Ca2+. (D-E) Ca2+ responses in untransfected (A, control)
and siControl-transfected hDP-MSCs (P4, 9F) not treated with TG. (F) Summary of
the average maximum change in F340/F380 after addition of extracellular Ca2+ in cells
without TG treatment. *, p< 0.05; **, p< 0.01; ***, p< 0.001; compared to the
control.
- 143 -
Figure 5.8 Effects of transfection with siRNA on the mRNA expression of Stim and Orai in hDP-MSCs.
(A) The mRNA expression level of Stim1, Stim2, Orai1, Orai2 and Orai3 relative to that of β-actin in hDP-MSCs from 21F and 32F transfected 
with specific siRNA and siControl. 21F, P4, N = 3 wells and 32F, P4, N = 3 wells; n/N = 2/6. (B) The mRNA expression level of Stim1, Stim2,
Orai1, Orai2 and Orai3 in hDP-MSCs transfected with specific siRNA (n/N = 2/6) as percentage of that in cells transfected with siControl. *, p<
0.05; **, p< 0.01; ***, p< 0.001; compared to siControl.
- 144 -
(Figure 5.9)
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Figure 5.9 Effects of transfection with siRNA for Orai and Stim on TG-induced
Ca2+ responses in hDP-MSCs.
(A-B) Typical Ca2+ responses in hDP-MSCs (P4, 21F) transfected with siControl and
siRNA for Orai1, Orai2, Orai3, Stim1 and Stim2 without (A) and with (B) treatment
with TG at 10 μM after addition of Ca2+ into the extracellular Ca2+-free solutions.
(C-E) Summary of the average maximum change in F340/F380 in control cells and
TG-treated cells, and TG-induced increases in the [Ca2+]i after addition of Ca2+ into
the extracellular Ca2+-free solutions in hDP-MSCs: (C) 21F; (D) 9F; (E) 32F. P4, N =
4 wells for each case. (F) The change in F340/F380 in hDP-MSCs transfected with
siRNA for Orai and Stim (9F, 21F and 32F) as percentage of those in cells transfected
with siControl. *, p < 0.05; **, p< 0.01; ***, p < 0.001; compared to siControl.
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(Figure 5.10)
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Figure 5.10 Effects of transfection with siRNA for Orai and Stim on ATP-induced
Ca2+ responses in hDP-MSCs.
(A) Typical Ca2+ responses to ATP in hDP-MSCs (P4, 32F) transfected with
siControl and siRNA for Orai1, Orai2, Orai3, Stim1 and Stim2 in the presence of
extracellular Ca2+. ATP at 300 μM was used. (B-D) Summary of the average 
maximum change of F340/F380 in cells: (B) 32F; (C) 9F; (D) 21F. P4, N = 4 wells for
each case. (E) The change in F340/F380 in hDP-MSCs (9F, 21F and 32F) as percentage
of that in cells transfected with siControl. *, p < 0.05; **, p< 0.01; ***, p < 0.001;
compared to siControl.
- 149 -
5.3.12 Effects of co-transfection with siRNA for Stim1 and Orai on
ATP-induced Ca2+ responses
In order to further investigate that the molecular composition of the SOC channels
were responsible for extracellular ATP-induced Ca2+ signalling, TG-induced Ca2+
entry and ATP-induced Ca2+ responses were examined in hDP-MSCs co-transfected
with siStim1/siOrai (siStim1/siOrai1, siStim1/siOrai2 and siStim1/siOrai3).
Figure 5.11A-B show typical Ca2+ responses in control cells or TG-treated cells after
co-transfection with siStim1/siOrai. Figure 5.11C-E summarize the increases in the
[Ca2+]i after addition of extracellular Ca2+ in cells from three donors. Figure 5.11F
shows the increases in the [Ca2+]i in control cells and TG-treated cells, and
TG-induced increases in the [Ca2+]i, expressed as percentage of those in cells
transfected with siControl. The results show that without TG treatment there was no
significant difference in extracellular Ca2+ entry between cells transfected with
siControl and cells co-transfected with siStim1/siOrai (Figure 5.11F). However,
co-transfection with siStim1/siOrai resulted in significant decrease in the extracellular
Ca2+ entry in TG-treated cells, and TG-induced extracellular Ca2+ entry (Figure
5.11F).
The effects of co-transfection with such siRNAs on ATP-induced Ca2+ responses
were also examined. As shown in Figure 5.12, co-transfection with siStim1/siOrai1,
siStim1/siOrai2, and siStim1/siOrai3 resulted in similar attenuation of the Ca2+
responses induced by 300 µM ATP in hDP-MSCs from all three donors. These results
indicated that all three Orai proteins may contribute to SOC channels and
ATP-induced Ca2+ signalling in hDP-MSCs.
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(Figure 5.11)
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Figure 5.11 Effects of co-transfected with siRNAs for Stim1 and Orai on
TG-induced Ca2+ responses in hDP-MSCs.
(A-B) Typical Ca2+ responses without (A) or with (B) treatment with TG at 10 μM in 
hDP-MSCs (P4, 9F) transfected with siControl, siStim1/siOrai1, siStim1/siOrai2, and
siStim1/siOrai3 after addition of Ca2+ into the extracellular Ca2+-free solutions. (C-E)
Summary of the average maximum change in F340/F380 in control cells (untreated with
TG) and TG-treated cells, and TG-induced maximal change in F340/F380 after addition
of Ca2+ into the extracellular Ca2+-free solutions in cells: (C) 9F; (D) 21F; (E) 32F. P4,
N = 4 wells for each case. (F) The change in F340/F380 in hDP-MSCs co-transfected
with siRNA for Stim1 and Orai (9F, 21F and 32F) as percentage of that in cells
transfected with siControl. *, p < 0.05; **, p< 0.01; ***, p < 0.001; compared to
siControl.
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Figure 5.12 Effects of co-transfected with siRNAs for Stim1 and Orai on
ATP-induced Ca2+ responses in hDP-MSCs.
(A) Typical ATP-induced Ca2+ responses in the presence of extracellular Ca2+ in
hDP-MSCs (P4, 9F) co-transfected with siControl, siStim1/siOrai1, siStim1/siOrai2,
and Stim1/Orai3. ATP at 300 μM was used. (B-D) Summary of the average maximum 
change of F340/F380 in cells: (B) 9F; (C) 21F; (D) 32F. P4, N = 4 wells for each case.
(E) The change in hDP-MSCs (9F, 21F and 32F) as percentage of that in
siControl-transfected cells. *, p < 0.05; **, p< 0.01; ***, p < 0.001; compared to
siControl.
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5.3 Discussion
The results from the study described in this chapter provide evidence to show that
Orai and Stim1 participate in formation of the SOC channels and contribute to
ATP-induced Ca2+ signaling in hDP-MSCs. In addition, the study has also revealed a
constitutively active Ca2+ conductance in the plasma membrane, which does not
contribute to ATP-induced Ca2+ signaling.
The results from single cell Ca2+ imaging and FLEXstation consistently showed a
modest increase in the [Ca2+]i in hDP-MSCs upon addition of extracellular Ca2+ back
into the extracellular Ca2+-free solution, indicating presence of a constitutively active
Ca2+ conductance (Figure 5.1A). Such increases in the [Ca2+]i has not been reported in
previous studies of hBM-MSCs (Kawano, Shoji et al. 2002). The functional
characterization of such a constitutively active Ca2+ conductance in hDP-MSCs
showed that the [Ca2+]i through the constitutively active Ca2+ conductance was
increased as in the extracellular Ca2+ concentration raised from 30 M to 5 mM and
the increase was very fast (Figure 5.3B), suggesting that such Ca2+ entry may be
mediated by Ca2+-permeable channels. Pretreatment with 2-APB at 10-100 μM 
significantly inhibited the Ca2+ entry via the constitutively active Ca2+ conductance
(Figure 5.3D). In contrast, pretreatment with Synta66 up to 10 μM, a potent SOC 
inhibitor (see 1.3.4.3), had no effect (Figure 5.3F). Furthermore, the reduction in the
expression of Orai and Stim alone or in combination did not also affect the Ca2+entry
via the constitutively active Ca2+ conductance (Figure 5.9F and Figure 5.10E),
indicating that Orai and Stim proteins are unlikely involved in the formation of
constitutively active Ca2+ conductance. Thus the molecular identify of the
constitutively active Ca2+ conductance is elusive and further studies are needed.
As discussed in the Introduction chapter (see section 1.3.4), depleting the ER Ca2+
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store with TG can induce extracellular Ca2+ entry via the SOC channels. In
hDP-MSCs, the increase in the [Ca2+]i upon Ca2+ add-back was remarkably larger
after treatment with TG (Figure 5.1C-D and Figure 5.4A-B). Moreover, pretreatment
of 2-APB at 5 μM, which did not induce intracellular Ca2+ release and did not alter the
Ca2+entry via the constitutively active Ca2+ conductance (Figure 5.3D), significantly
inhibited TG-induced Ca2+ entry (Figure 5.4E), indicating that 2-APB inhibits the
SOC channels without altering intracellular Ca2+ release mechanisms.. Synta66 at 10
μM also significantly blocked TG-induced Ca2+ entry without altering the basal
[Ca2+]i and extracellular Ca2+ entry through the constitutively active Ca2+ conductance
(Figure 5.3F and Figure 5.4H). Taken together, these results suggest that the SOC
channels are functionally expressed in hDP-MSCs. The functional expression of the
SOC channels was also reported for hBM-MSCs (Kawano, Shoji et al. 2002).
Therefore, the present and previous studies are consistent in supporting the expression
of SOC channels in MSCs.
As described in the previous chapter, ATP in the absence of extracellular Ca2+ induced
intracellular Ca2+ release by activating P2Y receptors, particularly P2Y1 and P2Y11
via the PLC-IP3 signalling pathway in hDP-MSCs. Subsequent addition of
extracellular Ca2+ resulted in significant extracellular Ca2+ entry (Figure 5.1E-F). In
the experiments shown in Figure 5.1E-F, ATP was removed before addition of
extracellular Ca2+ and therefore ATP-induced Ca2+ entry is mainly mediated by the
SOC channels. Consistent with this notion is that 2-APB at 5 µM and Synta66 at
10µM, blocked ATP-induced Ca2+ responses as well as TG-induced activation of the
SOC channels (Figure 5.5E and Figure 5.6E). Therefore, these results suggest that
functional SOC channels contribute to extracellular ATP-induced Ca2+ signalling in
hDP-MSCs as previously reported in hBM-MSCs (Kawano, Shoji et al. 2002).
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The molecular components of the SOC channels in MSCs remained unclear. The
RT-PCR results presented in this study for the first time showed that hDP-MSCs
expressed the mRNA transcripts for all the three SOC channel-forming proteins,
Orai1, Orai2, Orai3, and the two ER Ca2+ sensing proteins Stim1 and Stim2 (Figure
5.2 A). Transfection with specific siRNA significantly decreased their expression
levels (Figure 5.8), as reported in previous studies of the expression of these
molecules in endothelial cells (Li, Cubbon et al. 2011). Down-regulation of the
expression of each of these three Orai proteins and also Stim1, but not Stim2,
significantly inhibited TG-induced Ca2+entry (Figure 5.9F), indicating that Orai and
Stim1 contribute to formation of SOC channels in hDP-MSCs. Similarly, the
ATP-induced Ca2+ responses were significantly inhibited in hDP-MSCs transfected
with siRNA for each of the three Orai and Stim1, but not Stim2 (Figure 5.10E).
Furthermore, co-transfection with siStim1/siOrai1, siStim1/siOrai2, and
siStim1/siOrai3 inhibited TG-induced extracellular Ca2+ entry (Figure 5.11F) and
ATP-induced Ca2+ responses (Figure 5.11E), further supporting that Orai and Stim1
are important in forming the SOC channels contributing ATP-induced Ca2+ signalling
in hDP-MSCs.
In summary, the results described in this chapter have shown that Orai and Stim1
contribute to formation of the SOC channels that are significantly involved in
extracellular ATP-induced Ca2+ signalling in hDP-MSCs.
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Chapter 6
Roles of P2 Purinergic Receptors and SOC Channels in MSC
Migration and Differentiation
6.1 Introduction
Previous studies suggest that several P2 receptors and downstream signalling are
involved in the modulation of stem cells functions. For example, the P2Y11 receptor
was shown to be involved in the modulation by NAD+ of hBM-MSC migration
(Fruscione, Scarfi et al. 2011). The P2Y2 receptor and Stim1-mediated SOC channels
were also involved in ATP-induced cell migration of cancer stem cells (Xie, Xu et al.
2014). Recent studies have shown that stimulation by ATP of the P2X7 receptor
induced osteogenic differentiation of hBM-MSCs (Sun, Junger et al. 2013), whereas
activation of the P2Y1 and P2Y4 receptors by ATP might be involved in
adipogenic differentiation of hBM-MSCs (Ciciarello, Zini et al. 2013). The results in
chapter 3 show ATP can significantly regulate cell migration and differentiation of
hDP-MSCs.
The results in chapter 4 and chapter 5 have shown that P2X7, P2Y1 and P2Y11
receptors, and Stim1/Orai SOC channels are critically involved in extracellular
ATP-stimulated Ca2+ signalling in hDP-MSCs. It was interesting to determine
whether such signalling mechanisms are important in ATP-induced cell migration and
regulation of adipogenic and osteogenic differentiation. Therefore, the study
presented in this chapter aimed to investigate the role of P2X7, P2Y1 and P2Y11
receptors, and Stim1/Orai–mediated SOC channels in the regulation by extracellular
ATP of cell migration and differentiation of hDP-MSCs.
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6.2 Results
6.2.1 The role in hDP-MSC migration
6.2.1.1 Effects of inhibitors for P2 receptors and SOC channels
In order to investigate the potential role of P2X7, P2Y1 and P2Y11 receptors, and
Stim1/Orai SOC channels in mediating ATP-induced stimulation of hDP-MSC
migration, the effects of the inhibitors for these receptors and channels were examined
using the wound healing assays in combination with the IncuCyte real-time imaging
system. Figure 6.1A shows the reduction in the wound width as results of cell
migration for control cells, cells treated with 30 μM ATP alone or cells treated with 1 
μM AZ11645373, 10 μM PPADS and 5 μM 2-APB together with ATP. Figure 6.1B 
summarizes the migration area at 24, 36 or 48 hours and Figure 6.1C shows the
migration of cells treated with ATP alone or together with indicated inhibitors,
expressed as % of migration for the control cells. As described above in section 3.2.3,
ATP increased hDP-MSC migration. Treatment with PPADS resulted in significant
inhibition of cell migration at 24, 36 and 48 hours. Treatment with AZ11645373
significantly inhibited cell migration at 48 hours. Like PPADS, 2-APB was also
effective in blocking cell migration at 24, 36 and 48 hours. Unlike ATP-induced Ca2+
responses described in previous chapters that occurred within a few minutes after
addition of extracellular ATP, ATP-induced effects on cell migration was determined
over a much longer period of time. Under such conditions, ATP is degraded to ADP
and adenosine (see section in 1.3.1), and thus it remained possible that ATP-induced
increase in cell migration was in part or as a whole mediated indirectly by adenosine
receptors. In order to study such a possibility, cells were treated with ATP together
with CGS15943, a generic and potent antagonist of adenosine receptors with the Ki
values of 3.5, 4.2, 16 and 51 nM for the human A1, A2A, A2B and A3 adenosine
receptors, respectively (Ghai, Francis et al. 1987). There was no significant effect of
CGS15943 at 100 nM on ATP-induced increase in cell migration (Figure 6.1B-F).
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Taken together, the results from pharmacological interventions suggest that the P2X7,
P2Y receptor and SOC channels, but not the adenosine receptors, contribute in
mediating ATP-induced increase in hDP-MSC migration.
6.2.1.2 Effects of transfection with siRNAs on ATP-induced increase in cell
migration
The results described in previous chapters show that P2X7, P2Y1, P2Y11, Stim1 and
Orai1 are significantly engaged in extracellular ATP-induced Ca2+ signalling. In order
to further investigate their roles in ATP-stimulated cell migration, hDP-MSCs
transfected with siRNAs were examined. Figure 6.2A shows the representative results
of cell migration or reduction in the wound width for cells transfected with siControl
and siRNA for P2X7, P2Y1, P2Y11, Stim1 and Orai1. The results from hDP-MSCs
from the donor 9F at 24, 36 and 48 hours are summarized in Figure 6.2B, and
expressed as the percentage of those in cells transfected with siControl in Figure 6.2C.
The results from the cells from the 32F and 21F donors are summarized in Figure
6.2D-E. As described in chapter 3, these results show that ATP significantly enhanced
cell migration for hDP-MSCs from all three donors. Transfection with siRNA for
P2X7, P2Y1, P2Y11, Stim1 and Orai1 significantly reduced the stimulatory effect of
ATP on cell migration in cells from two of three donors (9F: Figure 6.2C; 32F: Figure
6.2D) but not the other (21F: Figure 6.2E). However, co-transfection with
siStim1/siOrai1 consistently resulted in a significant inhibition of ATP-induced
increase in cell migration at 24 and 36 hours for cells from all three donors (Figure
6.2E-F). The inhibition resulting from co-transfection with siStim1/siOrai1 was
slightly greater than that from transfection with siOrai1 alone. These results are
consistent with the results obtained using inhibitors, suggesting a significant role for
the P2X7, P2Y1 and P2Y11 and particularly Stim1/Orai1 SOC channels in mediating
ATP-induced stimulation of hDP-MSC migration.
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Figure 6.1 Effects of inhibitors on ATP-induced increase in hDP-MSC migration.
(A) Reduction in the wound width or cell migration for control or untreated cells (P4,
9F) and cells treated with ATP at 30 μM alone or together with CGS15943 (CGS) at 
0.1 μM, AZ11645373 (AZ) at 1 μM, PPADS at 10 μM, and 2-APB at 5 μM. (B) 
Summary of the migration areas at 24, 36 or 48 hours for cells (9F). (C-F) Summary
of the cell migration expressed as percentage of cell migration for matched control
cells at 24, 36 or 48 hours: (C) 9F, P4, N = 4 wells; (D) 21F, P4, N = 4 wells; (E) 32F,
P4, N = 4 wells; (F) 9F, 21F and 32F, n/N = 3/12. #, p< 0.05; ##, p< 0.01; ###, p<
0.001; compared to the control without ATP. *, p < 0.05; **, p < 0.01; ***, p < 0.001;
compared to ATP alone.
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(Figure 6.2)
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Figure 6.2 Effects of transfection with siRNA for P2X7, P2Y1, P2Y11, Stim1 and
Orai1 on ATP-induced increase in hDP-MSC migration.
(A) Reduction in the wound width or cell migration for siControl-transfected control
cells (P4, 9F) without exposure to ATP or cells transfected with siControl or siRNA
for P2X7, P2Y1, P2Y11, Stim1, Orai1 and Stim1/Orai1 and exposed to ATP (30 μM). 
(B) Summary of the migration areas at 24, 36 or 48 hours for cells (9F). (C-F)
Summary of the cell migration expressed as percentage of that for matched control
cells at 24, 36 or 48 hours: (C) 9F, P4, N = 4 wells; (D) 32F, P4, N = 4 wells; (E) 21F,
P4, N = 4 wells; (F) 9F and 32F, n/N = 2/8. #, p < 0.05; ##, p < 0.01; ###, p < 0.001;
compared to siControl without ATP. *, p < 0.05; **, p < 0.01; ***, p < 0.001;
compared to siControl with ATP.
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6.2.2 The role in osteogenic differentiation of hDP-MSCs
6.2.2.1 Effects of inhibitors for P2 receptors and SOC channels
In order to investigate the potential role of the P2X7 receptor, P2Y receptors, and
Stim1/Orai SOC channels in the down-regulation by extracellular ATP of osteogenic
differentiation, hDP-MSCs were cultured for 14 days in BM and ODM containing
ATP or ATP together with the inhibitors for P2 receptors and SOC channels: 0.1 μM 
CGS15943, 1 μM AZ11645373, 10 μM PPADS and 5 μM 2-APB. The effects of such 
inhibitors on osteogenic differentiation of hDP-MSCs were determined using the ALP
activity assays. Figure 6.3A shows the ALP activity under the above conditions.
Figure 6.3B-E show the ALP activity expressed as percentage of that in control cells.
As described in section 3.2.4 of chapter 3, ATP alone significantly down-regulated
the ALP activity or osteogenic differentiation of hDP-MSCs in BM or ODM (Figure
6.3E). For cells cultured in BM, PPADS significantly inhibited ATP-induced decrease
in the ALP activity but CGS15943 and AZ11645373 had no effect (Figure 6.3E).
Similarly, ATP-induced decrease in osteogenic differentiation in ODM was
significantly inhibited by PPADS, but not CGS15943 or AZ11645373. These results
suggest that the P2Y receptors are involved in ATP-induced inhibition of osteogenic
differentiation of hDP-MSCs, but the adenosine receptors and P2X7 receptor have no
major role.
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6.2.2.2 Effects of transfection with siRNAs on ATP-induced inhibition of
osteogenic differentiation
In order to further investigate the role of the P2X7, P2Y1, P2Y11, Stim1 and Orai1 in
extracellular ATP-induced inhibition of osteogenic differentiation, hDP-MSCs
transfected with siRNAs were examined. Figure 6.4A shows the ALP activity in cells
after transfection with siControl and siRNA for P2X7, P2Y1, P2Y11, Stim1, Orai1
and Stim1/Orai1 expressed as percentage of the ALP activity for siControl-transfected
and untreated cells (Figure 6.4B-E).
As described in untransfected cells in chapter 3 (section 3.2.4) and Figure 6.3E, ATP
significantly reduced the ALP activities in cells transfected with siControl in BM and
ODM (Figure 6.4E). Transfection with siP2Y1, siP2Y11, siStim1, siOrai1, or
co-transfection with siStim1/siOrai1, but not with siP2X7, significantly increased of
the ALP activity in ATP-treated cells as compared to that in cells transfected with
siControl. In addition, ATP-induced inhibition of the osteogenic differentiation in
ODM was significantly attenuated by transfection with siP2Y1, siP2Y11, siOrai1
alone or co-transfection with siStim1/siOrai1, but not with siP2X7 and siStim1 alone.
These results indicate that the P2Y1 and P2Y11 receptors and particularly
Stim1/Orai1 SOC channels contribute to ATP-induced inhibition of the osteogenic
differentiation of hDP-MSCs.
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Figure 6.3 Effects of inhibitors on osteogenic differentiation in ATP-treated
hDP-MSCs.
(A) The ALP activity in control cells (P4, 9F) or cells treated with 30 μM ATP alone 
or together with CGS15943 at 0.1 μM, AZ11645373 at 1 μM, PPADS at 10 μM and 
2-APB at 5 μM. Cells were cultured in BM and ODM for 14 days. (B-E) Summary of 
the ALP activity in treated cells as percentage of that in control or untreated cells: (B)
9F, P4, N = 4 wells; (C) 21F, P4, N = 4 wells; (D) 32F, P4, N = 4 wells; (E) 9F, 21F
and 32F, n/N = 3/12. Cells were cultured in BM (open bars) and ODM (hatched bars).
#, p < 0.05; ##, p < 0.01; ###, p < 0.001; compared to control without ATP. *, p <
0.05; **, p < 0.01; ***, p < 0.001; compared to ATP alone.
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(Figure 6.4)
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Figure 6.4 Effects of siRNAs on osteogenic differentiation in ATP-treated
hDP-MSCs.
(A) The ALP activities in siControl-transfected and untreated cells (P4, 9F) and cells
transfected with siControl or specific siRNA for P2X7, P2Y1, P2Y11 Stim1, Orai1
and Stim1/Orai and treated with ATP (30 μM) in BM and ODM. Cells were cultured 
in BM and ODM for 14 days. (B-E) Summary of the ALP activity as percentage of
that in matched control cells: (B) 9F, P4, N = 4 wells; (C) 21F, P4, N = 4 wells; (D)
32, P4, N = 4 wells; (E) 9F, 21F and 32F, n/N = 3/12. #, p < 0.05; ##, p < 0.01; ###, p
< 0.001; compared to siControl without ATP. *, p < 0.05; **, p < 0.01; ***, p < 0.001;
compared to siControl with ATP.
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6.2.3 The role in adipogenic differentiation of hDP-MSCs
6.2.3.1 Effects of inhibitors for P2 receptors and SOC channels
The potential role of the P2X7 receptor, P2Y1 and P2Y11 receptors, and Stim1/Orai
SOC channels in the up-regulation by extracellular ATP of adipogenic differentiation
of hDP-MSC were investigated by determining the OD510/DNA to quantify the Oil
red O staining of cells treated with ATP alone or together with various inhibitors of
the P2 receptors and SOC channels, including 0.1 μM CGS15943, 1 μM 
AZ11645373, 10 μM PPADS and 5 μM 2-APB. The DNA content was not 
significantly altered by these inhibitors (Figure 6.5A). Figure 6.5B shows the
OD510/DNA. Figure 6.5C-F show adipogenesis of cells treated with ATP alone or
together with indicated inhibitors, expressed as percentage of that in control cells.
As described above in section 3.2.5 of chapter 3, ATP significantly improved
adipogenic differentiation of hDP-MSCs cultured in ADM (Figure 6.5F).
ATP-induced increase in adipogenic differentiation of hDP-MSCs in ADM was
significantly inhibited by PPADS and 2-APB, but not AZ1164537, suggesting that the
P2Y receptors and SOC channels, but not P2X7 receptor, are critically involved in
ATP-induced facilitation of adipogenic differentiation (Figure 6.5 F). There was no
significant effect by CGS15943 (Figure 6.5F), indicating no major role for the
adenosine receptors.
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(Figure 6.5)
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Figure 6.5 Effects of inhibitors on ATP-induced increase in adipogenic
differentiation of hDP-MSCs.
(A) Summary of the DNA content in control cells or cells (P4, 9F, N = 4 wells)
treated with ATP alone or together with CGS15943 at 0.1 μM, AZ11645373 at 1 μM, 
PPADS at 10 μM and 2-APB at 5 μM. Cells were cultured in ADM for 21 days. (B) 
Summary of the Oil Red staining determined by the OD510 value per DNA (µg/ml) in
cells under the conditions shown in (A). (C-F) Summary of the adipogenesis in treated
cells as percentage of that in control cells: (C) 9F, P4, N = 4 wells; (D) 21F, P4, N = 4
wells; (E) 32F, P4, N = 4 wells; (F) 9F, 21F and 32F, n/N = 3/12. #, p < 0.05; ##, p <
0.01; ###, p < 0.001; compared to control without ATP. *, p < 0.05; **, p < 0.01; ***,
p < 0.001; compared to ATP alone.
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6.2.3.2 Effects of transfection with siRNAs on osteogenic differentiation
In order to further investigate the role of P2X7, P2Y1, P2Y11, Stim1 and Orai1 in
extracellular ATP-induced increase in adipogenic differentiation, hDP-MSCs
transfected with siRNAs were examined.
The effects of transfection with siRNA on ATP-induced increase in adipogenic
differentiation are shown in Figure 6.6A-C. Transfection with siP2Y1 and siP2Y11
significantly inhibited, whereas transfection with siP2X7 did not significantly alter,
ATP-induced increase in adipogenic differentiation from all these donors (Figure
6.6D), indicating that the P2Y1 and P2Y11 receptors contribute to ATP-induced
facilitation of adipogenic differentiation. However, transfection of siStim1 and
siOrai1, and even co-transfection with siStim1 and siOrai1 did not significantly affect
ATP-induced increase in adipogenic differentiation. The role of Orai3 was studied by
transfection with siOrai3 (Figure 6.6A-C). Transfection with siOrai3 significantly
reduced ATP-induced increase in adipogenic differentiation (Figure 6.6D). These
results suggest that the Orai3 channel is involved in the up-regulation by extracellular
ATP of adipogenic differentiation of hDP-MSCs.
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(Figure 6.6)
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Figure 6.6 Effects of transfection with siRNA on adipogenic differentiation in
ATP-treated hDP-MSCs.
(A-D) Summary of adipogenic differentiation of ATP-treated (30 μM) hDP-MSCs 
(P4, 9F) transfected with siControl or siRNA for P2X7, P2Y1, P2Y11, Stim1, Orai1,
Stim1/Orai1 and Orai3, presented as percentage of adipogenesis in
siControl-transfected control cells untreated with ATP: (A) 9F, P4, N = 4 wells; (B)
21F, P4, N = 4 wells; (C) 32F, P4, N = 4 wells; (D) 9F, 21F and 32F, n/N = 3/12.
Cells were cultured in ADM for 21 days. Adipogenesis was determined by the OD510
value (Oil red staining) per μg DNA. #, p < 0.05; ##, p < 0.01; ###, p < 0.001;
compared to siControl without ATP. *, p < 0.05; **, p < 0.01; ***, p < 0.001;
compared to siControl with ATP.
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6.3 Discussion
The study in this chapter provides evidence to show that the P2X7, P2Y1, P2Y11,
Stim1, Orai1 and Orai3 have differential roles in ATP-induced effects on hDP-MSCs
functions. Specifically, the P2X7, P2Y1 and P2Y11 receptors and Stim1/Orai1 are
involved in ATP-induced stimulation of cell migration. The P2Y1 and P2Y11
receptors and Stim1/Orai1 are engaged in ATP-induced inhibition of osteogenic
differentiation. Finally, the P2Y1 and P2Y11 receptors and Orai3 are important in
ATP-evoked increase in adipogenic differentiation.
ATP stimulated hDP-MSC migration. Such an effect was inhibited by PPADS, but
not by CGS15943, indicating a critical role for the P2 receptors and no or a very
minor role for the adenosine receptors (Figure 6.1F). ATP-induced effect on cell
migration was slightly but significantly inhibited by AZ11645373 (Figure 6.1F) to
inhibit the P2X7 receptor function and siRNA to reduce the P2X7 receptor expression
level (Figure 6.2F), supporting a role for the P2X7 receptor. ATP-induced stimulation
of cell migration was strongly blocked by down-regulation of the P2Y1 and P2Y11
receptor expression with siRNA (Figure 6.2F), and by 2-APB (Figure 6.1F) and
down-regulation of Stim1, Orai1 expression level with siRNA (Figure 6.2F). Taken
together, these results consistently show a significant role for the P2Y1 and P2Y11
receptors that are coupled to the Stim1/Orai1 SOC channels in ATP-induced increase
in hDP-MSC migration. It was reported that ATP increased hBM-MSC migration
using a transwell assay (Ferrari, Gulinelli et al. 2011). Ca2+ signalling was considered
to play an important role in hBM-MSC migration (Ding, Zhang et al. 2012). The
P2Y11 receptor has been shown to contribute to hBM-MSC migration stimulated by
extracellular NAD+ (Fruscione, Scarfi et al. 2011). The P2Y2 receptor is reported to
be involved in ATP-enhanced cell migration in hepatocellular carcinoma cells (Xie,
Xu et al. 2014) and UTP-enhanced cell migration in CD34+ HSCs (Lemoli, Ferrari et
al. 2004). However, the P2Y2 expression was not consistently observed in hDP-MSCs
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(see section 4.2.2). Stim1 in hepatocellular carcinoma cells was involved in
ATP-induced increase of cell migration (Xie, Xu et al. 2014). Additionally, the Stim1
and Orai1 expression levels and cell migration in breast cancer cells (MCF-7) are
up-regulated by silencing Oct4 with siRNA, although the causative relationship
between the Stim1/Orai1 expression and cell migration is unclear (Hu, Qin et al.
2011).
The present study shows that the ALP expression and activity in hDP-MSCs cultured
in BM and ODM were reduced by ATP. The ATP-induced effect on the ALP activity
in cells cultured in BM was significantly inhibited by PPADS, but not CGS15943
(Figure 6.3E). Treatment with 2-APB appeared to inhibit the decrease in the ALP
activity in ATP-treated cells cultured in BM, but the inhibition was not statistically
significant. ATP-induced inhibition of the ALP activity was not affected by
AZ11645373 to inhibit the P2X7 receptor function or using siP2X7 to reduce the
receptor expression, suggest no major role for the P2X7 receptor. Treatment with
siP2Y1, siP2Y11, siStim1, siOrai1 and siStim1/siOrai1 almost completely blocked
ATP-induced decrease in the ALP activity in cells cultured in BM (Figure 6.4E).
These results indicate that ATP inhibits the osteogenic differentiation potential of
hDP-MSCs via activating the P2Y1 and P2Y11 receptors and downstream
Stim1/Orai1 SOC channels.
The present study also shows that ATP can down-regulate the ALP expression and
activity or osteogenesis of hDP-MSCs cultured in ODM. Such an effect was also
attenuated by PPADS (Figure 6.3E). CGS15943 (Figure 6.3E) and AZ11645373 or
transfection of cells with siP2X7 failed to result in any effect. These observations are
not consistent with that reported in a recent study of hBM-MSCs (Sun, Junger et al.
2013). In the previous study, the P2X7 receptor was shown to be involved in
ATP-induced increase in osteogenic differentiation of hBM-MSCs. The difference
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may be due to the fact that different cell preparations and the duration of treatment
with ATP were different; hDP-MSCs were exposed to ATP during the osteogenic
differentiation in the present study, whereas hBM-MSCs were treated with ATP for 5
minutes before introduction of osteogenic differentiation in the previous study (Sun,
Junger et al. 2013). Treatment with siP2Y1, siP2Y11, siOrai1 and siStim1/siOrai1,
largely reversed the reduction by ATP in the osteogenesis of hDP-MSCs cultured in
ODM (Figure 6.4E). These results suggest that activation of the P2Y1 and P2Y11
receptors and Stim1/Orai1 SOC channels are significantly involved in the
down-regulation by ATP of hDP-MSC osteogenesis. It was also reported that the
expression level of the P2Y1 receptor was down-regulated during osteogenic
differentiation of AT-MSCs, although the causative relationship between the P2Y1
receptor expression and osteogenic differentiation is unclear (Zippel, Limbach et al.
2012; Scarfi 2014). In contrast with using siRNA to reduce the SOC channel
expression, there was no effect by 2-APB to block the SOC channels (Figure 6.4E).
The exact reason for such a discrepancy is still unclear. It is possible that inhibition of
the SOC channels by 2-APB was inefficient in preventing the action of
osteogenesis-inducing molecules present in ODM, by inducing additional effects on
other signalling molecules as it is well-known that 2-APB can activate and inhibit the
functions of a number of other proteins, including TRP channels (Jiang, Yang et al.
2010).
In contrast to the inhibition or negative modulation of osteogenic differentiation, ATP
facilitated the adipogenic differentiation of hDP-MSCs. Such an effect was
significantly inhibited by PPADS, but not CGS15943, again supporting the role of the
P2 receptors rather than the adenosine receptors (Figure 6.5E). Inhibition of the P2X7
receptor function using AZ1164537 or reduction of the P2X7 receptor expression
failed to block ATP-induced facilitation of adipogenic differentiation, largely
excluding a significant role for the P2X7 receptor. Transfection with siRNA for the
P2Y1 or P2Y11 receptor strongly blocked ATP-induced effect on adipogenesis
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(Figure 6.6D). These results suggest a significant role for the P2Y1 and P2Y11
receptors. Intriguingly, treatment with siStim1, siOrai1 and siStim1/siOrai1, which
can mitigate ATP-induced inhibition of osteogenic differentiation, had no effect on
ATP-induced facilitation of adipogenic differentiation. ATP-induced increase in
adipogenic differentiation was slightly inhibited by using siOrai3 to reduce the Orai3
expression (Figure 6.6D). The expression level of Orai3 showed much higher than
Stim1 and Orai1 in hDP-MSCs from all three donors (Figure 5.2 and 5.8). But, how
the Orai3 channel was indirectly activated by ATP through downstream signalling
pathways following activation of the P2Y1 and/or P2Y11 receptor is unclear and
further studies are required. To date, it has been reported that ATP by activating the
P2Y1 receptor up-regulates adipogenic differentiation of hBM-MSCs (Ciciarello, Zini
et al. 2013). It was also reported that the expression level of the P2Y11 receptor was
significantly up-regulated in adipogenic differentiation of hAT-MSCs, although the
causative relationships between the P2Y11 receptor expression and adipogenic
differentiation are unclear (Zippel, Limbach et al. 2012; Scarfi 2014).
In summary, the results from this chapter have demonstrated that the P2X7, P2Y1,
P2Y11 receptors and Stim1/Orai1 SOC channels in hDP-MSCs contribute in
ATP-induced increase in hDP-MSC migration. The P2Y1 and P2Y11 receptors and
Stim1/Orai1 SOC channels also have a significant role in the down-regulation by ATP
of osteogenic differentiation, whereas the P2Y1 and P2Y11 receptors and Orai3 are
critically engaged in ATP-induced facilitation of adipogenic differentiation in
hDP-MSCs.
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Chapter 7
General Discussion
MSCs found in several tissues and organs (Figliuzzi, Bonandrini et al. 2014) exhibit
the capacity of differentiating into multiple lineages, including osteoblasts, adipocytes,
chondrocytes, myocytes, and neural precursors (Jiang, Jahagirdar et al. 2002; Phinney
2007; Bonfield, Nolan Koloze et al. 2010). Due to their easy accessibility,
regenerative potential, potent immunoregulatory functions, and lack of ethical issues
(Lee, Lim et al. 2014; Wuchter, Bieback et al. 2014), MSCs provide promising
approaches of regeneration medicines, including tissue engineering (Abdallah and
Kassem 2008; Farini, Sitzia et al. 2014). So far, on one hand, there is a large body of
evidence supporting the therapeutic potential of hMSCs for cell therapy and tissue
engineering. On the other hand, there is little understanding of the intrinsic signalling
mechanisms that determine or regulate the proliferation, migration and differentiation
potentials of hMSCs, although such properties of MSCs are known to be strongly
influenced by the local microenvironments (Shi and Li 2008; Biver, Wang et al. 2013;
Biver, Thouverey et al. 2014). A better understanding of the signalling mechanisms
underlying such functions in hMSCs is expected to facilitate applications of hMSCs.
There is emergent evidence to suggest extracellular ATP plays a significant role in a
diversity of cell functions, including proliferation, migration and differentiation of
stem cells, including ESCs, HSCs, NSCs and BM-MSCs (Burnstock and Ulrich 2011;
Scarfi 2014). In previous studies, extracellular ATP was shown to promote cell
migration, osteogenesis and adipogenesis in hBM-MSCs (Ferrari, Gulinelli et al. 2011)
(Ciciarello, Zini et al. 2013; Sun, Junger et al. 2013). However, our understanding of
the intrinsic signalling mechanisms responding to extracellular ATP is still
contentious. Therefore, the study presented in this thesis aimed to investigate the
- 182 -
effects of extracellular ATP on the proliferation, migration and differentiation of
hDP-MSCs and the intrinsic signalling mechanisms activated by ATP.
In this study, hMSCs were isolated from dental pulp tissues from four donors with
different age and gender (Figure 3.1-3.3; Table 3.1). The hDP-MSCs expressed
STRO-1 (a MSC marker), a high level of CD105, CD90 and CD73, and a very low
level of CD45, CD34 and CD14 (Table 3.1). Although the CD105 expression was
slightly low and the CD14 expression was slightly high, hDP-MSCs in the present
study displayed a potential of multipotent differentiation including osteocytes,
adipocytes and chondrocytes (Figure 3.3).
Results from the XTT assay and cell counting methods indicate that treatment with
extracellular ATP has no significant effect on cell proliferation in hDP-MSCs (Figure
3.4 and 3.5). In contrast, scratch wound assays demonstrated that ATP enhanced cell
migration in hDP-MSCs (Figure 3.6 and 3.7). In addition, the ALP activity assay
showed that ATP inhibited osteogenic differentiation of hDP-MSCs (Figure 3.8) and,
by contrast, Oil red O staining revealed that ATP promoted adipogenic differentiation
of hDP-MSCs (Figure 3.9).
The results from single cell Ca2+ imaging showed that ATP induced increases in the
[Ca2+]i in the extracellular Ca2+-containing or Ca2+-free solutions (Figure 4.1G).
Furthermore, results from real-time RT-PCR and effects of selective inhibitors and
siRNA knockdown on ATP-induced Ca2+ responses demonstrated functional
expression of the ATP-sensitive P2X7, P2Y1 and P2Y11 receptors in hDP-MSCs (see
chapter 4). Stim1/Orai SOC channels also contributed to extracellular ATP-induced
Ca2+ signalling in hDP-MSCs (see chapter 5). The present study using inhibitors and
transfection with siRNAs (see chapter 6) provided evidence to demonstrate that the
P2X7 receptor is involved in ATP-induced increase in hDP-MSC migration, but not
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in ATP-induced effects on osteogenic and adipogenic differentiation. Moreover, the
P2Y1 and P2Y11 receptors are involved in mediating ATP-induced modulation of
hDP-MSC migration, osteogenic and adipogenic differentiation. Stim1/Orai1 SOC
channels are also involved in ATP-induced effect on hDP-MSC migration and
osteogenic differentiation, while Orai3 is engaged in ATP-induced modulation of
adipogenic differentiation. The final chapter aims to provide an integral discussion of
the main findings described in this thesis.
7.1 Expression and function of the P2X7 receptor in hDP-MSCs
The results from real-time RT-PCR showed mRNA expression of P2X4, P2X6 and
P2X7, but not P2X1, P2X2, P2X3 and P2X5 in hDP-MSCs (Figure 4.2). This finding
is not completely consistent with a previous study reporting mRNA expression of all
P2X receptors except P2X2 in hBM-MSCs (Ferrari, Gulinelli et al. 2011). Thus, both
studies support the mRNA expression of P2X4, P2X6 and P2X7 but are different in
terms of the mRNA expression for P2X1, P2X3 and P2X5. The present study has not
examined the protein expression of P2X4, P2X6 and P2X7, but determined the effects
of selective P2X antagonists on ATP-evoked Ca2+ responses in the extracellular
Ca2+-containing solutions. ATP-induced Ca2+ responses were insensitive to 5-BDBD,
a P2X4 selective antagonist (Figure 4.6), suggesting lack or a very low level of
functional expression of the P2X4 receptor. It is generally thought that the P2X6
protein does not form functional receptor on its own but can interact with the P2X2 or
P2X4 protein to form heteromeric receptors (Khakh, Proctor et al. 1999; Schwindt,
Trujillo et al. 2011). It is unlikely that P2X4 and P2X6 form a heteromeric receptor in
hDP-MSCs although the present study could not rule out such a possibility.
However, there is clear evidence to support that hDP-MSCs express functional P2X7
receptors. First of all, both ATP and BzATP evoked robust Ca2+ responses in the
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extracellular Ca2+-containing solutions. BzATP-induced Ca2+ responses were
consistently greater that those by ATP in hDP-MSCs from three donors (Figure
4.4D-F), and thus BzATP was more potent than ATP, a pharmacological property of
the P2X7 receptor (see section 1.3.2.7). Secondly, ATP-induced Ca2+ responses were
significantly inhibited by AZ11645373, a hP2X7 receptor selective antagonist (Figure
4.7). Finally the Ca2+ responses induced by ATP and BzATP were strongly attenuated
using siRNA to reduce the P2X7 receptor expression (Figure 4.10). Taken together,
these observations strongly support the expression of functional P2X7 receptor in
hDP-MSCs. Consistent with this finding, previous studies showed protein and
functional expression of the P2X7 receptor in hBM-MSCs (Riddle, Taylor et al. 2007;
Ferrari, Gulinelli et al. 2011). The present study further investigated the potential of
the P2X7 receptor in ATP-induced effect on hDP-MSC migration and differentiation.
Inhibition of the P2X7 receptor with AZ11645373, or reduction of the P2X7 receptor
expression with siP2X7, attenuated ATP-induced stimulation of cell migration (Figure
6.1F and Figure 6.2F), providing consistent evidence to suggest a significant role for
the P2X7 receptor. In contrast, such pharmacological and genetic interventions failed
to prevent ATP-induced inhibition of osteogenesis (Figure 6.3E and Figure 6.4E) and
stimulation of adipogenesis of hDP-MSCs (Figure 6.5F and Figure 6.6D), suggesting
no major role for the P2X7 receptor in ATP-induced regulation of osteogenic and
adipogenic differentiation of hDP-MSCs. A recent study has shown that ATP released
by shockwave or pretreatment with ATP for 5 minutes before osteogenic
differentiation increased the osteogenic differentiation of hBM-MSCs and such
ATP-induced stimulation was attenuated by using siP2X7 to reduce the
P2X7 receptor expression and using selective P2X7 receptor antagonist KN62 to
inhibit the P2X7 receptor function (Sun, Junger et al. 2013). The exact reasons for
such discrepancies are unclear. The different concentrations of ATP and exposure
duration used in the previous and present studies may contribute to such differences in
ATP-induced effect on osteogenesis and the role of the P2X7 receptor.
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In summary, the present study shows that the P2X7 receptor is functionally expressed
in hDP-MSCs and plays a role in ATP-induced increase in cell migration, but not in
ATP-induced effects on osteogenic and adipogenic differentiation.
7.2 Expression and function of the P2Y1 and P2Y11 receptors in
hDP-MSCs
In addition to the P2X receptors, extracellular ATP can activate the P2Y1, P2Y2 and
P2Y11 receptors that are coupled to the PLC-IP3 signalling pathways to leading to
intracellular Ca2+ release from the ER and subsequent activation of the SOC channels
mediating extracellular Ca2+ entry (see section 1.3.3). The results from RT-PCR in
this study showed the mRNA expression of P2Y1 and P2Y11 receptors in
hDP-MSCs. The P2Y2 mRNA expression was not consistently detected in
hDP-MSCs isolated from all three donors and the expression level in the 9F donor
was very low (Figure 4.2). ATP induced Ca2+ release in hDP-MSCs in the
extracellular Ca2+-free solution (Figure 4.8). ADP, an agonist at the P2Y1 receptor,
and BzATP, an agonist at the P2Y11 receptor, also evoked Ca2+ release in the
extracellular Ca2+-free solution (Figure 4.8). ATP-evoked Ca2+ responses in the
extracellular Ca2+-containing solutions were inhibited by PPADS (Figure 4.3).
Furthermore, transfection with siP2Y1 significantly decreased ATP- and ADP-evoked
Ca2+ responses (Figure 4.11), while transfection with siP2Y11 reduced ATP-evoked
Ca2+ responses (Figure 4.12). These results provide clear evidence to indicate
functional expression of the P2Y1 and P2Y11 in ATP-induced Ca2+ signalling in
hDP-MSCs. Consistent with the present study, previous studies detected the mRNA
expression of the P2Y1 and P2Y11 receptors in hBM-MSCs (Ferrari, Gulinelli et al.
2011) and hAT-MSCs (Zippel, Limbach et al. 2012; Scarfi 2014). The protein
expression of P2Y1 and P2Y11 receptors were further observed in hBM-MSCs by the
immunostaining and Western blotting (Ichikawa and Gemba 2009).
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The role of the P2Y1 and P2Y11 receptors in ATP-induced regulation of stimulation
of hDP-MSC migration and differentiation was investigated in the present study.
ATP-induced increase in cell migration was strongly blocked by PPADS (Figure
6.1F) and siRNAs to reduce the P2Y1 or P2Y11 receptor expression (Figure 6.2F).
The ATP-induced decrease in osteogenesis and increase in adipogenesis of
hDP-MSCs were also blocked by PPADS (Figure 6.3E and Figure 6.5F) and siP2Y1
or siP2Y11 (Figure 6.4E, and Figure 6.6D). These results show a significant role for
the P2Y1 and P2Y11 receptors in mediating ATP-induced modulation of cell
migration osteogenesis and adipogenesis. Consistently with the present study, the
P2Y11 receptor has been shown be involved in hBM-MSC migration induced by
extracellular NAD+ (Fruscione, Scarfi et al. 2011), and the P2Y1 receptor is involved
in ATP-induced promotion of adipogenic differentiation of hBM-MSCs (Ciciarello,
Zini et al. 2013).
7.3 Expression and function of Stim1/Orai SOC channels in
hDP-MSCs
The results from single cell Ca2+ imaging (Figure 5.1C-D) and FLEXstation (Figure
5.4A-B) showed that depletion of the ER Ca2+ store using TG induced a robust
increase in the [Ca2+]i in hDP-MSCs upon addition of extracellular Ca2+into the
extracellular Ca2+-free solutions (Figure 5.1C-D and Figure 5.4A-B), supporting
expression of the SOC channels in hDP-MSCs. Inhibition of the SOC channels using
2-APB or Synta66 significantly blocked TG-induced Ca2+ entry without altering the
basal [Ca2+]i and Ca2+ entry through the constitutively active Ca2+ conductance
(Figure 5.3 and Figure 5.4), further supporting that the functional expression of the
SOC channels in hDP-MSCs. The functional expression of the SOC channels was
also reported in hBM-MSCs, but the molecular identity was completely unknown
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(Kawano, Shoji et al. 2002). The present study using RT-PCR for the first time
showed the mRNA expression of Stim1, Stim2, Orai1, Orai2 and Orai3 in hDP-MSCs
(Figure 5.2). Reducing the expression level of all three Orai and Stim1 but not Stim2
(Figure 5.9F and Figure 5.11F) significantly inhibited TG-induced Ca2+ entry. The
results from the FLEXstation experiments revealed that ATP-induced Ca2+ responses
were also attenuated by 2-APB and Synta66 (Figure 5.5E and Figure 5.6E).
Furthermore, ATP-induced Ca2+ responses were significantly reduced by transfection
with siRNA for Stim1 and each of three Orai (Figure 5.10E), and co-transfection with
siStim1/siOrai (Figure 5.12E), but not transfection with siStim2 alone (Figure 5.10E).
Taken together, these results suggest that Stim1 and Orai contribute to formation of
the SOC channels and mediate ATP-induced Ca2+ signalling in hDP-MSCs.
In a previous study, treatment with siRNA to reduce the Stim1 expression level
inhibited ATP-induced increase of cell migration in hepatocellular carcinoma cells
(Xie, Xu et al. 2014). Consistently, the present study has shown that the Stim1/Orai
SOC channels play a role in ATP-induced regulation of hDP-MSC migration.
Inhibition of the SOC channels with 2-APB (Figure 6.1F) or reduction in the
expression of Stim1 and Orai1 using siStim1, siOrai1 and in combination strongly
blocked ATP-induced increase of cell migration (Figure 6.2F). Such treatments also
blocked ATP-induced decreases in osteogenesis in BM (Figure 6.3E and Figure 6.4E).
Treatment with siOrai1 and siStim1/siOrai1 but not with siStim1 or 2-APB prevented
ATP-induced reduction in osteogenesis of hDP-MSCs in ODM (Figure 6.3E and
Figure 6.4E). However, there was no effect of treatment with siStim1, siOrai1 and
siStim1/siOrai1 on ATP-induced stimulation of adipogenesis (Figure 6.6D).
Treatment with 2-APB and siOrai3 slightly inhibited ATP-modulated increase of
adipogenesis (Figure 6.5F and Figure 6.6D).
Taken together, these results show a significant role for the Stim1/Orai1 SOC
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channels in ATP-induced increase in cell migration and osteogenesis of ATP-treated
hDP-MSCs in BM or ODM, while Orai3 is importantly involved in ATP-modulated
facilitation of adipogenic differentiation in ADM.
7.4 Future studies
This present study has provided clear evidence to show that extracellular ATP as an
extrinsic signal regulates migration and differentiation of hDP-MSCs through the
purinergic P2 receptors, particularly those involved in intracellular Ca2+ signalling.
Further studies on the following aspects are required to help to gain a better and more
mechanistic understanding.
In this study, the mRNA expression of P2Y2 was only detected in hDP-MSCs from
one donor (9F), but not detected in hDP-MSCs from other two donors (21F and 32F),
possibly due to the age-dependent change in gene expression. Moreover, the results in
this study were obtained from three female donors. Therefore, future studies on the
expression of P2 purinergic receptors in donors (males and females) from different
age groups, would help to improve the understanding of genetic influences on aging.
This study has shown that ATP improves cell migration of hDP-MSCs using the
IncuCyte real-time imaging system. More studies are needed to investigate that how
ATP-induced Ca2+ signalling leads to enhanced cell migration.
Furthermore, this study has shown that ATP down-regulates osteogenic differentiation
potential of hDP-MSCs using the ALP activity assay and up-regulates adipogenic
differentiation using oil red O staining. In the future, studies on the gene expression
and histochemical analysis of osteoblast-related (e.g., Runx2, osteocalcin) or
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adipocyte-related differentiation markers (e.g., PPARγ2) would help to better 
understand the molecular mechanism of cell differentiation regulated by ATP in
hDP-MSCs. It would be also important to investigate that how cell differentiation was
mediated by ATP-induced Ca2+ signalling, which would enable a deeper insight into
the signalling mechanisms that mediate cell differentiation.
In the present study, cells were cultured in 2-dimensional (2D) plastic or glass
surfaces. However, cells in vivo primarily exist and operate in a three-dimensional
(3D) extracellular environment that contains multiple extracellular matrix (ECM)
components. Moreover, the results presented in this thesis have shown that
extracellular ATP significantly stimulates cell migration and regulates osteogenic and
adipogenic differentiation potential of hDP-MSCs. Therefore, future studies should
use a 3D-scaffold to culture hDP-MSCs with the treatment of ATP to corroborate the
findings made based 2D culture.
7.5 Conclusion
In conclusion, the study described in this thesis shows that exposure to extracellular
ATP results in significant increase in cell migration and adipogenic differentiation
and inhibition of osteogenic differentiation of hDP-MSCs. The study provides
pharmacological and genetic evidence to indicate that the P2X7, P2Y1 and P2Y11
receptors, and Stim1/Orai SOC channels are functionally expressed as intrinsic
mechanisms activated by extracellular ATP in hDP-MSCs. These signalling
molecules play a differential role in ATP-induced regulation of hDP-MSC migration
and differentiation. As summarized in Figure 7.1, the P2X7, P2Y1 and P2Y11
receptors all contribute in ATP-induced stimulation of cell migration. The P2Y1 and
P2Y11 receptors, not the P2X7 receptor, are involved in ATP-induced inhibition of
osteogenesis and stimulation of adipogenesis. The Stim1/Orai1 SOC channels have a
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role in mediating ATP-induced stimulation of cell migration and inhibition of
osteogenesis, but not ATP-induced stimulation of adipogenesis. The Orai3 protein is
engaged in ATP-enhanced adipogenesis. These findings will provide a substantial
insight into the intrinsic mechanisms underlying the regulation of MSC functions by
extracellular ATP. Such information will facilitate developing better MSC-based cell
therapies and regenerative medicines.
Figure 7.1 Schematic summary of ATP-induced Ca2+ signalling mechanism in
migration and differentiation of hDP-MSCs.
(A) Extracellular ATP induces Ca2+ entry through the P2X7 receptor to increase the
[Ca2+]i, which contributes to the increase of cell migration. (B) Extracellular ATP
induces Ca2+ release through the P2Y1 or P2Y11 receptor to activate the Stim1/Orai1
channel and subsequently increase the [Ca2+]i, which contributes to the increase of
cell migration and the decrease of cell osteogenesis. (C) Extracellular ATP induces
Ca2+ release through the P2Y1 or P2Y11 receptor to activate the Orai3 channel and
subsequently increase the [Ca2+]i, which contributes to the increase of cell
adipogenesis.
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